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Abstract 
Since a long time, the interest toward protein-based bioconjugates and bioinspired 
composites has been dramatically raising because of their importance in many fields of 
application. Immobilized enzymes, for example, can be employed as catalysts in mild, green, 
controlled and physiological conditions. Moreover, several medical devices are indeed 
biomaterials. Instead regarding bioconjugates, the functionalizations — e.g. PEGylation or 
glycosylation — permit to improve certain features of the target (stability, solubility, 
specificity, immunogenicity, etc.). Furthermore biocojugation can be employed to attach 
biomarkers for diagnostic applications, design biosensors or develop strategies for studies of 
biological interactions. Therefore, it is clear the importance of a biophysical and structural 
characterization at atomic details of these systems, but often the absence of order impedes 
the crystallization and consequently the use of X-ray crystallography. Analogously, solution 
nuclear magnetic resonance (NMR) employment is restricted because this technique suffers 
from molecular weight limits. Viceversa solid-state NMR (SSNMR) has been becoming a 
powerful tool and it has been applied for a number of different samples, such as sediments, 
membranes, lyophilized samples, fibrils, etc. This is because SSNMR can be employed also 
for large molecular assemblies and moreover does not strictly require crystallization. Hence, 
the aim of my PhD project focused on the possibility to develop an approach for the structural 
and functional characterization of bioconjugates and bioinspired composites of industrial 
and medical interest, based on SSNMR. 
Two proteins were chosen as models: Escherichia coli L-asparaginase II (ANSII) and human 
α-carbonic anhydrase 2 (hCAII). Both systems have medical interest, being the former used 
in the treatment of acute lymphoblastic leukemia in children and the latter found to be 
overexpressed in several pathologies, thus being an interesting target for drug development. 
The choice of ANSII and hCAII relied not only on their importance in medicine but also 
because they show very high quality NMR spectra.  
ANSII is mainly administered in its PEGylated formulation; however no structural 
characterization at an atomic level had ever been reported. Therefore, the first part of my 
work dealt with the functionalization of ANSII with 1000 Da PEG chains and the 
characterization of the synthesized bioconjugate by SSNMR. This tool turned out to be a 
powerful method to assess the preservation of protein folding after PEGylation which is a 
central issue in the structural study of bioconjugates. The superimposition of SSNMR 
carbon-carbon correlation spectra of PEGylated and free crystalline ANSII indeed 
demonstrated that the functionalization did not affect the structural integrity of the protein. 
Encouraged by this result, ANSII was even functionalized with 5 nm core size gold 
nanoparticles (GNPs). Protein-conjugated GNPs are well-established tools for 
immunochemistry and promising agents for photodynamic therapy, near-infrared optical 
imaging and drug delivery, thus making these systems interesting subjects of study. ANSII-
GNP conjugate was deeply characterized by SSNMR and even in this case it was confirmed 
that conjugation did not modify the global protein structure. It was also possible to reassign, 
for the first time, the resonances of the protein grafted onto GNPs and investigate the details 
of local changes caused by the formation of new bonds between the protein and the 
nanoparticles. 
Still in the frame of this research, SSNMR was found to be a versatile and reliable technique  
for the characterization of the conjugation pattern in a large polysaccharide-protein 
conjugate too. Glycosylation is a common approach used for the design of glycovaccines 
which are known to be the most efficient and safest weapons for the prevention of infectious 
diseases but it often leads to polydispersity. Therefore, the possibility to estimate the degree 
of conjugation is a breakthrough in this field. Even if it is not an immunogenic protein, 
ANSII was used as model to be glycosylated with the meningococcal serogroup C capsular 
polysaccharide (MenC CP). By integrating perdeuteration of the protein, selective labeling 
of lysine residues and solution and SSNMR analyses, it was possible to get a 
semiquantitative evaluation of the conjugation pattern in ANSII-MenC CP conjugate and 
classify lysine residues according to their degree of functionalization. 
ANSII was also employed in biomaterial design and characterization. The administration of 
this protein, even in its PEGylated formulation, often provokes severe side effects; therefore 
it is interesting to develop a medical device in which ANSII is immobilized for an 
extracorporeal processing of blood thus minimizing the contact with the immune system. 
With this aim, a hydroxyapatite (HA) composite containing ANSII was designed by fusing 
the protein with a HA binding peptide (HABP) which triggers the formation of HA. The 
ANSII-HABP/HA biomaterial was enzymatically and structurally characterized by using 
integrated techniques, among which SSNMR turned out to be crucial in the study of 
morphology and biological and inorganic layers of the composite. 
The last part of my work instead focused on the development of a strategy to probe protein-
ligand interaction also when the protein is entrapped in a bioinspired material. In particular, 
hCAII was immobilized into a silica matrix and then screened with two of its inhibitors, the 
stronger furosemide and the weaker sulpiride. Even in this case, SSNMR was used as tool 
of investigation and again it revealed to be a powerful method to look into structure local 
effects due to the interaction of ligands with an entrapped enzyme, thus expanding the 
plethora of tools and approaches for drug discovery. 
In summary, all my PhD project was aimed to attest the efficiency and versatility of SSNMR 
as tool of choice for the structural characterization of very different bioconjugate and 
biomaterial systems. This method was found to be extremely useful to check the preservation 
of protein integrity after every kind of functionalization, get a semiquantitative evaluation of 
the conjugation pattern, assign a protein grafted onto nanoparticles, study the morphology 
of biomaterials, screen protein-ligand interactions when the enzyme is immobilized onto an 
inorganic support. As further development, SSNMR could be applied in the study of other 
kind of bioconjugates, either varying the protein moiety (for instance, immunogenic proteins 
to design “real” glycovaccines) or the attached systems (e.g. other kind of nanoparticles). 
Finally, novel enzyme-based materials, composites, biomimetic reactors could be 
investigated by exploiting all the potentiality of a such powerful and versatile technique as 
(SS)NMR. 
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Chapter 1 
INTRODUCTION 
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Drugs of biological provenance — known as biological medical products, biologics, 
biomedications, biotherapeutics or biopharmaceuticals1 — are the fastest-growing category 
of approved and marketed pharmaceuticals. Most of them are proteins2 found in nature. 
Another important part is composed of entities that are the result of a synthetic or 
semisynthetic modification of biological substances. This is the case of bioconjugates and 
biomaterials. Since the growing diffusion of biologics in medicine, diagnosis, imaging and 
therapy and the potential applications of bioconjugates and protein-based biomaterials, the 
development of new methodologies for the characterization of these elusive heterogeneous 
systems are more and more required. This introductive chapter indeed holds a brief outline 
focused on the foremost bioconjugation approaches and some examples of differently 
employed biomaterials. 
 
1.1. Bioconjugates 
Bioconjugation is a chemical approach that consists in the functionalization of a target 
biomolecule with other molecules or macromolecules to form a new unique system having 
the combined properties of its individual components3 [Fig. 1.1]. The coupling between the 
partners must lead to the formation of a stable covalent or noncovalent linkage. Natural or 
synthetic compounds with their specific features can be involved in bioconjugation in order 
to create a substance (a bioconjugate, indeed) possessing carefully engineered 
characteristics. Lots of biological molecules can be used as substrates for bioconjugation: 
nucleic acids, amino acids, (oligo)nucleotides, (oligo)peptides, sugars, lipids, even though 
the largest employed targets are the proteins. 
 
 
Figure 1.1 - Bioconjugation is the attachment of one or more molecular 
components (colored elements) to a target biomolecule (black sphere). 
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Bioconjugation is an evergreen field of research because of its important and swelling role 
in medicine, diagnostics, metabolomics, biology, cell biology, industrial synthesis, 
technology and nanotechnology. Many drugs, probes, catalysts, biomarkers and biosensors 
are indeed products of synthesis of a biomolecule with another attaching substrate. The 
reason why bioconjugates increasingly catch interest relies on their versatility and improved 
properties in respect to the single constituting components. 
Firstly, bioconjugation can enhance water solubility of the biological target. Betaines, 
for instance, are attached to N-terminus of polypeptides increasing solubility and reducing 
the tendency of their aggregation4. Zhang et al. demonstrated instead how the solubility of 
Paclitaxel, a chemotherapeutic used to treat a number of types of cancer, drastically 
increased following the conjugation with polyvalent DNA-nanoparticle systems5. However, 
the most known moieties used for increasing solubility are oligo- and polyethylene glycol 
chains. Recently Hegedüs et al. described the effect of incorporation of various oligoethylene 
glycol groups into the structure of daunorubicin-GnRH-III bioconjugates: all synthesized 
bioconjugates turned out to be more soluble in cell culture medium than the unmodified 
equivalents6. Likewise, Basu et al. functionalized the human interferon-β-1b (INF-β-1b) with 
a polyethylene glycol moiety in order to optimize the features of the target, i.e. solubility7. 
They observed that, when native INF-β-1b was formulated in aqueous solution in the absence 
of a detergent, the protein rapidly and quantitatively precipitated as insoluble aggregates, 
whereas the 40 kDa polyethylene glycol conjugated INF-β-1b did not. 
Solubility is just only one of the characteristics that can be modulated. Bioconjugation 
is also used to improve stability of the target. Again oligo- and polyethylene glycol chains 
— but likewise other polymers, dextrans or even coupled proteins like human serum albumin 
(HSA) — are routinely used to extend the half-life in circulation by limiting proteolytic 
degradation8. The attachment of specific moieties to the drugs can indeed dramatically affect 
their pharmacokinetics, pharmacodynamics, biodistribution, bioavailability, toxicity and 
uptake by organs. First Beel and later Podobnik deeply studied the effect of polyethylene 
glycol coating for the human interferon-α-2a (INF-α-2a) and demonstrated that the 
functionalization with these repeating units prolonged both in vitro and serum protein half-
lives9,10. Still about this aspect, a number of studies concerned the so-called antibody drug 
conjugates (ADCs). Since often antibody fragments used to induce an immune response 
display rapid blood clearance profiles, lots of attempts to extend their half-life consist in their 
bioconjugation with polymers or even other proteins11–13 without affecting tissue uptake. 
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Bioconjugation is a very important technique applied also for the design of conjugated 
vaccines and the modulation of immunogenicity of biological drugs14. These kinds of 
substances are advanced forms of immune system modulators that are used extensively to 
generate protection against invading pathogens or to produce specific antibody systems. 
Many carrier options and conjugation reactions are employed to create immunogen 
conjugates and glycovaccines, a very widespread and successful type of saccharide-protein 
systems. 
Another field of employment of bioconjugation regards the preparation of biomarkers 
and biosensors for diagnostic purposes15,16. Analogously reactive fluorescent probes are one 
of the most diffuse modification agents for labeling targeting molecules17. The addition of a 
fluorescent label to an antibody or a protein, for instance, provides detection capability that 
they alone cannot possess18. The resultant conjugates can be used in a wide variety of in vitro 
or in vivo fluorescence-based assays and provide a highly sensitive complex for application 
in bioresearch still as biomarker or biosensor. Also DNA can be labeled with this kind of 
probes in order to detect, localize or quantify target DNA sequences. 
A particular mention goes to the (strept)avidi-biotin interaction which can be exploited 
to develop particular bioconjugation approaches19–22. The (strept)avidin-biotin interaction is 
among the most frequently used affinity binding events: the small-molecules biotin can be 
used to modify nearly any biomolecules, or other organic systems, and then facilitate affinity 
biding to (strept)avidin conjugates. This strong and highly specific interaction permits the 
sensitive detection and capture of biotinylated molecules for tracking, imaging, delivery, 
separation and purification.  
Finally, bioconjugation finds increasing applications in industry: some enzymes or 
catalysts are immobilized onto a matrix by the reaction of specific designed groups of the 
support with specific reactive moieties of the target itself. Another similar application is the 
immobilization of ligands onto affinity chromatography supports23. 
Since all these wide applications, it is clear the importance of the development of new 
methods for the preparation of bioconjugates and of course their detailed characterization in 
terms of both function and structure. 
From a chemical point of view, many strategies are currently applied for the synthesis 
of bioconjugates. The central aspect is the design of specific reactive moieties which are 
inserted onto the “bioconjugating” reagent engaged to modify the target [Fig. 1.2]. During 
the years, diverse functional groups have been implemented with the attempt to selectively 
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functionalize one or more sites of the biomolecule, and bioconjugation methodologies can 
be classified according to the types of reaction24. 
 
 
Figure 1.2 - The bioconjugating reagent bears a reactive moiety which 
functionalizes a specific site of the target molecule. 
 
Reactive functions able to couple with amino-containing molecules are the most common 
functional groups present on cross-linking or modification reagents [Fig 1.3]. An amino-
coupling process can be used to conjugate with nearly all proteins or peptides as well as a 
host of other (macro)molecules. The primary coupling chemical reactions for modification 
of amines proceed by acylation or alkylation. Most of these reactions are rapid and clean, 
and occur in very high yield to give stable new amide or amine bonds. 
 
 
Figure 1.3 - Typical functional groups used for the coupling with amino group-containing targets. 
 
N-hydroxysuccinimide (NHS) ester is perhaps the most common activation chemical for 
creating reactive acylating agents. NHS esters were first introduced as reactive ends of 
homobifuncional cross-linkers. Nowadays the majority of amine-reactive cross-linking or 
modification reagents commercially available utilizes NHS esters, or their more soluble 
homolog sulfo-NHS esters. 
An NHS ester may be formed by the reaction of a carboxylate with NHS in the presence 
of a carbodiimide. To prepare stable NHS ester derivatives, the activation must be done in 
nonaqueous conditions using water-insoluble carbodiimides or condensing compounds. 
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NHS ester-containing reagents react with nucleophiles with release of the NHS leaving 
group to form an acylated product; in particular the reaction with amines creates stable amide 
bonds [Fig 1.4]. Therefore, in peptides and proteins, NHS ester conjugating reagents couple 
principally with the α-amines at N-terminals and the ε-amines of the lysine side chains. Since 
NHS esters have a half-life on the order of hours under physiological pH conditions, to 
maximize the modification of amines and minimize the effects of hydrolysis, the 
maintenance of a high concentration of the target biomolecule in the reaction mixture is 
demanding. By adjusting the molar ratio between the cross-linker and the target, the level of 
modification and conjugation may be controlled to create an optimal product. 
 
 
Figure 1.4 - An amino group of a target biomolecule reacts with NHS ester to form a 
bioconjugate containing a novel amide with the release of N-hydroxysuccinimide. 
 
Other reagents which couple with an amino group are isocyanates and isothiocyanates that 
undergo a similar mechanism to the NHS ester reaction. Compounds containing NCO and 
NCS functionalities are however unstable in aqueous solution as well as azides and 
sulphonyl chlorides which couple with primary amines to form amide and sulfonamide 
bonds, respectively. Both classes of compounds tend to be rapidly hydrolyzed, especially in 
conditions of alkaline pH (8.0-10.0) required to amine group to be non-protonated and thus 
responsive to the coupling. Other amine reactive moieties are epoxides that react with 
nucleophiles in a ring-opening process. Different enzymes, for instance, are immobilized 
onto so-called epoxy-supports25. Recently instead a new approach developed by Dovgan and 
others employs benzoyl fluorides which allows for lysine modification of proteins under 
very mild conditions (low temperature, physiological pH)26. 
Reactive moieties able to couple with sulfhydryl-containing molecules are the second 
most common functional groups present on cross-linking or modification reagents27. The 
primary coupling chemical reactions for modification of sulfhydryls proceed by alkylation 
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or disulfide exchange. Many of the reactive groups that undergo these reactions are stable 
enough in aqueous solutions and most of these coupling are rapid and happen in good yield 
to give thioether and disulfide bonds. 
Generally, in protein e peptide bioconjugation, thiol-reactive chemical reactions involve 
the SH terminal function of cysteines. Because free cysteine rarely occurs on protein surface, 
it is a very good choice for chemoselective modification. Under basic conditions, the 
cysteine is not protonated and generates a thiolate which reacts with electrophiles such as 
iodoacetamides [Fig. 1.5a], acryloyl derivatives, maleimides [Fig. 1.5b] and aziridines. In 
all these cases a sulfur-carbon bond is formed. Alternatively the employment of disulfide 
derivatives is an efficient approach that consists in the disulfide exchange: the most used 
reactive reagents are pyridyl disulfide (PDS) compounds [Fig. 1.5c]. 
 
 
Figure 1.5 - Bioconjugations achieved by different sulphydryl-reactive reagents. 
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The sulfhydryls of the target biomolecule are often employed also for the attachment of 
metallic systems, in particular gold nanoclusters, nanoparticles, nanodiscs, nanorods, etc. 
The high stability of gold-sulfur bonds indeed can drive the direct coupling between a protein 
or another molecule or macromolecule with the gold atom [Fig 1.6]. 
 
 
Figure 1.6 - Thiols of a target biomolecule can be used for the attaching of a gold atom. 
 
Another category of reactions involves hydroxyl-reactive bioconjugating reagents. These 
reactions comprise both those agents able to form a stable linkage with an OH group and 
also a broad range of reagents which are designed to activate a target group for a successive 
connection with another functional group. Many of the chemical methods for modifying 
hydroxyls originally were developed for use with chromatography supports in the coupling 
of affinity ligands. Some of these same chemical reactions have found application in 
bioconjugation techniques for cross-linking a hydroxyl-containing molecule with another 
substance. For instance, carbohydrate-containing molecules such as saccharides, 
polysaccharides or glycoproteins can be coupled through their sugar moiety using hydroxyl-
specific reactions. 
Despite amino-, sulfhydryl- and hydroxyl-reactive reactions are the most commonly 
used, other chemical approaches are sometimes employed for bioconjugation. For example, 
tyrosine residues of proteins and peptides are often used to attach probes and similar systems 
by using clean click reactions28 or couplings with diazonium compounds29. These kinds of 
reactions involve the reactive hydrogen located on the ortho position of tyrosine. Other 
times, the designed coupling requires prearranged local modification of the target in order to 
activate it. This is the case of aldehyde-reactive compounds. Since formyl group is seldom 
present on biomolecules, it has to be introduced by periodate oxidation of carbohydrates or 
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modification of an available amino group with reagents that contain or produce a terminal 
CHO. Once formyl group is present, the aldehyde can be coupled with different moieties 
such as guanidines, hydrazines, oximes or even specific compounds used for the trapped 
Knoevenagel reaction30–32. 
Regardless of coupling methods and attaching moieties, above fleetingly described, the 
important issue of bioconjugation concerns the kind of motif which is linked to the target 
and modifies its features. As previously mentioned, polyethylene glycol (PEG) chains, 
nanoparticles (NPs), saccharides or polysaccharides are commonly conjugated to proteins 
and other systems. PEGylation, NP-conjugation and glycosylation are the terms used for the 
corresponding bioconjugation approaches, which are below shown in detail. 
 
1.1.1. PEGylation 
PEGylation is the chemical procedure of attachment of linear or nonlinear polyethylene 
glycol (PEG) chains [Fig. 1.7] to molecules, macromolecules or macrostructures which are 
then described as PEGylated33. Usual targets of PEGylation are drugs, therapeutic peptides 
or proteins34, vesicles35, liposomes36, antibody and antibody fragments37, nanoparticles38. 
 
 
Figure 1.7 - Polyethylene glycol (PEG) chains are constituted of repeating ethylene glycol units. 
 
The first step of PEGylation is the functionalization of the PEG chain with reactive moieties. 
If PEGylation is attained just to coat a unique target, only one terminus of the PEG chain has 
to be modified. Viceversa, if PEGylation is used to connect a couple of targets (e.g. a protein 
to a particle) both terminals of the PEG chain need to be functionalized with specific reactive 
groups. PEG chains that are activated at each terminus with the same reactive moiety are 
known as “homobifunctional”, whereas if the functional groups are different, the PEG 
derivative is referred as “heterobifunctional”. Nowadays a great number of PEG reagents for 
bioconjugation with different reactive ends are commercially available and ready-to-use. 
The choice of the suitable functional moiety for the PEG derivate is based on the type 
of available reactive group on the biomolecule that undergoes PEGylation. For proteins, 
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typical reactive amino acids are lysines, cysteines, histidines, arginines, aspartic acids, 
glutamic acids, serines, threonines and tyrosines. Even the terminal amino group can be used 
as site for the conjugation with aldehyde functionalized PEG chains39. 
An early class of PEGylating reagents is constituted of reactive moieties used to react 
with hydroxyl groups, typically anhydrides, formates, chloroformates, carbonates and acid 
chlorides. Later, PEGyation chemistry introduced couplings involving aldehydes, esters and 
amides. However, currently one of the most used reactive moiety for PEGylation is NHS 
and sulfo-NHS esters which can functionalize the ε-amino groups of protein lysines.  
Once PEG chains are conveniently functionalized, the proper PEGylation can take place. 
The overall PEGylation processes are sketchily classified into two types: a solution phase 
batch process and an on-column fed-batch process. The former consists in the simple mixing 
of reagents together in a suitable buffer solution and a following incubation at a temperature 
generally comprised between 4°C and 6°C. This process requires subsequent separation and 
purification steps of the desired product using a suitable technique, such as size exclusion 
chromatography (SEC), ion exchange chromatography (IEC) or even hydrophobic 
interaction chromatography (HIC). The latter process instead directly combines reaction, 
separation and purification in a single unique operation. The process — termed size 
exclusion reaction chromatography (SERC)40 — simultaneously allows control of the extent 
of reactions in which the molecular size is altered and the separation of products and 
reactants. 
The effects of PEG coating of peptide and protein-based drugs are multiple and 
diverse41,42. As mentioned in the previous paragraph, PEGylation can provide water 
solubility to hydrophobic drugs, proteins and peptides6,7. Moreover the increasing of the 
hydrodynamic radius (size in solution) can prolong the circulatory half-life by dropping renal 
clearance9,10. It is indeed known that one of the most common drawback of peptide and 
protein-based drugs is their tendency to be degraded by proteolytic enzymes and rapidly 
cleared by the kidneys. PEG coating in this sense can enhance their stability to degradation 
and also “mask” from host’s immune systems43. A lot of studies investigated how 
PEGylation modifies pharmacokinetics and pharmacodynamics7,44 of drugs even influencing 
the binding affinity to the cell receptors and altering absorption and distribution patterns. 
The incredible improvement and effectiveness in targeting and delivery of PEGylated drugs 
— in respect to the “naked” drugs45,46 — have made PEGylation technology a basis for the 
growing multibillion-dollar pharmaceutical industry47. Nowadays indeed the clinical value 
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of PEGylation is well established and a massive number of PEGylated drugs are currently 
commercialized.  
The history of PEGylation started around 1970s48, when Abuchowski et al. described 
the PEGylation reactions applied on bovine liver catalase49 and bovine serum albumin50. 
Pegadamase — the PEGylated adenosine deaminase (trade name: ADAGEN) — was instead 
the first PEGylated protein approved by FDA in 1990 to enter the market. It is still used to 
treat a form of severe combined immunogenicity disease (SCID)51. Following Pegadamase, 
lots of PEGylated peptide and protein pharmaceuticals were introduced to the global market 
and others are under experimental trials or development stages. An exemplifying list of 
PEGylated drugs is below: 
• Pegaspargase (trade name: Oncaspar), the PEGylated E. coli L-asparaginase II, used 
for the treatment of acute lymphoblastic leukemia (ALL) in chilhood52; 
• Pegvisomant (trade name: Somavert), a PEG-human growth hormone mutein 
antagonist to treat acromegaly53; 
• Pegfilgrastim (trade name: Neulasta), a PEGylated recombinant methionyl human 
granulocyte colonu-stimulating factor for severe cancer chemotherapy-induced 
neutropenia54; 
• Pegvaliase (trade name: Biomarin), the PEGylated recombinant phe-ammonia lyase, 
recently approved by FDA for the treatment of phenylketonuria55; 
• Peginterferon α-2a (Pegasys) and Peginterferon α-2b (PegIntron), the PEGylated 
forms of the respective α-interferons for use in the treatment of chronic hepatitis C56; 
• Pegloticase (trade name: Krystexxa), the PEGylated uricase to treat the gout57; 
• Peginesatide (trade name: Omontys), a once-monthly medication for the treatment 
of anemia associated with chronic kidney disease in patients on dialysis58. 
 
1.1.2. NP-conjugation 
Protein-inorganic conjugate nanomaterials and nanostructures find increasing applications 
in nanotechnology, biology, cell biology and medicine59. The most popular systems are 
nanoparticle (NP)-conjugates60 which contain particles between 1 and 100 nm in size to 
which a biomolecule is attached. The intrinsic hybrid nature of these systems is the crucial 
strength of their use because it determines their adaptability of employment and versatility. 
NP-conjugates are primarily used for targeting61. Drugs can be efficiently delivered by 
nanoparticles with several benefits: the nanosize allows for access into the cell and various 
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cellular compartments62 or even for passing the blood brain barrier63. This kind of application 
is still considered an innovative and developing method for the administration of drugs since 
it can help to overcome some limits of the traditional approaches. 
NP-conjugates are also used for imaging with analytical and diagnostic purposes64. 
Moreover nanoscale-based therapies [Fig. 1.8] are currently widespread because of the 
precision of these kind of systems in the treatment of specific diseases and forms of cancer. 
For instance, NP-conjugates find application in photothermal and photodynamic 
therapies65,66. The major reason why nanoscale systems are used in this form of therapies is 
correlated to their enhanced permeability and preservation effects. Particles in the range of 
nanometers indeed are known to preferentially accumulate in tumor tissue. When a tumor 
forms, it requires new blood supply in order to fuel its growth. The new formed vessels have 
different proprieties if compared to regular blood vessels, such as poor lymphatic drainage 
and a disorganized vasculature. These factors lead to a significantly higher concentration of 
certain particles. Therefore, once NP-conjugates are delivered to the tumor tissue, they can 
be photostimulated by the irradiation with IR wavelengths. This activation brings the 
sensitizer to an excited state where it then releases heat which is what kills the targeted cells. 
 
 
Figure 1.8 - NP-conjugates are employed in a lot of therapy methods. 
 
Other correlated applications of NP-conjugates regard chemotherapy and magnetic 
nanoparticle hyperthermia. Again exploiting the tendency of nanoparticles to amass in the 
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tumor tissue, bioconjugated chemotheraupetic agents or drugs can be carefully delivered to 
the target thus limiting the adverse effects of the therapy67–71. Nowadays, lastly NP-
conjugated biomolecules are often used as theranostics for the diagnose and the treatment of 
genetic diseases. The process generally involves binding between a vector carrying the 
genetic material and a nanoparticle which provides the signals for imaging. This approach is 
known as nanoparticle (cancer) gene therapy72,73. 
Regardless the medicinal applications, a crucial aspect of the employment of 
nanoparticles — and consequently NP-conjugates — is obviously the evaluation of their 
toxicity, which is essentially correlated to the metal core. The “nanotoxicity” of different 
nanoparticles has been a subject of excellent available reviews74–76 in which it is always 
highlighted the vital roles played by gold nanoparticles (GNPs). 
GNPs have attracted enormous scientific and technological interest over the time due to 
their chemical stability, ease of synthesis, unique optical features and, above all, safety77,78. 
Colloidal gold can be different in terms of nanoparticle dimensions which determine the 
plasmonic characteristics (and also the macroscopical color of the solutions). The sizes 
(typical comprised between 5 and 100 nm) and the shape of GNPs influence the uptake of 
tissues making the choice of the suitable particles a fundamental and determinative issue. 
Another crucial aspect in the employment of GNPs concerns their superficial 
stabilization.  The so-called capping process is essential during GNP synthesis and a lot of 
agents are used in order to stabilized the new formed particles79. Lipoic acid, thiotic acid, 
citrate, folate and cetyltrimethylammonium bromide (CTAB) are just only few examples of 
capping reagents, which are eventually substituted with other oligomer, polymers or in 
general linkers, e.g. PEG chains.  
PEG coating of nanoparticles is accomplished with several purposes. PEGylation of 
GNPs is for instance essential to decrease the uptake of mononuclear phagocytic system 
(MPS) cells and increase the circulation half-life. Lipka et al. studied the effects in 
biokinetics after intraveneous and intratracheal applications of PEG grafted GNPs compared 
to the “naked” GNPs80. PEG chains are moreover excellent spacers between the GNP and a 
target biomolecule. With this aim, bifunctional PEG chains are employed. In a standard 
approach, a thiol group present on one of the two edges of the PEG chain reacts with the 
GNP to form of a stable gold-sulfur bond, then another reactive group (such as a NHS ester, 
sulfo-NHS ester or maleimide) pending from the other edge of the PEG chain is used to 
functionalize the target protein, peptide or antibody81 [Fig 1.9].  
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Figure 1.9 - PEG chains are often employed as spacer in GNP-conjugation. A thiol group is used 
to attach the GNP, whereas another reactive group X functionalizes the target biomolecule. 
 
As already showed in general for nanoparticles, (PEGylated) GNP conjugates have been 
found always larger interest in medical diagnostic and therapeutic applications, since 
principally their unique combination of properties. The main field is of course the targeted 
drug delivery82,83, especially in the treatment of several forms of tumor84,85. Vast applications 
of GNP conjugates regard also photothermal and photodynamic therapies86,87 even if the so 
profound attention to these systems could trigger the development of other fields of 
application not yet explored. 
 
1.1.3. Glycosylation 
Glycosylation is the reaction by which a glycosyl donor (i.e. a saccharide) is covalently 
attached to a target functional group of a glycosyl acceptor88. Glycosylation mainly refers to 
the enzymatic process that connects glycans to proteins during co- or post-translation 
modifications and produces fundamental biopolymers found in cells. When the process is 
not promoted by enzymes, the proper name is glycation88. Despite this subtle difference in 
definition, in biotechnology the term glycosylation can be simply used to indicate a kind of 
bioconjugation approach employed to functionalize a target biomolecule (such as peptides, 
proteins, antibodies, lipids, etc.) with an oligo- or polysaccharide, producing a 
glycoconjugate88 [Fig. 1.10]. 
 
 
Figure 1.10 - Glycosylation consists in the attachment of a saccharide to a target biomolecule. 
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The importance of glycosylation is evident in natural routes. Indeed, several proteins in the 
rough endoplasmic reticulum undergo glycosylation; similarly glycosylation happens in 
cytoplasm or even in the interior of the nucleus. Glycosylation serves various functions89. 
For example, a number of proteins do not fold correctly unless they are conjugated to 
particular saccharides90. The influence of glycosylation on the folding and stability of 
glycoproteins regards two aspects. Firstly, the high soluble glycans mediate a critical quality 
control check point. Moreover, glycosylation can play a role in cell-to-cell adhesion via 
sugar-binding proteins called lectins91, which recognize specific saccharide moieties. 
Glycosylation is also at the basis of the AB0 blood group system. Lastly, it is often used by 
viruses to shield the underlying viral protein from immune response. A crucial example is 
the dense glycan shield of the envelope spike of the HIV92. 
Also from a biomedical engineering point of view, glycosylation is a process of 
exceptional and widespread interest. Jointly with PEGylation, it is perhaps one of the most 
commonly used procedures of bioconjugation for biomedical applications93. For instance, 
glycoconjugates are engaged in targeted drug delivery94–96 and in the treatment of several 
forms of tumor97 even coupling saccharide-base conjugates with nanosystems98. However 
glycosylation plays its main role in the design of glycovaccines99. These are indeed among 
the safest and most efficacious and successful vaccines developed during the last forty years. 
They are a potent tool for prevention of life-threatening bacterial infectious diseases like 
meningitis and pneumonia. 
Several bacteria — such as Gram-negative Neisseria meningiditis and Haemophilus 
influenzae and Gram-positive Streptococcus pneumoniae — are surrounded by a gelatinous 
substance forming a covering envelope around the cell wall. This is known as capsule and is 
a very large well-organized polysaccharide layer that protects the microorganism from 
unfavorable environmental conditions100,101. When an encapsulated bacterium invades a 
host, the presence of capsule prevents or at least reduces the activation of the immune system 
and improve adhesion, determining their virulence102. For this reason, capsular 
polysaccharides of pathogens have been used to produce vaccines103,104. 
However, if the pathogen capsular polysaccharide alone based vaccines are effective in 
adults, it does not happen for infants105,106. In children, indeed pathogen capsular 
polysaccharides are T-cell independent antigens, therefore they do not induce B-cell memory 
and do not produce immunoglubulins G (IgGs) [Fig. 1.11a]. Anyway, a T-cell-dependent 
response — thus inducing B-cell memory and production of IgGs — can be obtained by a 
chemical coupling of polysaccharides to immunogenic proteins [Fig. 1.11b]. 
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Nowadays, glycoconjugated vaccines are routinely employed and commercialized107–
109. A lot of serious diseases provoked by bacteria such as Neisseria meningitidis, 
Escherichia coli, Haemophilus influenzae, Streptococcus pneumoniae, Pasteurella 
haemolytica, etc. are efficiently prevented by the employment of this kind of medical 
defenses110–112. Therefore, the research concerning project, synthesis and characterization of 
novel glycoconjugates usable as more efficient vaccines (eventually against other diseases) 
or in general as drugs is still essential, making glycoconjugation an evergreen field of study. 
 
 
Figure 1.11 - In children, vaccines constituted by the sole pathogen capsular polysaccharide (a) 
can not induce B-cell memory, however it is possible to make the immune system T-cell 
dependent if the polysaccharide is chemically conjugated to an immunogenic protein (b). 
 
1.2. Biomaterials 
In a strict sense, biomaterials are materials exploited in contact with living tissues, organisms 
or microorganisms, such as medical devices or parts of medical devices introduced in the 
human body with the aim of supporting, enhancing or replacing organs or biological 
functions113. In a broad sense, here instead assumed, biomaterials can be considered all 
systems in which a biological molecule or macromolecule (i.e. an enzyme) is immobilized 
to an inorganic substrate for medical, industrial or research applications. Biomineralization 
mimicking approaches and silica matrix entrapment are just only some examples of 
processes producing a biomaterial. 
The importance of employment of biomaterials is evident114,115. In surgery, devices of 
biological or semibiological origins are routinely implanted116,117. Analogously, biomaterials 
of novel generation includes surface modification to overcome nonspecific protein 
adsorption in vivo, precise immobilization of signaling groups on surfaces or supports, 
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development of synthetic materials with controlled properties for drug and cell carriers, 
biologically inspired (bioinspired) materials that mimic natural routes115, and design of 
sophisticated three-dimensional architectures to produce well-defined patterns for 
diagnostics and delivery systems118. 
 
1.2.1. Immobilization 
One of the most common approach in the creation of a biomaterial is the immobilization of 
an enzyme onto or into an inorganic substrate which can be a support, a carrier or a matrix119–
121. There are a lot of immobilization methodologies, classified as adsorption, attachment, 
encapsulation and entrapment [Fig 1.12]. 
 
 
Figure 1.12 - An enzyme (red sphere) can be immobilized in a biomaterial with several methods. 
 
Adsorption-based enzyme immobilization was one of the first immobilization 
methodologies. In 1916 Nillson and Griffin reported the first trial: they immobilized the 
enzyme invertase to charcoal demonstrating that the enzyme was still catalytically active122. 
The first industrially employed immobilized enzyme instead was tested in late 1960s and it 
was prepared by adsorption of amino acids acylase on DEAE-cellulose123. 
Adsorption can be defined as a method in which an enzyme (or in general, biological 
molecules) is connected to a specific surface by the means of very weak physical interactions 
generated between the surface and the enzyme themselves, such as van der Waals forces, 
ionic interactions an hydrogen bonding124. Generally, adsorption is not characterized by 
covalent linkage, otherwise it is properly defined as attachment. 
In the last few decades, adsorptive enzyme immobilization techniques have been deeply 
studied, because of the intrinsic advantages of biomaterials prepared with this approach125: 
• reversibility, which enables the purification of proteins and the re-use of the carriers; 
• simplicity, which guarantees very mild conditions in the immobilization; 
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• possible high retention of activity because this kind of immobilization does not 
affect or change the native structure of the enzyme. 
However, the immobilized enzymes prepared by adsorption tend to leak from the substrate, 
owing to the relatively weak interaction which can be destroyed by desorption forces: high 
temperature, high ionicity, extreme pH values, etc. can indeed break the delicate structure of 
these biomaterials. 
A second method of immobilization is the covalent attachment of an enzyme to a suitable 
substrate126. Covalent bonds usually provide the strongest linkages, compared with other 
types of enzyme immobilization method (e.g. adsorption), thus leakage of enzyme from the 
matrix is often minimized if not completely prevented. 
In general, covalent binding of an enzyme to a carrier is based on chemical reactions 
between the active amino acids located on the enzyme surface and the active functionalities 
that are present on the carrier surface126 [Fig. 1.13]. To achieve efficient linkage, the 
functionality of the carrier and the enzyme must be activated before immobilization. 
Intuitively, the selected carrier functions only as a scaffold. However, it has been 
increasingly appreciated that the selected carrier also strongly dictates the performance of 
the biomaterial obtained by immobilization of the target enzyme.  
 
 
Figure 1.13 - Covalent linkage based enzyme immobilization method. 
 
Since the complexity of these systems, several parameters and properties can affect the 
performance of a covalently carrier-bound immobilized enzyme126: 
• the physical and chemical nature of the carrier (e.g. pore size, porosity, shape, active 
functionality, other non-active functionality, etc.); 
• the nature of the linkage or binding chemistry; 
• the conformation of the enzyme before, during and after immobilization; 
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• the enzyme orientation; 
• the nature and length of an eventually inserted spacer on the carrier; 
• the number of the bonds formed between the enzyme and the carrier; 
• the enzyme distribution. 
Over the years, a number of examples of immobilized enzymes by a covalent binding has 
been tested127–130 because of their versatility and variability in several applications, from 
diagnostics to organic synthesis, from medicine to industry. 
Another immobilization method consists in the so-called encapsulation. This approach 
is defined as the formation of a membrane-like physical barrier surrounding the enzyme (or 
even cells)131, which turns out to be confined inside micro- or nanocapsules. Encapsulation 
is not a such diffuse method if compared to the other methods, however some interesting 
examples are found132–134. Entrapment is viceversa much more known and diffuse. 
Entrapment is the process by which the enzymes are embedded in a matrix formed by 
chemical or physical means such as cross-linking or gelation135. Generally, the matrix is 
formed during the immobilization, therefore it is important that the precursors of the matrix 
and the conditions used for its formation are compatible with the enzyme. The formation of 
matrix is usually achieved by polymerization of unsaturated monomers and co-monomers 
used as cross-linkers or inorganic substrates which undergo condensation of several identical 
molecules. All these reactions are usually irradiation-induced or photo- or chemically-
initiated. The geometric properties of the entrapped enzymes can be easily adapted in various 
forms such as beads, films, fibers, etc., depending on the application and the method of 
entrapment. 
One of the vital issue of entrapment is the retention of enzyme activity, since of the 
diffusion inside the matrix is quite limited. However, there are several examples of entrapped 
enzymes which do not dramatically lose their catalytic functions. This is because the 
entrapment method is usually very mild compared with covalent enzyme immobilization. A 
significant example in this sense regards the YADH enzyme, of which the maximum 
retention was 90% and 24% for entrapment and covalent binding, respectively136. 
Conventionally, in the entrapment the enzyme is usually embedded by dispersing the 
enzyme–polymer solution in an immiscible medium, followed by chemical or physical 
gelation. Thus, the formation of the non-catalytic function of the entrapped enzyme and the 
immobilization occur concomitantly. However, the enzyme can also be entrapped in the 
ready-made matrix such as Sepharose or Sephadex beads, often used in chromatography137. 
Compared with the classic method, if a ready-made matrix approach is used, the enzyme can 
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freely enter the matrix and the accessibility of the enzyme itself might be higher (thus 
showing a higher activity) than for the enzyme that is dispersed in the matrix. 
Immobilization finds large interest in a lot of fields, essentially because this kind of 
functionalization can improve activity, stability and selectively of the enzyme138. Adsorbed 
and entrapped enzymes are widely used for industrial applications139,140, specifically as 
biocatalysts which can drive selective reactions141 that are indeed controlled by engineered 
bioreactors142. Recently, even nanoscale enzyme complexes have been entrapped in scaffolds 
in order to create efficient reactors for biomass conversion143. Immobilization of enzymes is 
finally used for analytical purposes, in the design of medical devices, or in frontier research, 
e.g. in the study of protein-protein, protein-ligand, protein-DNA or RNA interactions 
employing immobilized partners. 
 
1.2.2. Biomineralization mimicking approaches 
Immobilization of enzymes, molecules and cells for the preparation of biomaterials destined 
to all the applications just briefly showed often traces a natural process called 
biomineralization. This term indicates the process by which living organisms and 
microorganisms produce minerals, usually to harden or stiffen existing tissues, such as 
shells, bones, teeth, etc144. It is an extremely widespread phenomenon and over 60 different 
minerals have been identified in members of all taxonomic kingdoms. Examples of minerals 
include silicates in diatoms, but the most diffuse are phosphate and carbonate salts of calcium 
which are found in both vertebrates and invertebrates. 
Since the fascinating mechanisms of formation and variability of employment, 
biomineralization has been used so far as model to develop methodologies of enzyme 
immobilization. One of these is the biosilica matrix immobilization that mimics the natural 
formation of silica biomass exploited by plants, radiolaria, siliceous sponges and above all 
diatoms. 
Diatoms [Fig. 1.14] are abundant in fresh water and sea and are famous for their complex 
and versatile silica structured cell walls, which are functionally important145. Mechanical 
strength measurement for several species showed that the frustules can withstand a very huge 
pressure stress146. It is also possible that the special features of the frustules allow them to 
act as a proton buffer147, essential function for the conversion of bicarbonate to carbonic 
anhydride. Fuhrmann et al. moreover demonstrated the existence of a photonic resonance in 
the visible spectral range for valves from Coscinodiscus granii148. 
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Figure 1.14 - Diatoms have enormous morphological diversity encompassing 
multiple features and patterns on their surface. 
 
Diatoms use silicic acid present in low concentration in oceans as silica precursor to build 
their unique walls. The polymerization [Fig. 1.15] takes place inside an organelle called 
silica deposition vesicle (SDV) in slightly acidic environment. The diatom shell is made out 
of hard plates or valves of silica. As the diatom grows, small plates are added to allow cell 
growth. The process of formation of biosilica structures in diatoms have been extensively 
investigated but several details are still unknown. However, it is quite clear that a peculiar 
group of proteins plays a crucial role in this phenomenum. These protein are called 
silaffins149,150. 
Silaffins are highly charged proteins principally found indeed in diatoms. Some diatom 
species have only one silaffin form, whereas others are suspected to possess even up to 20 
different forms. Nevertheless, there are several similarities that suggest their belonging to an 
evolutionary protein family. 
 
 
Figure 1.15 - Schematic representation of silicic acid polymerization. 
 
Silaffins are generally rich in serines and lysines and are highly post-translationally modified 
with phosphoryl, glycosyl and sulfonyl groups. For interaction between proteins and 
minerals, attractive elettrostatic forces and hydrogen bindings are needed. The positive 
chains of lysines can interact with negative charges on the surface of the biosilica. Moreover, 
hydrogen linkages can be formed between silanol groups on the silica surface and amine 
	
34	
	 	
groups. The serines instead can be phosphorilated or de-phosphorylated as a regulatory 
mechanism of the overall enzyme charge, thereby making the interaction with the silica 
tunable. 
The initial studies concerned silaffins were carried out by Kröger et al. who execrated 
and isolated silaffin Sil1 in both its native form with post translation modifications and its 
non-native form deprived of post translational modification. An extensive research showed 
that silaffins lacking post translation modifications (i.e. Sil1) are active in a neutral setting 
and induce polymerization of silicic acid in spherical shaped silica nanoparticles. Viceversa, 
native silaffins, thus possessing post translation modifications (i.e. natSil1), are active in a 
more acidic setting, just like SDV environment, and polymerize silica into diverse shapes, 
depending on the mixture of silaffins and the presence of long chain polyamines (LCPAs)151. 
On the basis of these and further studies, lots of works have been published concerning 
the development of methods for the enzyme immobilization in biosilica supports by 
mimicking the silaffin-induced polymerization of silicic acid152. The crucial point is always 
the choice of the silaffins or their equivalents. The most popular and applied silaffin-
analogue catalyst is the 19-mer syntetic peptide R5 (SSKKSGSYSGSKGSKRRIL)153. This 
peptide can be directly added in the mixture containing silicic acid and the protein that has 
to be immobilized, otherwise it can be fused to the sequence of the protein itself by means 
of genetic manipulations. Alternatives to natural silaffins and R5 peptide are oligo- or poly-
L-lysines which are oligo- or polycathionic systems that efficiently mimic the effect of 
silaffins154,155. 
Been clear the ease of preparation of biomaterials constituted by enzymes immobilized 
in bioinspired silica matrix, the importance of these attractive systems is due to several 
aspects: this approach indeed ensures higher immobilization than mere adsorption and, at 
the same time, does not create covalent linkages, thus not perturbing the native fold of the 
enzyme. Furthermore, enzymes immobilized through this approach have been reported to 
show high stability, making them applicable in industry as biocatalysts. 
Even if biosilification finds large attention, silicates are not the most abundant 
biominerals. Calcium phosphate and calcium carbonates instead are the most diffuse and, 
among these, hydroxyapatite (HA) is probably the most famous. 
HA is a naturally occurring mineral form of calcium apatite with the formula 
Ca5(PO4)(OH), but is usually written Ca10(PO4)6(OH)2 since the crystal unit cell comprises 
two entities. The hydroxyl ion can be replaced by fluoride, chloride or carbonate, producing 
other complexes. HA crystallizes in the hexagonal crystalline system [Fig. 1.16].  
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Figure 1.16 - Hexagonal crystalline structure of HA. 
 
HA can be found principally in bones within the human body. It is indeed well known that 
up to 50% by volume and up to 70% by weight of human bones is a modified form of HA. 
However also teeth and other structures are characterized by the presence of HA in their 
interior. Therefore, it is quite clear why HA-based engineered systems have been widely 
used in surgery, medicine and vaccinology. Many modern implants — e.g. dental implants, 
ocular implants and bone conduction inserts — are coated with HA and a lot of new 
biomedical HA-based devices are currently employed156–159. HA is even used as carrier for 
drugs160–163 and vaccines164 and this is a field of growing interest. Frontier research moreover 
tries to combine the proprieties of HA and nanoparticles in order to create particular crystals 
with dose-dependent antibacterial activity165. 
Since their importance as biomaterials, HA-based composites are constantly under study 
with the aim to develop methods for their green, rapid and efficient preparation and 
characterization. The most elegant approach consists in the self-assembly of calcium 
phosphates promoted by a HA binding peptide (HABP) fused with the enzyme which has to 
be immobilized in the HA-based support. Gungormus et al. studied several HABPs for the 
in vitro calcium phosphate biomineralization166 and later Wang et al. applied this approach 
in the synthesis of a specific vaccine164. 
W6p is an example of HABP. Its sequence RWRLEGTDDKEEPESQRRIGRFG is an 
acidic analog of the amino-terminal 15-residue fragment of salivary statherin and core motifs 
of dentin matrix protein 1 (DMP1), an acidic protein that can trigger indeed HA formation 
in vitro by binding calcium ions167. A standard protocol for the W6p promoted formation of 
HA consists in the mixing of the protein to be immobilized fused with W6p peptide, a soluble 
calcium salt, β-glycerophosphate (BGP) and alkaline phosphatase (ALP). ALP allows the 
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diffusion of calcium and the hydrolysis of BGP with the release of the phosphate, which 
interacts with calcium to form HA stabilized by the presence of W6p168. 
In summary, biomineralization mimicking approaches, such as entrapment in 
bioinspired silica matrix and formation of HA composites, potentially permits to create 
versatile and efficient systems of immobilized enzyme which can be used to design medical 
devices, bioinspired microreactors or even tools for supported drug discovery research. 
 
1.3. How to characterize bioconjugates and biomaterials 
The great interest towards different protein-based bioconjugates and bioinspired composites 
constantly pushes to the development of methods which integrate different techniques for a 
thorough characterization of these complex systems. In particular, when a protein is 
covalently bioconjugated to other molecules or macromolecules or immobilized onto/into a 
matrix, many questions are challenging: 
1. how much is the variation of the molecular weight (MW) due to the bioconjugation? 
2. is the protein folding maintained after functionalization/immobilization? 
3. which are the protein residues predominantly functionalized? 
4. which is the degree of functionalization of each bioconjugated protein residue? 
5. is it possible to selectively drive the bioconjugation? 
6. are there conformational modifications close to each bioconjugated protein residue? 
7. which is the morphology of the novel protein-based biomaterial? 
Several techniques have been used for answering to all these issues [Fig. 1.17]. This 
paragraph gives a brief overview about the most commonly used techniques, even focusing 
on their strengths and drawbacks. 
A preliminary characterization of a bioconjugate consists in the evaluation of the number 
of moieties which are attached to the target biomolecule, in other words the increasing of 
MW. Numerous techniques are used with this aim, the most simple and commonly of which 
is the polyacrylamide gel electrophoresis (PAGE), generally performed in denaturizing 
conditions by using sodium dodecyl sulfate (SDS) which helps to identify and isolate 
unfolded proteins and protein-based complexes. SDS-PAGE can actually provide just an 
initial and rough estimation of the MW of the bioconjugate. A very recent study, for instance, 
has used SDS-PAGE (coupled with silver staining phase) even to identify and separate 
carbon nanotube fragments after conjugation with lysozyme169. 
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Figure 1.17 - A general overview of techniques which can be employed in the characteri-
zation of bioconjugates and biomaterials. Black spheres contain the main issues about the 
study of these systems. 
 
More exhaustive information about MW of bioconjugates can be achieved using dynamic 
light scattering (DLS) and analytical gel filtration chromatography (analytical-GF). DLS is 
a physical technique used to determine the size distribution profile and hydrodynamic radius 
of small particles in suspension or polymers, molecules and macromolecules in solution170. 
Several examples are reported for the characterization of GNP-conjugates by DLS171,172. 
Alternatively analytical-GF is employed for a similar purpose173 even though it requires a 
previous calibration with standards with well defined MWs. A very late study has been 
carried out using this method: the viscosity radii and MWs of various PEG-proteins have 
been efficiently evaluated174. Jumel et al. instead performed a study of estimation of mean 
molecular masses of three different meningococcal C saccharide-protein conjugate vaccines 
using analytical-GF with multiangle laser light scattering (MALLS) detection175. 
Another technique routinely used in bioconjugate MW evaluation is mass spectrometry 
(MS), coupled with a specific ionization method, such as matrix-assisted desorption 
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ionization (MALDI-MS) or electrospray ionization (ESI-MS). MS can provide qualitative 
information about the MW of complex protein and peptide-based systems and sometimes it 
can also give structural evidences about the covalent linkage pattern176–182. MS is quite 
popular in the characterization of vaccines and glycovaccines and many studies involve MS 
as techniques combined with other several methods183–186. 
Despite their simplicity and immediate application in a first-step characterization, SDS-
PAGE, DLS, analytical-GF and MS are all techniques which give information only about 
the effectiveness of the bioconjugation and an estimation of the average number of 
functionalized sites of the conjugated protein by comparing the MWs of the protein before 
and after bioconjugation. However, this evaluation is strongly affected by polydispersion in 
bioconjugation, which needs more complex methods for its assessment. Additionally, the 
preservation of protein folding following the functionalization or immobilization in 
biomaterials cannot be assured, even if it is occasionally possible to observe differences in 
DLS profile and analytical-GF chromatogram between folded and unfolded systems. For this 
purpose, circular dichroism (CD) spectroscopy may be more informative and worthwhile. 
CD is essentially engaged to evaluate the presence of random coil, α-helix and β-strand 
regions of a given chiral system187. Slocik et al. for example used CD to characterize peptide-
functionalized GNPs with the aim to tune chiroptical proprieties of nanomaterials188. Azizi 
et al. instead studied the possibility to enhance the plasmonic CD signal of GNPs by 
attaching DNA-based linkers189, whereas Wangoo et al. capped GNPs with protein 
molecules and studied tertiary structure changes by CD spectroscopy190. In their integrated 
physicochemical characterization of glycoconjugated vaccines, Bardotti et al. exploited CD 
measurements to achieve carrier conformational analyses185. CD is therefore an effective 
technique to follow folding changes of proteins191, but the information that it can furnish 
regards only a global point of view, whereas residue-specific folding characterization cannot 
be achieved. 
Among other forms of spectroscopy, UV-Vis and fluorescence spectrophotometries are 
complementary techniques routinely used in protein characterization, although in 
bioconjugation and biomaterial preparation they can provide only limited information. In 
fact, UV-Vis protein profile at 280 nm does not alter after conjugation unless drastic changes 
in protein folding. However UV-Vis spectroscopy can be interestingly employed in the 
evaluation of the yield of immobilization of a specific enzyme onto a support by the 
measurement of the decreasing absorption in reaction solution192. UV-Vis spectroscopy 
becomes more informative whether the functionalization involves metal particles or 
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nanoparticles which absorb at different nanometers. The changes in absorption wavelength 
may indeed indicate the effects of bioconjugation: in literature some examples of 
functionalization with GNPs193, colloidal Al2O3194 or graphene195 and monitoring by UV-
Vis spectroscopy are reported.  
As regards fluorescence spectroscopy instead, this kind of technique can be remarkably 
used if the protein itself bears a fluorophore or if the bioconjugation introduces fluorophore 
moieties. This is the case of the attachment of the so-called quantum dots (QDs)196–198 or 
even fluorescent nanoclusters199. When the characterization exploits interactions between 
different fluorophores — eventually located both on the protein and the attaching molecule 
— Förster resonance energy transfer (FRET) principle can be applied in order to describe 
the structural distances between the QD center and the partners of the bioconjugate200,201. 
However, fluorescence can be exhibited even without strong fluorophores, and 
conformational changes due to conjugation can be detected. In the already cited paper of 
Bardotti et al., for example, fluorescence spectroscopy revealed conformational differences 
between the free and the conjugated CRM197 protein185. 
Therefore, CD, UV-Vis and fluorescence spectroscopies can give information 
concerning tertiary structure of proteins before and after functionalization. Nevertheless, 
none of them reaches a level of atomic details, thus impeding the assurance of maintenance 
of protein folding. Often, it is assumed that the preservation of the functionality of a 
bioconjugated/immobilized enzyme (assessed by diverse enzymatic assays) is a proof of 
preservation of protein folding, however this is not always strictly true. Therefore, other 
more powerful and parallel methods have to be implemented, e.g. X-ray scattering 
techniques. 
Among these, small-angle and wide-angle X-ray scattering (SAXS and WAXS) methods 
are very popular in biomaterial and nanoparticle-bioconjugate characterization202–205, in 
particular for the evaluation of averaged sizes, shapes, distribution and surface-to-volume 
ratios. These methods are accurate, non-destructive and usually requires only few operations 
in sample preparation. Sometimes deeper studies are carried out by combining SAXS and 
WAXS with their neutron counterpart techniques, in particular small-angle neutron 
scattering (SANS). Recently Spinozzi et al. indeed proposed a method for determining the 
thermodynamic and structural properties of nanoparticle-protein complexes by using both 
SAXS and SANS approaches206. However, the principal limitation of X-ray scattering 
techniques is correlated to the achievable resolution, which is not sufficient to get 
information at an atomic level. SAXS and WAXS, in fact, are mainly used to describe the 
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macroscopic morphology of biomaterials, but cannot furnish data about local structural 
changes due to functionalization or immobilization. Alternatively, X-ray diffraction (XRD) 
techniques can be used, but in this case crystal or crystal-like samples are required [Fig. 
1.18]. XRD is the core of X-ray crystallography, one of the most powerful and employed 
methods for the characterization of proteins207–209. Nevertheless, crystallization represents a 
bottleneck in the employment of XRD210, especially when systems that lack long range order 
are object of study. Some attempts to extend this technique to allow the imaging of 
noncrystalline materials, complexes and cells have been tried211, but no remarkable studies 
about large bioconjugates or even biomaterials carried out by X-ray crystallography have 
never been reported. 
 
 
Figure 1.18 - Schematic illustration of XRD diffraction principle for X-ray crystallography. 
 
Another group of techniques which can be used for structural analysis is constituted of 
electron microscopies, in particular transmission electron microscopy (TEM) and scanning 
electron microscopy (SEM), usually employed to record images of biomaterial morphology. 
In literature, some interesting materials have been characterized by these techniques — e.g. 
hydroxyapatite-composites212,213 — but again atomic resolution is rarely reached. For this 
reason, recently the cryogenic version of the electron microscopy (cryo-EM) has been 
becoming popular in structural biology studies214–217. Cryo-EM is indeed a promising tool 
which can compete with X-ray crystallography and nuclear magnetic resonance (NMR) 
spectroscopy since it can characterize biomolecular complexes across a wide MW range 
from proteins with several tens kiloDaltons to virus-particles, entire viruses and whole 
cells218,219, therefore potentially it can be exploited in the deep characterization of large, 
complex, disordered systems such as bioconjugates or whatever materials, even solving 
challenging questions, e.g. the evaluation of conjugation pattern in functionalized enzymes. 
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One of principal drawbacks in the use of cryo-EM is paradoxically opposite to the issues 
correlated to X-ray crystallography and solution NMR: the smaller the system, the harder 
the achievable resolution [Fig. 1.19]. Indeed cryo-EM studies concerning structure and 
dynamic of system below 100 kDa is still a challenge220. 
 
 
Figure 1.19 - Challenge in cryo-EM is to attain structures of small MW systems. [Image credits: ref. 220] 
 
On the contrary, a still developing and promising, versatile, complementary technique for 
the characterization of any kind of system — from simple proteins to bioconjugates and 
protein complexes, from small molecules to multifaceted biomaterials — is the NMR 
spectroscopy, in particular magic angle spinning (MAS) solid-state NMR (SSNMR) 
spectroscopy221. The strength of SSNMR-based methods relies on the possibility to achieve 
a very deep structural description and dynamic analysis of extremely large or complex 
systems222, such as protein assemblies223–225 and molecular machines226 [Fig. 1.20]. 
Moreover if applied on perdeuterated samples and coupled with ultra-fast MAS proton-
detection approaches227–234, MAS-SSNMR spectroscopy can be defined as one of the most 
powerful technique in structural and molecular biology. 
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Figure 1.20 - A landscape of SSNMR structures of diverse systems. [Image credits: ref. 221] 
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As widely shown in the former chapter, a lot of methods [Fig. 1.17] for functional and 
structural characterization of bioconjugates and biomaterials have been developed so far, 
combining techniques which provide integrated information1,2. However, atomic detailed 
studies of large or disordered multicomponent systems are problematic. During the three 
years of my PhD course, I focused on the development of an approach involving SSNMR 
spectroscopy as method of choice for the analysis of different bioconjugate systems and 
biomaterials, bearing recombinant proteins as the main component. Hence, this chapter 
concerns motivations and guide lines of my project and the description of two proteins used 
as models for my studies: Escherichia coli L-asparaginase II and human α-carbonic 
anhydrase 2. 
 
2.1. The aim 
Since their importance and variability of application, protein-based bioconjugates and 
biomaterials must undergo a detailed characterization, not only from a functional point of 
view but also structural. This is strictly needed especially when they are used as medical 
devices, drug or vaccine carriers and biocatalysts. 
Generally, the maintenance of the enzymatic activity after the bioconjugation or 
immobilization is rather simply assessed by chemical or biochemical assays, whereas 
structural characterization requires more and hard efforts. Indeed, when a protein is 
covalently bioconjugated to other molecules or macromolecules or immobilized onto/into a 
matrix, many questions are challenging: 
1. how much is the variation of the MW due to the bioconjugation? 
2. is the protein folding maintained after functionalization/immobilization? 
3. which are the protein residues predominantly functionalized? 
4. which is the degree of functionalization of each bioconjugated protein residue? 
5. is it possible to selectively drive the bioconjugation? 
6. are there conformational modifications close to each bioconjugated protein residue? 
7. which is the morphology of the novel protein-based biomaterial? 
Several techniques have been used for answering to all these issues (see paragraph 1.3), but 
many of them presents restraints of employment which often impede atomic detailed 
characterization. SSNMR instead is potentially applicable for this purpose. Therefore, the 
aim of my PhD project regarded the possibility to develop an approach for the structural and 
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functional characterization of bioconjugates and bioinspired composites of industrial and 
medical interest, based on SSNMR.  
The choice of SSNMR was due to two fundamental observations. 
1. Bioconjugates and, even more, biomaterials or bioinspired composites lack a long 
range order which prevents crystallization, making XRD inaccessible and therefore useless. 
Currently only an example of a bioconjugate structure solved by X-ray crystallography has 
been reported, i.e. PEG-plastocyanine3. This protein carriers a single PEG chain, and protein-
protein crystal contacts can still take place owing to the rather large distance between the 
PEG moieties. Except for this, no other studies showed crystal structures of large 
bioconjugates. 
2. Bioconjugation always increases the MW of the target. This has been widely 
studied for PEGylation which generally enhances the hydrodynamic volume more then an 
equal increase in protein MW would do4,5. Solution NMR therefore cannot be employed in 
this field since it strongly suffers in MW limitations. Exception are PEG-interferon6 and, 
again, PEG-plastocyanine3, where the protein size remains quite small. Of course, an 
additional hindrance regards the insolubility of biomaterials, such as biosilica-based systems 
and HA-composites, which cannot be obviously studied in solution. 
While the employment of XRD and solution NMR is limited in the field of 
bioconjugation and bioinspired material science, SSNMR might represent an alternative and 
efficient approach, because it does not strictly require crystalline samples. SSNMR has been 
already applied for the structural characterization of several samples7 and does not suffer 
from the MW limitations. Thus, a SSNMR-based approach integrated, when possible, with 
other techniques, was employed not only to assess the protein folding after functionalization 
(e.g. PEGylation and glycosylation) or immobilization (e.g. HA-composites), but also to: 
• evaluate the conjugation pattern in glycoconjugates, since polydispersity is one of 
the most crucial issues in the design of glycovaccines, 
• characterize GNP-grafted proteins, even trying to achieve for the first time a 
resonance assignment of a protein conjugated onto nanoparticles, 
• monitor protein-ligand interactions using matrix-entrapped enzymes, therefore 
opening to the possibility of a novel drug discovery methodology. 
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2.2. Protein models 
In order to develop a SSNMR-based method for the detailed structural characterization of 
bioconjugates and biomaterials of numerous interests, two protein systems were chosen: 
Escherichia coli L-asparaginase II and human α-carbonic anhydrase 2. Both enzymes show 
very good characteristics in terms of their medical interest and spectral features. 
 
2.2.1. Escherichia coli L-asparaginase II (ANSII) 
Escherichia coli L-asparaginase II (ANSII) is an enzyme that catalyzes the hydrolysis of L-
asparagine to L-aspartic acid with the release of ammonia [Fig. 2.1]. 
 
 
Figure 2.1 - Reaction of hydrolysis of L-asparagine to L-aspartic acid with the release of ammonia. 
 
This enzyme is a complex of four identical subunits, each of them of about 34.6 kDa (326 
amino acids). Each subunit consists of two α/β domains connected by a linker. According to 
the crystal structure8 [Fig. 2.2], the tetramer belongs to the D2 point group and can be 
considered a dimer of two identical intimate dimers. 
 
 
Figure 2.2 - Crystal structure of ANSII (PDB: 3ECA). 
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The catalytic site sits at the interface of each couple of intimate dimers for a total of four 
catalytic sites per tetramer. Threonine-12 is known to have an important catalytic role as 
observed by the loss of enzymatic activities of the T12A mutant9. Viceversa, other residues, 
such as histidines, threonine-119 and serine-122, are functionally less fundamental but are 
crucial in binding the substrate10,11. 
When expressed, ANSII bears a 22-mer signal peptide [Fig. 2.3] which is then cut after 
delivering the protein towards periplasmic space. The efficiency of secretion is such that not 
only recombinant ANSII but also some other engineered constructs are overexpressed with 
the ANSII signal peptide to promote their ejection towards periplasm12,13 and facilitate the 
extraction from cells. 
 
 
Figure 2.3 - Amino acid sequence of ANSII. The signal peptide is reported in red. 
 
The medical interest for ANSII was born during 1960s when it was found that this enzyme 
could have effects against lymphoma, leukemia and other malignant neoplasms14–23. In 
particular, several medical formulations of ANSII are still currently used for the treatment 
of acute lymphoblastic leukemia (ALL) in children. The antitumor activity of ANSII is 
correlated to its effect in depletion of L-asparagine. In normal cells [Fig. 2.4a] circulatory 
L-asparagine is hydrolyzed into L-asparatic acid which is pumped inside the cell and then 
reconverted into L-asparagine destined to protein synthesis by the action of asparagine 
synthase. Tumor cells instead [Fig. 2.4b] lack asparagine synthase, thus they are forced to 
use directly exogenous L-asparagine for the protein synthesis. However, whether they are 
treated with ANSII-based drug [Fig. 2.4c], L-asparagine level is drastically depressed and 
tumor cells head for apoptosis. 
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Figure 2.4 - Schematic representation of the action of ANSII. (a) Health cells (blue circle) use 
ANSII to covert L-asparagine (L-Asn) into L-aspartic acid (L-Asp) which can be delivered inside 
the membrane and reconvert to L-Asn by asparagine synthase. (b) Tumor cells (red circle) 
instead employ directly (bold black arrow) circulatory L-Asn since they lack asparagine 
synthase. (c) If a ANSII-based drug (black square) is administered, the depletion of circulatory 
L-Asn (grey font) causes the apoptosis of the cell (dot red circle). 
 
Several medical preparations of ANSII were or are commercially available. Colaspase is the 
British Approved Name (BAN) for the native ANSII used as drug, marketed with trade 
names such as Elspar or Kidrolase. Recently a new formulation of ANSII is sold in UE with 
the name Spectrilia. Not only Escherichia coli derived asparaginase is used in the treatment 
of ALL: Crisantaspase, for example, is the BAN of Erwinia chrysanthemi homolog, mainly 
commercialized in USA and Canada with the trade name Erwinase. However, since 1990s, 
Pegasparaginase — a 5 kDa PEG coated ANSII formulation — is mainly used as drug. Its 
trade name is Oncaspar and is sold in UE, USA and Canada as injectable solution. As already 
described in the previous chapter, PEGylation of an enzyme is achieved in order to reduce 
immunogenicity24. 
Considering its relevance as biological drug and the quality of the NMR spectra 
collected in solution and at the solid state, ANSII was chosen as a model for several studies 
concerning my PhD project. In the frame of my PhD project, PEGylated formulation of 
ANSII was prepared and structurally characterized by SSNMR. No atomic details had never 
been reported indeed for the PEGylated enzyme. ANSII was also used to prove that it is 
possible to use SSNMR to characterize at atomic detail proteins grafted onto PEGylated gold 
nanoparticle. In the wake of this purpose, ANSII underwent glycosylation too. In this case 
the attempt was to develop a NMR-based method for the characterization of the conjugation 
pattern in a large saccharide-protein bioconjugate, a crucial aspect in the design of 
glycovaccines25–27. Finally, ANSII was chosen even for the design of HA-based bioinspired 
microreactor. Side effects due to the treatment with Colaspase, Crisantaspase and 
Pegasaspargase are well known28–30, thus a radically different strategy could be to avoid 
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contact with the immune system of the patient. A medical device containing immobilized 
ANSII could be used to process blood without injecting the enzyme in circulation and 
reducing the drawbacks of the direct assumption of the drug. With this aim in mind, a 
structural characterization of a such designed biomaterial is demanding and an integrated 
approach involving EM, XRD and SSNMR was developed. 
 
2.2.2. Human α-carbonic anhydrase 2 (hCAII) 
Carbonic anhydrases are a large group of enzymes present in numerous organisms and 
microorganisms. Families β, γ, δ and ζ are mainly found in bacteria, whereas family α is 
characteristic of vertebrates, included humans. In particular, the isoform 2 is one of the 
sixteen human forms of α-carbonic anhydrase and it is located in cytosol. Like the other 
forms, human α-carbonic anhydrase 2 (hCAII) catalyzes reversible hydration of carbon 
dioxide with formation of bicarbonate [Fig. 2.5], a reaction which would occur too slowly 
on the physiological time scale. 
 
 
Figure 2.5 - Reversible hydration of carbon dioxide CO2 to bicarbonate. 
 
The enzyme is constituted of 260 amino acids [Fig. 2.6] with a molecular weight of about 
29.2 kDa. A crystalline structure is known since 198831 [Fig. 2.7] and an NMR assignment 
of 1H, 13C and 15N resonances is available32. 
 
 
Figure 2.6 - Amino acid sequence of hCAII. Histidines 94, 96 and 119 (in red) 
participate in the coordination of zinc ion in the catalytic site. 
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Figure 2.7 - Crystal structure of hCAII (PDB: 1CA2). 
 
hCAII is actually a metalloprotein: the native form indeed bears a zinc ion in the catalytic 
site which is essential for its enzymatic activity. The metal shows a tetrahedral geometry in 
which three histidines (His94, His96 and His119) and a water molecule form the 
coordination sphere33. However, for research reasons, zinc ion is often removed by using 
chelating reagents (e.g. dipicolinic acid)34 and the apo form is then remetalated with different 
metal ions35 such as copper36–39 and cobalt40–43. This kind of replacement — which can lead 
also to changes in coordination of the metal center — is generally exploited to better study 
the interaction of hCAII with diverse ligands, understand the kinetics of the enzymatic 
mechanism44 or to fine tune methodologies for structural and functional characterization41, 
even based on paramagnetic proprieties of some of those metals40. 
The importance of hCAII relies anyway on its variegated applications45–47. Immobilized 
hCAII has an industrial relevance48, especially for CO2 sequestration49–51, and its esterase 
activity can have biotechnological uses52. hCAII finally shows a typical attitude to bind a lot 
of organic ligands, which can act as inhibitors or activators of the enzymatic activity, making 
hCAII itself a very good candidate for therapeutic applications53,54. hCAII is indeed found 
to be overexpressed in several pathologies, therefore it is an interesting target for drug 
development55 and medicinal chemistry56. 
This last aspect is strictly linked to one of the aims of my PhD project: the possibility to 
develop a SSNMR-based method employed to detect the interaction between an immobilized 
enzyme with its ligands. hCAII was chosen as target enzyme and two different sulfonamide 
ligands have been tested: the weaker sulpiride and the stronger furosemide [Fig. 2.8]. This 
approach could be a proof of concept that also immobilized enzymes — which can be 
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potentially washed from ligands after every study — might be used for protein-based 
SSNMR protein-ligand interactions for drug discovery. 
 
 
Figure 2.8 - Sulpiride and furosemide are two known sulfonamide ligands of hCAII. 
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The present chapter describes all the experimental procedures for the production of ANSII 
and hCAII, the two proteins used as models for my PhD project. Then, protocols for their 
functionalization and/or immobilization is reported, in particular PEGylation, GNP-
conjugation and glycosylation of ANSII, silica entrapment of hCAII and formation of 
ANSII-HA-composite. Enzymatic, biophysical and NMR characterization of the proteins 
before and after modification is showed too. 
 
3.1. Materials and methods - ANSII 
Samples of ANSII with different isotopic labeling patterns were prepared, e.g. not labeled 
ANSII (nl-ANSII), 13C and 15N uniformly labeled ANSII ([U-13C,15N] ANSII), 13C and 15N 
uniformly labeled ANSII bearing perdeuterated C-H bonds, ([U-2H,13C,15N] ANSII) and not 
labeled ANSII bearing perdeuterated C-H bonds, except for lysine residues which are 
protonated and 13C and 15N-labeled ([U-2H, Lys-1H,13C,15N] ANSII). The protocol for the 
expression was adapted according to the medium used for the different labelings. ANSII 
samples then underwent different bioconjugation reactions, here described. 
 
3.1.1. Expression, extraction and purification 
E. coli C41(DE3) cells were transformed with pET-21a(+) plasmid encoding ANSII (with 
the signal peptide). Different culture media, always supplied with 0.1 mg mL-1 ampicillin 
sodium salt, were used for the expression of differently isotopic labeled ANSII and different 
expression approaches were employed [Fig. 3.1]. 
For the expression of nl-ANSII, transformed cells were inoculated into 10 mL LB medium. 
After shaking at 37°C overnight, the preculture was poured in 1 L LB fresh medium which 
was let again shake at 37°C until OD600 nm reached 0.6. The culture was then induced with 
750 µM IPTG, shaken at 25°C overnight and pelleted by centrifugation at 7500 rpm for 15 
minutes. 
For the expression of [U-13C,15N] ANSII, a Marley-like method1 was applied. Transformed 
cells were indeed inoculated in 10 mL LB medium and the preculture was incubated at 37°C 
for 8 hours under shaking, then 100-fold scaled up and kept on shaking at 37°C overnight. 
The culture was centrifuged at 4000 rpm for 20 minutes at 4°C, then the harvested pellet was 
resuspended in 1 L M9 minimal medium, supplied with 2.0 mM MgSO4, 0.2 mM CaCl2, 3.0 
g 13C-D-glucose and 1.2 g 15N-ammonium sulfate. After one hour of shaking at 37°C, the 
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culture was induced with 750 µM IPTG, let shake at 25°C for 5 hours and pelleted by 
centrifugation at 7500 rpm for 15 minutes. 
Regarding the expression of [U-2H,13C,15N] ANSII, transformed cells were inoculated into 
10 mL 2H, 13C, 15N-enriched Silantes OD2 medium. After shaking at 37°C overnight, the 
preculture was scaled up to 1 L of the same enriched medium which was let again shake at 
37°C until OD600 nm reached 0.6. The culture was then induced with 750 µM IPTG, shaken 
at 25°C overnight and pelleted by centrifugation at 7500 rpm for 15 minutes. 
For the expression of [U-2H, Lys-1H,13C,15N] ANSII, transformed cells were inoculated into 
10 mL 2H-enriched Silantes OD2 medium. After shaking at 37°C overnight, the preculture 
was scaled up to 1 L of the same enriched medium, supplied with 1.25 mM 13C,15N-L-lysine 
(Sigma-Aldrich). The culture was let shake at 37°C until OD600 nm reached 0.6, then induced 
with 750 µM IPTG, shaken at 25°C overnight and pelleted by centrifugation at 7500 rpm for 
15 minutes. 
 
 
Figure 3.1 - Different strategies for the expression of differently isotopic labeled ANSII. 
 
Despite the expression protocol, all samples of ANSII were extracted and purified in the 
same way. In particular, the cellular pellet was resuspended in 10 mM Tris-HCl, pH 8.0, 15 
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mM EDTA, 20% w/V sucrose buffer (60 mL per liter of culture). The suspension was stirred 
at 4°C for 20 minutes, then centrifuged at 10000 rpm for 30 minutes. The supernatant was 
discarded, whereas the pellet redissolved in H2O milli-Q (30-60 mL per liter of culture) and 
incubated at 4°C for 20 minutes under stirring. The mixture was again centrifuged at 10000 
rpm for 30-60 minutes. The pellet was discarded, while the supernatant was treated with 
solid ammonium sulfate, which was added slowly under stirring at 4°C until reaching 50% 
of saturation. The precipitate was collected by centrifugation and then discarded, whereas 
the supernatant similarly treated with solid ammonium sulfate until reaching 90% of 
saturation. This time, the supernatant was discarded, while the precipitate was redissolved 
in a minimal amount of 20 mM Tris-HCl, pH 8.6 buffer. The solution was dialyzed against 
4 L of 20 mM Tris-HCl, pH 8.6 buffer, which was refreshed once after a night. ANSII was 
further purified by anionic exchange chromatography using a HiPrep 16/10 Q FF column 
(GE Healthcare) which was preliminary equilibrated with 20 mM Tris-HCl, pH 8.6 buffer. 
The sample was loaded onto the column at 3 mL min-1. After washing with 3 CV of binding 
buffer, the protein was eluted with a 0-300 mM NaCl gradient in 15 CV. 5 mL fractions were 
collected and then checked by Coomassie staining SDS-PAGE gels. Fractions containing 
the protein were joined and concentrated down to 3 mg mL-1. An additional purification was 
achieved by size-exclusion chromatography using a HiLoad Superdex 75 pg column (GE 
Healthcare). The protein was eluted in 150 mM NaPi, pH 7.5 buffer. Fractions of pure 
protein were joined and the solution stored at 4°C. 
The yield of ANSII production depended on the expression procedure: 20-25 mg per liter of 
culture for nl-ANSII, 30-35 mg per liter of culture for [U-13C,15N] ANSII, 45 mg per liter of 
culture for [U-2H,13C,15N] ANSII and [U-2H, Lys-1H,13C,15N] ANSII. 
 
3.1.2. Crystallization 
Crystallization of ANSII was achieved by using sit-drop vapor diffusion approach. Several 
buffers were screened by testing other reported conditions for the crystallization of wild-
type ANSII and some mutants2–4. For XRD studies nl-ANSII was used, whereas for SSNMR 
[U-13C,15N] and [U-2H,13C,15N] ANSII were employed. ANSII solution in 100 mM MES-
NaOH, pH 6.5 buffer was concentrated down to 1 mM, then each well of 24-well plate was 
filled with 5 µL of protein sample and 5 µL of 100 mM MES-NaOH, pH 6.5, 25% V/V PEG-
MME 550, 10 mM ZnSO4, which was used also as reservoir buffer (800 µL per well). The 
plate was sealed and stored at 20°C and crystals [Fig. 3.2] were formed in a week. 
 
	
76	
	
 
Figure 3.2 - ANSII crystal pictures 
 
3.1.3. PEGylation 
PEGylation reaction of [U-13C,15N] ANSII was performed using MS(PEG)24 (ThermoFisher 
Scientific) as PEGylating reagent [Fig. 3.3]. A 120 µM protein solution in 150 mM NaPi, 
pH 7.5 buffer was incubated at 4°C under magnetic stirring, then an amount of a 250 mM 
MS(PEG)24 in DMF was added (20 times the moles of the protein). The solution was kept 
stirring at 4°C overnight, then the effectiveness of the reaction was evaluated by Coomassie 
staining SDS-PAGE. The reaction mixture was washed with 2 mM Tris-HCl, pH 8.0 buffer 
by cyclical concentration-redilution steps using a 10K Amicon Centrifugal Device 
(Millipore).  
 
 
Figure 3.3 - MS(PEG)24 structure (MW = 1214.396 Da) 
 
3.1.4. GNP-conjugation 
GNP-conjugation of [U-2H,13C,15N] ANSII was performed with GNPs with core size of 5 
nm functionalized with 5 kDa PEG chains and bearing NHS-ester (~1 NHS group/nm2) 
(Cytodiagnostics). Protein Re-suspension Buffer (PRSB), Reaction Buffer (RB) and 
Quencher Solution (QS) were provided in the 5 nm NHS-Activated GNP conjugation kit 
(Cytodiagnostics). The protocol was modulated in order to optimize the protein loading, 
avoid protein-mediate GNPs aggregation and minimize the amount of protein needed for the 
reaction. 200 μL of 20 mg mL-1 [U-2H,13C,15N] ANSII solution in 150 mM NaPi, pH 7.5 
buffer were diluted with PRSB, then further diluted up to 900 µL with RB. The solution was 
split in ten 90 µL aliquots which were directly transferred in ten vials containing lyophilized 
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NHS-activated GNPs. The reaction mixtures were immediately mixed by pipetting, 
incubated at room temperature for 2 hours, then quenched with 10 µL (per vial) of QS. All 
the reaction mixtures were joined, then the whole reaction product was washed from the 
unreacted protein by multistep washings using a 100K MWCO microsep advance centrifugal 
device (Pall Corporation). Three concentration-redilution washings were performed using 2 
mM Tris-HCl, pH 8.0 buffer until all the unreacted protein was removed, as checked by an 
SDS-PAGE gel. 
 
3.1.5. Glycosylation 
Glycosylation of nl-, [U-13C,15N], [U-2H,13C,15N] and [U-2H, Lys-1H,13C,15N] ANSII was 
achieved using the meningococcal serogroup C capsular polysaccharide (MenC CPS) 
glycosylating reagent, terminally activated with an NHS ester [Fig. 3.4], provided by GSK 
Vaccines (Siena, Italy). 
 
 
Figure 3.4 - MenC CPS glycosylating reagent structure. 
 
An about 30 µM protein solution in 100 mM NaPi, pH 7.2 buffer underwent the reaction 
with the MenC CPS glycosylating reagent, added in a large excess (12-fold molar ratio) in 
respect to ANSII. The reaction mixture was therefore incubated overnight at room 
temperature under stirring, then the occurrence of the reaction was evaluated by Coomassie 
staining SDS-PAGE. The conjugate was purified by size-exclusion chromatography using a 
HiLoad Superdex 75 pg column (GE Healthcare). The conjugate was eluted in 150 mM 
NaPi, pH 7.5 buffer. Fractions were joined and the solution of pure glycosylated ANSII 
buffer exchanged to 2 mM Tris-HCl, pH 8.0 buffer by cyclical concentration-redilution steps 
using a 10K Amicon Centrifugal Device (Millipore). 
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3.1.6. UV-Vis spectroscopy 
The free or functionalized ANSII concentrations in solution were always achieved by UV-
Vis spectroscopy using a Varian Cary 50 UV-Vis Spectrophotometer (Agilent) implemented 
with Cary WinUV software. Absorbance profile in the range of 250-350 nm was recorded 
and the value at 280 nm was used for the estimation of protein amount. The molar extinction 
coefficient at 280 nm was 23505 M-1 cm-1 as calculated by the on-line ExPASy - ProtParam 
tool. In each experiment, a baseline correction was applied by acquiring a spectrum of the 
blank. 
 
3.1.7. Analytical-GF chromatography  
Analytical-GF chromatography of free and PEGylated ANSII was performed using a 
Superdex 200 HR 10/300 column (GE Healthcare) connected to an ÄKTA pure 25 L system 
(GE Healthcare) equipped with a LED-based UV absorption detector. Elutions were 
performed at 0.5 mL min-1 with 50 mM Tris-HCl, pH 7.5, 10 mM NaCl buffer. Aldolase 
(158 kDa) and conalbumin (75 kDa) from LMW Gel Filtration Calibration Kit (GF 
Healthcare) were used as standards. Data were recorded and processed using UNICORN 6.3 
software. 
Analytical-GF chromatography of free and glycosylated ANSII was instead performed using 
a TSK 3000GelSW column with TSKguard column (Tosoh Bioscience) connected to an 
Ultimate TM3000 HPLC system (Dionex-ThermoFisher Scientific) equipped with a PDA 
detector. Chromatography was performed at 0.5 mL min-1 with 100 mM NaPi, pH 7.2, 5% 
CH3CN buffer. Data were recorded and processed using Chromeleon 6.7 software. 
 
3.1.8. DLS analysis  
DLS analyses of free and PEGylated ANSII were performed using a coupled method 
involving SEC and multi-angle laser light scattering (MAALS) detection. The system was 
composed of several modules: 
• an HPLC system (Knauer) equipped with a Superdex 200 HR 10/300 column (GE 
Healthcare) and a Optilab rEX interferometric refractometer detector (Wyatt 
Technology Corp.) for monitoring dRI elution profiles, 
• a quasi-elastic light scattering (QELS) module for RH measurements, 
• a DAWN EOS MAALS module set at 690 nm for scattering evaluation. 
100 µL of 5-10 mg mL-1 sample solutions were injected onto the column, previously 
equilibrated with 50 mM Tris-HCl, pH 7.5, 10 mM NaCl buffer. The sample was eluted at 
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0.5 mL min-1 for a volume of column. Data were acquired and processed using the ASTRA 
5.4.3 software (Wyatt Technology Corp.) which recorded dRI and scattering profiles and 
estimated MWs and hydrodynamic radii. 
 
3.1.9. Solution NMR samples and experiments  
All samples for solution NMR experiments were prepared in 20 mM NaPi, pH 7.5 buffer 
supplied with 0.02% NaN3, 0.1 mg mL-1 4-(2-aminoethyl)benzenesulfonyl fluoride 
(AEBSF) and 10% D2O with a protein concentration range of 0.5-1.0 mM. 1H-detected 
spectra were recorded at 310 K on Bruker AVANCE III HD NMR spectrometers operating 
at 900 or 950 MHz proton Larmor frequencies, equipped with a triple resonance cryoprobes. 
13C-detected spectra instead were acquired at 310 K on Bruker AVANCE spectrometer 
operating at 700 MHz proton Larmor frequency, equipped with a triple resonance cryoprobe 
optimized for 13C-direct detection. 
Samples and solution NMR experiments are reported in the table below: 
 
Sample Labeling List of 
1H-detected 
experiments 
List of 13C-detected 
experiments 
free ANSII [U-2H,13C,15N] 
• 1D 1H 
• 2D 1H-15N tr-HSQC 
• 3D tr-HNCA 
• 3D tr-HNCACB 
• 3D tr-HNCO 
• 3D tr-HN(CA)CO 
• 3D 1H-15N NOESY-TROSY 
• 2D 13C-13C NOESY 
• 2D 13C-15N CON 
• 2D 13C-15N CACO 
• 2D 13C-15N CBCACO 
glycosylated ANSII [U-2H,13C,15N] • 1D 1H 
• 3D tr-HNCA 
• 3D tr-HNCACB 
- 
PEGylated ANSII [U-2H,13C,15N] • 2D 13C-13C FLOPSY 
free ANSII [U-2H, Lys-1H,13C,15N] • 1D 
1H 
• 2D 1H-15N tr-HSQC 
• 3D 1H-15N NOESY-TROSY 
• 3D 1H-1H-1H NOESY-NOESY 
- 
glycosylated ANSII [U-2H, Lys-1H,13C,15N] 
 
3.1.10. SSNMR samples and experiments  
SSNMR experiments were acquired using alternatively spectrometers operating at 850 MHz 
proton Larmor frequency, equipped with 3.2 or 1.3 mm DVT MAS probe heads in triple 
resonance mode (working temperature ~280 K, conditions A) or at 800 MHz proton Larmor 
frequency, equipped with a 3.2 or 1.3 mm E-free HCN probehead (working temperature 
~291 K, conditions B). When a 1.3 mm rotor was used, MAS was set at 60 kHz, whereas 3.2 
mm rotors were spun at 14 kHz. 
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In detail, crystals of free [U-13C,15N] and [U-2H,13C,15N] ANSII were collected from the 
plate wells and introduced respectively in a 3.2 and 1.3 mm zirconia rotors using suitable 
ultracentrifugal devices. Rotors were sealed with plugs. Spectra of crystalline ANSII were 
recorded at conditions A. 
Free ANSII was characterized also in its frozen-dried formulation. In particular, a solution 
containing [U-2H, Lys-1H,13C,15N] ANSII was frozen with liquid N2 and lyophilized. A 3.2 
mm rotor was filled with the powder and then re-hydrated by addition of aliquots of water 
until reaching good intensity and resolution of the peaks in the 1D {1H}-13C CP spectrum. 
This experiment and following 2D spectra were recorded at conditions B. 
Analogous procedures for preparation and spectra acquisition were applied for PEGylated 
and glycosylated [U-13C,15N] ANSII, but in this case conditions A was applied. 
As in the case of crystalline [U-2H,13C,15N] ANSII, proton-detected experiments for the 
assignment were acquired for PEGylated and GNP-conjugated [U-2H,13C,15N] ANSII. Again 
solutions of these preparations were frozen with liquid N2 and lyophilized, and then the 
powders were used to fill 1.3 mm zirconia rotors. Again, water was added in order to restore 
intensity and intensity of peaks. Conditions A were used for PEGylated sample, whereas 
conditions B for GNP-conjugated sample. 
Finally, a glycosylated [U-2H, Lys-1H,13C,15N] ANSII solution was frozen with liquid N2 
and lyophilized. The powder was used to completely fill a 3.2 mm rotor and again a titration 
with water was carried out to increase the resolution and the signal intensity of 1D {1H}-13C 
CP spectrum, acquired at conditions B. The same setup was then used to acquire 2D spectra. 
All samples and SSNMR experiments are reported in the table below. In blue experiments 
acquired at conditions A are reported, in green at conditions B: 
 
Sample Labeling List of 
1H-detected 
experiments 
List of 13C-detected 
experiments 
free crystalline ANSII [U-13C,15N] - 
• 1D {1H}-13C CP 
• 2D 13C-13C DARR 
• 2D 15N-13C NCO 
PEGylated ANSII [U-13C,15N] - 
• 1D {1H}-13C CP 
• 2D 13C-13C DARR 
• 2D 15N-13C NCO 
• 2D 15N-13C NCA 
• 3D NCACX 
• 3D CANCO 
glycosylated ANSII [U-13C,15N] - 
• 1D {1H}-13C CP 
• 2D 13C-13C DARR 
• 2D 15N-13C NCO 
• 2D 15N-13C NCA 
• 3D NCACX 
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free crystalline ANSII [U-2H,13C,15N] 
• 2D 1H-15N CP-HSQC 
• 3D (H)CONH 
• 3D (H)CO(CA)NH 
• 3D (H)CANH 
• 3D (H)CA(CO)NH 
• 3D (H)(CA)CB(CA)NH 
• 3D (H)(CA)CB(CACO)NH 
• 1D {1H}-13C CP 
PEGylated ANSII [U-2H,13C,15N] • 2D 
1H-15N CP-HSQC 
• 3D (H)CANH • 1D {
1H}-13C CP 
GNP-conjugated ANSII [U-2H,13C,15N] 
• 1D 1H NOESY 
• 2D 1H-15N CP-HSQC 
• 2D 1H-13C plane of 3D (H)CANH 
• 2D 1H-13C plane of 3D (H)CONH 
• 1D {1H}-13C CP 
free lyophilized ANSII [U-2H, Lys-1H,13C,15N] 
- 
• 1D {1H}-13C CP 
• 2D 13C-13C DARR 
• 2D 15N-13C NCA glycosylated ANSII [U-2H, Lys-1H,13C,15N] 
 
3.2. Materials and methods - ANSII-HABP 
For the studies of HA composite containing ANSII, a recombinant ANSII construct fused 
with the W6p HA binding peptide (hereafter ANSII-HABP) was cloned and then expressed. 
ANSII-HABP was enzymatically and structurally characterized before and after the 
immobilization in HA.  
 
3.2.1. Cloning 
The multiple cloning site (MCS) of pET-21a(+) plasmid [Fig. 3.5a] was removed using XbaI 
and XhoI restriction enzymes and sequentially replaced with a DNA sequence encoding for 
(a) a His6 tag, (b) a TEV protease cleavage site, (c) a W6p HABP sequence, (d) a thrombin 
protease cleavage site, (e) a new MCS containing NdeI and BamHI restriction enzyme sites, 
(f) a second W6p HABP sequence, (g) a STOP codon, obtaining a new plasmid named 
pET21-HABP [Fig. 3.5b]. Successively ANSII sequence (with its preceding signal peptide) 
was cloned between NdeI and BamHI restriction enzyme sites [Fig. 3.5c]. 
Subcloning standard approaches involving restriction enzymes for digestion and ligases 
for cloning were used to produce all plasmids, whose sequences were then confirmed by 
DNA sequencing. 
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Figure 3.5 - Schematic representation of (a) pET-21a(+) plasmid and (b) pET21-HABP plasmid. 
pET21-HABP containing ANSII sequence (c) is also reported. Restriction enzyme sites are 
indicated by arrows. Bold lines instead correspond to MCS. 
 
3.2.2. Expression, extraction and purification 
ANSII-HABP expression, extraction and purification protocol was adapted from the one 
used for simple ANSII. Since the signal peptide is cleavage during the secretion towards 
periplasm, even if the plasmid construct contained two W6p peptides, the final expressed 
construct had only one HABP [Fig. 3.6]. 
 
 
Figure 3.6 - Schematic representation of the expressed recombinant ANSII-HABP construct 
before (a) and after (b) secretion towards periplasm. 
 
E. coli C41(DE3) cells were transformed with pET21-HABP plasmid encoding ANSII-
HABP. Transformed cells were inoculated into 10 mL LB medium supplied with 0.1 mg 
mL-1 ampicillin sodium salt. After shaking at 37°C overnight, the preculture was poured in 
1 L LB fresh medium, again supplied with ampicillin, which was let again shake at 37°C 
until OD600 nm reached 0.6. The culture was then induced with 750 µM IPTG, shaken at 25°C 
overnight and pelleted by centrifugation at 7500 rpm for 15 minutes. The pellet was 
resuspended in 10 mM Tris-HCl, pH 9.5, 15 mM EDTA, 20% w/V sucrose buffer (60 mL 
per liter of culture). The suspension was stirred at 4°C for 20 minutes, then centrifuged at 
10000 rpm for 30 minutes. The supernatant was discarded, whereas the pellet redissolved in 
H2O milli-Q (30-60 mL per liter of culture) and incubated at 4°C for 20 minutes under 
stirring. The mixture was again centrifuged at 10000 rpm for 30-60 minutes. The pellet was 
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discarded, whereas the supernatant was treated with solid ammonium sulfate, which was 
added slowly under stirring at 4°C until reaching 30% of saturation. The precipitate was 
collected by centrifugation and then discarded, whereas the supernatant similarly treated 
with solid ammonium sulfate until reaching 90% of saturation. This time the supernatant 
was put apart, while the precipitate was redissolved in a minimal amount of 20 mM Tris-
HCl, pH 9.5 buffer. The solution was dialyzed against 4 L of 20 mM Tris-HCl, pH 9.5 buffer, 
which was refreshed once after a night. ANSII was further purified by anionic exchange 
chromatography using a HiPrep 16/10 Q FF column (GE Healthcare) which was preliminary 
equilibrated with 20 mM Tris-HCl, pH 9.5 buffer. The sample was loaded onto the column 
at 3 mL min-1. After washing with 3 CV of binding buffer, the protein was eluted with a 0-1 
M NaCl gradient in 30 CV. 5 mL fractions were collected and then checked by Coomassie 
staining SDS-PAGE gels. Fractions containing the protein were joined and concentrated 
down to 3 mg mL-1. A further purification was achieved by size-exclusion chromatography 
using a HiLoad Superdex 75 pg column (GE Healthcare). The protein was eluted in 25 mM 
Tris-HCl, pH 7.5 buffer. Fractions of pure protein were joined and the solution stored at 4°C. 
The overall yield of purified protein was about 35 mg L-1. 
 
3.2.3. HA/ANSII-HABP composite formation 
The preparation of HA/ANSII-HA composite was achieved by using a biomimetic 
biomineralization reaction adapted from already optimized protocols5–7. In a vial, a 0.4 mM 
solution of ANSII-HABP in 25 mM Tris-HCl, pH 7.4 buffer was supplied with 24.0 mM of 
any soluble calcium salt and 14.4 mM of BGP. Then 1.4 µg mL-1 of ALP were added and 
the reaction mixture was incubated at 37°C for 24 hours. The suspension was centrifuged at 
10000 rpm for 15 minutes. Then, the supernatant was removed and the pellet washed with 
milli-Q water by cyclical resuspension and centrifugation. 
 
3.2.4. UV-Vis spectroscopy 
The concentrations of free ANSII-HABP in solution or HA/ANSII-HABP composite in 
suspension were always achieved by UV-Vis spectroscopy using a Varian Cary 50 UV-Vis 
Spectrophotometer (Agilent) implemented with Cary WinUV software. Absorbance profile 
in the range of 250-350 nm was recorded and the value at 280 nm was used for the estimation 
of protein amount. The molar extinction coefficient at 280 nm was 23505 M-1 cm-1 as 
calculated by the on-line ExPASy - ProtParam tool. In each experiment, a baseline correction 
was applied by acquiring a spectrum of the blank. 
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3.2.5. DLS analysis  
DLS analysis of ANSII-HABP in solution was performed using a coupled method involving 
SEC and multi-angle laser light scattering (MAALS) detection. The system was composed 
of several modules: 
• an HPLC system (Knauer) equipped with a Superdex 200 HR 10/300 column (GE 
Healthcare) and a Optilab rEX interferometric refractometer detector (Wyatt 
Technology Corp.) for monitoring dRI elution profiles, 
• a quasi-elastic light scattering (QELS) module for RH measurements, 
• a DAWN EOS MAALS module set at 690 nm for scattering evaluation. 
100 µL of differently concentrated ANSII-HABP samples (4.1, 8.2 and 20.5 mg mL-1) were 
injected onto the column, previously equilibrated with 24 mM Tris-HCl, pH 7.4. The sample 
was eluted at 0.5 mL min-1 for a volume of column. Data were acquired and processed using 
the ASTRA 5.4.3 software (Wyatt Technology Corp.) which recorded dRI and scattering 
profiles and estimated MWs and hydrodynamic radii. 
 
3.2.6. Enzymatic activity measurements 
Enzymatic activities of free ANSII-HABP and HA/ANSII-HABP composite were evaluated 
by Nessler’s reagent assay. Nessler’s reagent is a 2.5 M KOH solution containing 90 mM 
K2[HgI4] which reacts with ammonium ions to form a yellow complex that absorbs at 436 
nm [Fig. 3.7]. 
 
 
Figure 3.7 - Nessler’s reagent reaction. 
 
ANSII converts L-asparagine to L-aspartic acid, releasing ammonia in solution, which, in 
presence of Nessler’s reagent, stoichiometrically turns to the yellow complex which can 
quantitatively measured by UV/Vis spectroscopy. 
For each single test, 2 mL of 10 mM L-asparagine solution in 25 mM Tris-HCl, pH 8.6 buffer 
was incubated at 37°C for 10 minutes, then 100 µL of sample (solution of ANSII-HABP or 
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suspension of HA/ANSII-HABP composite) with a suitable protein concentration were 
added. The mixture was incubated at 37°C for 30 minutes, then treated with 100 µL of 1.5 
M trichloroacetic acid (TCA) to stop the reaction. For the black, instead adding 100 µL of 
sample before 30 minute incubation, 100 µL of the enzyme were added after treatment with 
TCA. Calibration curves were built by repeating the same procedures but adding known 
amount of (NH4)2SO4 in the initial L-asparagine solution. 
Once treated with TCA, 200 µL of reaction mixture were diluted up to 4.5 mL with milli-Q 
water, then 500 µL of Nessler’s reagent were added. After 60 seconds of incubation, 
absorbance measurements at 436 nm were acquired at RT using a Varian Cary 50 UV-Vis 
Spectrophotometer (Agilent) implemented with Cary WinUV software. Data were always 
collected in triplicate, then plotted using Microsoft Excel software. 
 
3.2.7. Enzyme kinetics by solution NMR 
Solution NMR experiments for the evaluation of the enzyme kinetics of ANSII-HABP and 
HA/ANSII-HABP composite were carried out at 310 K on Bruker AVANCE NMR 
spectrometers equipped with triple-resonance cryoprobes and operating at the proton Larmor 
frequency of 700 and 900 MHz. 
Samples containing 9.45 mM L-asparagine in 25 mM Tris-HCl, pH 7.4 buffer supplied with 
10% D2O were treated with (1) a solution of ANSII-HABP (545 nM final protein 
concentration in the NMR tube) or (2) a suspension of HA/ANSII-HABP composite (16 µM 
final protein concentration). Immediately repeated 1D 1H spectra were acquired over the 
time and variation in intensity of Hα and Hβ proton signals of L-asparagine was monitored.  
 
3.2.8. SSNMR analysis 
SSNMR experiments for the characterization of HA/ANSII-HABP (whose pellet was used 
to fill a 4.0 mm rotor) were achieved using a Bruker Avance III spectrometer operating at 
500 MHz proton Larmor frequency, equipped with a 4 mm MAS VTN probe. The MAS 
frequency was adjusted to 10 kHz. Several 1D and 2D experiments were carried out: 
• 1D 1H Bloch decay (BD) and window phase-modulated-Lee-Goldburg (wPMLG) 
experiments, 
• 1D 13C CP measurements, 
• 1D 31P CP measurements, 
• 2D 1H-31P heteronuclear correlation (HETCOR) spectrum. 
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3.3. Materials and methods - hCAII 
Two differently labeled samples of hCAII were produced. Both underwent silicification, 
here described. Free and silica-entrapped not labeled hCAII (nl-hCAII) was used to 
accomplish enzymatic assays, whereas free 13C and 15N uniformly labeled hCAII ([U-
13C,15N] hCAII) was employed for backbone assignment in solution. Immobilized [U-
13C,15N] hCAII was finally used for SSNMR studies of interaction with inhibitors. 
 
3.3.1. Expression, extraction and purification 
E. coli BL21(DE3) Codon Plus RIPL cells were transformed with pCAM plasmid encoding 
hCAII. A Marley-like protocol was employed for the expression1; all following expression 
media were supplied with 0.100 mg mL-1 ampicillin sodium salt and 0.034 mg mL-1 
chloramphenicol. Transformed cells were inoculated in 10 mL LB medium and the 
preculture was incubated at 37°C for 8 hours under shaking, then 100-fold scaled up and 
kept on shaking at 37°C overnight. The culture was centrifuged at 4000 rpm for 20 minutes 
at 25°C, then the harvested pellet was resuspended in another medium: 
• 1 L of LB for the expression of nl-hCAII, 
• 1 L of M9 supplied with 2.0 mM MgSO4, 0.2 mM CaCl2, 3.0 g 13C-D-glucose and 
1.2 g 15N-ammonium sulfate for the expression of [U-13C,15N] hCAII. 
After 30 minutes of shaking at 37°C, 0.5 mM ZnSO4 were added to the culture which was 
then induced with 1.0 mM IPTG, let shake at 37°C for 5 hours and pelleted by centrifugation 
at 7500 rpm for 15 minutes. The pellet was resuspended in 20 mM Tris-sulfate, pH 8.0, 0.5 
mM ZnSO4 buffer (100-200 mL per liter of culture). Cell disruption was performed on ice 
by sonication, alternating 30 seconds of pulses and 5 minutes of resting for 10 cycles. The 
suspension was ultracentrifuged at 40000 rpm for 30 minutes at 4°C. The residual pellet was 
discarded, whereas the supernatant, containing crude hCAII, was purified by nickel affinity 
chromatography, using a 5 mL HisTrap HP column (GE Healthcare) which was preliminary 
equilibrated with 20 mM Tris-sulfate, pH 8.0, 0.5 mM ZnSO4 buffer. The sample was loaded 
onto the column at 5 mL min-1. After washing with 10 CV of binding buffer, the protein was 
eluted with a 0-500 mM imidazole gradient in 30 CV. Fractions containing purified hCAII 
were identified by Coomassie staining SDS-PAGE gels, then joined and concentrated down 
to 10 mg mL-1. A further purification was achieved by size-exclusion chromatography using 
a HiLoad Superdex 75 pg column (GE Healthcare). The protein was eluted in 10 mM 
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HEPES-NaOH, pH 7.2 buffer. Fractions of pure hCAII were joined and the solution stored 
at 4°C. The overall yield of purified protein was about 250 mg L-1. 
 
3.3.2. Silicification 
The silicification of hCAII was performed in 10 mM HEPES-NaOH, pH 7.2 buffer (reaction 
buffer), using poly-L-lysine (PLL) as promoter, according to a previous protocol8. 400 µL 
of 40 mg mL-1 hCAII in the reaction buffer and 100 µL of 10 mg mL-1 PLL (MW of 4000-
15000 rpm) were mixed in a 1.5 mL vial, incubated at RT for 10 minutes under shaking, 
then 500 µL of 100 mM Si(OH)4 solution were added and the mixture was left for further 10 
minutes at RT to react. The white pellet was harvested by centrifugation at 14000 rpm for 5 
minutes, then it was washed with 10 mM HEPES-NaOH, pH 7.2 buffer by cyclical 
resuspension and centrifugation. 
Note - 100 mM Si(OH)4 solution was prepared by dilution with H2O milli-Q of a 1 M stock, 
which was freshly prepared by hydrolysis of 150 µL of pure tetramethyl orthosilicate 
(TMOS) with 850 µL of 1 mM HCl solution. 
 
3.3.3. UV-Vis spectroscopy 
The free or immobilized hCAII concentrations in solution were always achieved by UV-Vis 
spectroscopy using a Varian Cary 50 UV-Vis Spectrophotometer (Agilent) implemented 
with Cary WinUV software. Absorbance profile in the range of 250-350 nm was recorded 
and the value at 280 nm was used for the estimation of protein amount. The molar extintion 
coefficient at 280 nm was 50420 M-1 cm-1 as calculated by the on-line ExPASy - ProtParam 
tool. In each experiment, a baseline correction was applied by acquiring a spectrum of the 
blank. 
 
3.3.4. Enzymatic activity measurements 
Enzymatic activity of free and immobilized hCAII was evaluated by exploiting the enzyme-
promoted conversion of p-nitrophenol acetate (PNPA) to p-nitrophenoxide (PNP) and 
monitoring the formation of PNP (yellow colored) by measuring its absorbance at 410 nm 
[Fig. 3.8]. 
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Figure 3.8 - Since its esterase activity, Zn(II)-hCAII promotes the hydrolysis of PNPA to 
PNP which exhibits a strong absorbance at 410 nm. 
 
Each test was performed on a 555 µM solution of nl-hCAII in 40 mM NaPi, pH 7.5 buffer. 
Free hCAII was simply concentrated down or dilute to the designated concentration, whereas 
immobilized hCAII was resuspended in an amount of buffer such that the concentration was 
555 µM in term of protein fraction. 900 µL of the sample (either the free or silica-entrapped 
protein) were mixed with 0.5 mM PNPA solution in CH3CN and transferred in a plastic 
cuvette. Immediately, absorbance measurements at 410 nm were acquired at RT using a 
Varian Cary 50 UV-Vis Spectrophotometer (Agilent) implemented with Cary WinUV 
software. Data were collected every 15 seconds for 60 minutes. Measurements were repeated 
three times, then plotted using Microsoft Excel software. 
 
3.3.5. Solution NMR samples and experiments 
For the backbone assignment, solution NMR experiments were performed on a Bruker DRX 
500 spectrometer equipped with a triple-resonance cryoprobe. A 0.4 mM [U-13C,15N] hCAII 
sample in 20 mM HEPES, pH 7.5 buffer supplied with 0.02% NaN3, protease inhibitors and 
10% D2O was prepared and a set of spectra were acquired at 310 K, in particular 3D HNCA, 
3D HNCO, 3D HN(CA)CO, 3D HNCACB, and 3D CBCA(CO)NH. 
 
3.3.6. SSNMR samples and experiments 
For the characterization and evaluation of hCAII-ligand interactions, SSNMR experiments 
on the immobilized [U-13C,15N] hCAII were performed with a Bruker AvanceIII HD 
spectrometer operating at 800 MHz proton Larmor frequency, equipped with a 3.2 mm E-
free HCN probehead. All spectra were acquired at ~291 K and MAS frequency was set at 14 
kHz. All data were processed with the Bruker TopSpin 3.2 software package and analyzed 
with the program CARA (ETH Zürich). 
The pellet of silica-entrapped [U-13C,15N] hCAII was used to fill a 3.2 zirconia rotor using 
an ultracentrifugal device as formerly reported9–11. The rotor was then sealed with silicon 
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plugs (courtesy of Bruker Biospin) to preserve hydration12. Two different spectra were 
acquired: 2D 15N-13C NCA13 and 2D 13C-13C DARR14. 
The interaction with furosemide was studied by the addition of a inhibitor solution directly 
inside the rotor containing immobilized [U-13C,15N] hCAII. A 2D 15N-13C NCA spectrum 
was again recorded with the same setup of the not inhibited sample, except for the number 
of scans which was set to 1216. For the interaction of sulpiride, instead, the sample of 
furosemide-inhibited hCAII sample was removed from the rotor and washed with 10 mM 
HEPES-NaOH, pH 7.2 buffer by cyclical resuspension and centrifugation. The pellet was 
suspended in a sulpiride solution and then re-introduced into the rotor. Finally a 2D 15N-13C 
NCA spectrum was acquired with the same parameters. 
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This chapter describes all studies and results regarding my PhD project which focused on 
the characterization of bioconjugates and protein-based biomaterials of medical, research 
and industrial interest, as largely explained in chapters 1 and 2. The first three paragraphs 
concern three different bioconjugation approaches applied on ANSII and the successive 
structural analysis achieved by SSNMR and integrated methodologies. Paragraph 4.4 instead 
focuses on the formation and studies of a HA composite containing again ANSII with the 
perspective to develop a biomimetic microreactor. Finally, paragraph 4.5 describes how 
SSNMR can be even used to develop a strategy for protein-ligand interaction studies using 
an immobilized protein (i.e. hCAII). 
 
4.1. Characterization of PEGylated ANSII 
The first part of my PhD project was aimed to prove that SSNMR is a powerful, versatile 
and reliable method for the characterization of PEGylated proteins which are widely used as 
drugs in the treatment of many diseases. PEGylation indeed produces reduced clearance, 
increased stability and limited immunogenic response1,2. In particular, I dealt with ANSII 
which is a well-known drug used for the treatment of acute lymphoblastic leukemia (ALL) 
in children. Nowadays ANSII is marketed in its PEGylated formulation, Pegaspargase3 
(trade name: Oncaspar) but its atomic detailed characterization had never been reported 
because it does not crystallize, impeding the use of X-ray crystallography, and has a too large 
size for solution NMR. 
I started working on PEGylated ANSII primarily fine tuning the conditions for the E. coli 
expression of the recombinant ANSII encoded in a pET-21a(+) plasmid. I tested five 
different cell strains — BL21(DE3), BL21(DE3) Gold, BL21(DE3) C41p Rosetta, 
BL21(DE3) CodonPlus RIPL and C41(DE3) — and I found out that C41(DE3) cell strain 
was the best for a larger yield of expression. Therefore I expressed, extracted and purified 
samples of ANSII, as widely described in chapter 3.  
It is well known that the active form of ANSII is a dimer of intimate dimers with a MW of 
about 138.4 kDa. Thus, it was essential to assess that the expressed recombinant protein was 
effectively a tetramer. Analytical-GF and DLS analysis were carried out on a nl-ANSII 
sample. The elution volume of ANSII was found in between the peaks of two standards with 
a known MW, aldolase (158 kDa) and conalbumin (75 kDa) [Fig 4.1]. This proved that the 
protein was not a monomer. A more trustworthy result was also achieved by the DLS 
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analysis which allowed to estimate an average MW of 1.389 ･ 105 g mol-1, consistent with 
the weight of a tetramer [Fig. 4.2a]. 
 
 
Figure 4.1 - Analytical-GF chromatograms of ANSII (red), PEGylated ANSII (black), aldolase (violet) 
and conalbumin (green) performed with a Superdex 200 HR 10/300 column. Samples were eluted at 0.5 
mL min-1 with a 50 mM Tris-HCl, pH 7.5, 10 mM NaCl buffer. 
 
 
Figure 4.2 - DLS analyses of (a) ANSII and (b) PEGylated ANSII. The average MW of the samples 
was estimated with the ASTRA 5.4.3 software implemented with the DLS workgroup. 
 
Assessed the tetrameric structure of the protein, nl-ANSII was then used to screen 
crystallization conditions using a sitting drop vapor diffusion technique. More than 20 
crystallization buffers were tested and finally I found that 100 mM MES-NaOH, pH 6.5 
buffer containing 25% PEG-MME 550 and 10 mM ZnSO4 as precipitating agents was the 
best. In these conditions crystals appeared after a week of incubation at 20°C. 
With this preliminary results in hand, I moved to express [U-13C,15N] ANSII in a M9 
minimal medium, slightly modifying the expression conditions as reported in chapter 3. [U-
13C,15N] ANSII samples were used either to prepare crystals and to perform the PEGylation 
reaction. 
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PEGylation of [U-13C,15N] ANSII was achieved using MS(PEG)24 [Fig. 3.3], an amino-
reactive methyl-PEG reagen containing 24 ethyleneglycol units. Each attached unit had a 
MW of about 1100 Da, differently from 5000 Da PEG chains which are usually used to 
functionalize ANSII in the commercial Pegaspargase. The choice of a shorter PEGylating 
reagent was due to the necessity to have a larger protein/PEG ratio in the samples to be 
characterized by SSNMR. The success of PEGylation was proved by SDS-PAGE [Fig. 4.3]. 
From the gel it was possible to get a preliminary rough estimation of the number of PEG 
chains attached to the protein. Since the electrophoresis was performed in denaturing 
conditions, the bands before and after PEGylation corresponded to monomeric structures. In 
particular, before PEGylation the monomer of ANSII had a MW of about 35 kDa as 
expected, whereas after PEGylation the band was spread around 45 kDa. This meant that 
about 8-9 PEG chains were attached per monomer of ANSII. 
 
 
Figure 4.3 - SDS-PAGE gel with ANSII samples before and after PEGylation. 
 
In order to evaluate whether a tetrameric structure was maintained after PEGylation and to 
better estimate the increasing of MW due to the attachment of PEG chains onto the ANSII 
surface, again analytical-GF and DLS analyses were performed and compared with the ones 
carried out on native free ANSII. Analytical-GF showed that PEG-ANSII had a larger MW 
than aldolase (158 kDa) [Fig. 4.1]. Also the DLS result was consistent, since the average 
MW of the PEGylated protein was 1.709 ･ 105 g mol-1 [Fig. 4.2b]. By comparing the MW 
of the tetrameric free ANSII and the PEGylated ANSII, it was possible to count about 28-29 
PEG chains per tetramer, or rather 7-8 PEG chains per monomer, confirming the rough 
estimation achieved by SDS-PAGE [Fig. 4.3]. 
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However, a detailed structural characterization of PEGylated ANSII was achieve by 
SSNMR. Samples of free crystalline [U-13C,15N] ANSII and PEGylated [U-13C,15N] ANSII 
were both studied and compared in order to verify if the structural integrity of the protein 
was preserved after the functionalization. SSNMR experiments for both samples were 
performed at 850 MHz proton Larmor frequency spectrometer at ~282 K under 14 kHz 
MAS. 3.2 mm rotors were used. 
Crystals of free ANSII were simply transferred into the rotor, which was sealed with silicon 
plugs to preserve hydration. A 2D 13C-13C DARR spectrum was acquired and turned out to 
be of very good spectral resolution [Fig. 4.5a]. 
The solution containing PEGylated [U-13C,15N] ANSII was frozen with liquid N2 and then 
lyophilized. The powder was used to fill a 3.2 mm rotor. A reference 1D {1H}-13C CP 
spectrum was acquired but its resolution was not good [Fig. 4.4a]. In order to restore 
resolution, small aliquots of water were added inside the rotor until a good quality of the 
monodimensional spectrum was reached [Fig. 4.4b]. Re-hydration of freeze-dried materials 
for SSNMR studies is a well known approach applied for the first time by Kennedy et. al. 
on another protein4. 
 
 
Figure 4.4 - 1D {1H}-13C CP spectra of freeze-dried PEGylated [U-13C,15N] 
ANSII (a) before and (b) after re-hydration. 
 
Successively a 2D 13C-13C DARR spectrum of PEGylated protein was acquired [Fig. 4.5b]. 
The first observation was that even in this case a very good quality of the spectrum both in 
terms of intensity and resolution was achieved, showing the power of SSNMR as technique 
for an atomic detailed study of PEGylated proteins. The second observation, even more 
crucial, was correlated to the maintenance of protein folding after PEGylation. The spectra 
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of the pelleted PEGylated ANSII and the crystalline native protein were indeed largely 
superimposable [Fig. 4.5c], thus demonstrating for the first time a negligible effect of PEG 
coating on protein structure and assembly. In particular, preservation of chemical-shift (CS) 
patterns of well-resolved isoleucine residues indicates and intact hydrophobic core. Even 
extracting 1D traces from the 2D 13C-13C DARR a remarkable superimposition was evident 
[Fig. 4.6]. 
 
 
Figure 4.5 - 2D 13C-13C DARR spectra of native crystalline ANSII (a) and PEGylated ANSII 
(b), acquired at ~282 T, at 850 MHz, MAS = 14 kHz. (c) Superimposition of the two spectra. 
 
 
Figure 4.6 - 1D traces of (a) 11.0 ppm and (b) 61.4 ppm rows of the 2D 13C-13-C DARR spectra 
of crystalline (red) and PEGylated (blue) ANSII. 
 
The preservation of structural integrity of ANSII after PEGylation was also demonstrated by 
comparing 2D 15N-13C NCO spectra of the native and functionalized protein [Fig. 4.7]. Even 
this kind of experiment turned out to be informative and of good quality. 
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Figure 4.7 - 2D 15N-13C NCO spectra of crystalline free ANSII (red) 
and PEGylated ANSII (blue). 
 
The very good quality of the spectra also made it possible to acquire 3D spectra for 
assignment [Fig. 4.8]. Since almost all carbon atoms could be observed with simple uniform 
13C and 15N labeling, and assignment does not need to rely upon extensive mutagenesis 
and/or selective labeling, SSNMR was expected to lift the limitations for the study of 
PEGylated biologics. Here this was indeed demonstrated for ANSII (and other two proteins, 
human Cu(II)-Zn(II) superoxide dismutase 1 and human H ferritin), but potentially this 
approach could be potentially extended to all PEGylated (or in generally, bioconjugated) 
proteins. 
 
 
Figure 4.8 - 3D CANCO and NCACX spectra acquired for PEGylated ANSII. 
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4.2. Characterization of a ANSII-GNP conjugate 
A further progress in my PhD project regarded the formulation and characterization of a 
nanoparticle-based bioconjugate. In particular, ANSII grafted onto PEGylated GNPs. As 
already explained, the development of a methodology for the structural characterization at 
atomic detail of proteins conjugated to nanoparticles would be a breakthrough in 
nanotechnology and a SSNMR-based approach turned out to be one of the best strategy to 
evaluate protein folding maintenance and local changes and effects after conjugation with 
GNPs. 
For this study I expressed, extracted and purified a sample of triple labeled protein — here 
indicated as [U-2H,13C,15N] ANSII — adapting the protocol for the production of nl-ANSII. 
A 2H, 13C, 15N-enriched Silantes OD2 medium was used and the overall yield of the purified 
protein was 45 mg per liter, even more than the yield of expression in LB medium (around 
20-25 mg per liter). Successively ANSII-GNP conjugate was synthesized starting from 
commercially available PEGylated GNPs with a core size of 5 mm. The protocol of 
bioconjugation was modulated from Cytodiagnostic as described in chapter 3. Once the 
ANSII-GNP was formed, the reaction mixture was washed from the unbound protein using 
a suitable device. After three washings, all unreacted ANSII was discarded [Fig. 4.9], 
whereas the solution containing the conjugate was frozen with liquid N2 and lyophilized. 
 
 
Figure 4.9 - SDS-PAGE gel of [U-2H,13C,15N] ANSII. Line 1 - pure protein 
before conjugation reaction with GNPs; Line 2 - protein marker (kDa); 
Line 3 - unbound protein after first washing; Line 4 - unbound protein after 
second washing; Line 5 - unbound protein after third washing 
 
Lyophilized ANSII-GNP was used to fill a 1.3 mm rotor. Because the small quantity of the 
sample, re-hydration was achieved by a direct and single addition of water before sealing the 
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rotor, in an amount which was evaluated to be proportional if compared to the other 
lyophilized samples. The restoring of resolution was assessed by acquiring a proton 
monodimensional version of a 2D 1H-15N CP-HSQC experiment. Even in this case, the 
spectrum appeared of good quality, therefore a detailed characterization could be possible. 
The 1D 1H NOESY spectrum of ANSII-GNP showed a large group of signals in the region 
between 6.8 and 10.5 ppm, and one very intense peak around 3.6 ppm [Fig. 4.10]. The CS 
values in the 6.8-10.5 ppm range are typical for protein amide protons, while the intense 
peak observed at 3.6 ppm nicely matched with the methylene signals of the PEG forming 
the coating of the investigated nanoparticles. The large CS dispersions of the amide protons 
and the presence of signals downfield of 8.5 ppm were positive markers of the protein folding 
and prompted the application of heteronuclear correlation experiments. 
 
 
Figure 4.10 - 1D 1H NOESY SSNMR spectrum acquired on the ANSII-GNP 
sample using a spectrometer operating at 800 MHz proton Larmor frequency, at 
~282 K and MAS of 60 kHz. The top panel displays an enlargement, with a 
different intensity scale, of the region between 6 and 12 ppm, where the protein 
amide protons resonate. 
 
The 2D 1H-15N CP-HSQC SSNMR spectrum of ANSII-GNP [Fig. 4.11, panel 1] was of very 
good quality, and comparable to the corresponding spectra collected on PEGylated ANSII 
and on the crystalline preparation of the free ANSII [Fig. 4.12]. In the three spectra, the 
resonances were largely superimposable, immediately demonstrating that the native three-
dimensional structure of the protein was preserved after the conjugation with the 
nanoparticles. Furthermore, the spectra were sufficiently resolved so that 184 signals over a 
total of 224 visible cross-peaks could easily be assigned [Fig. 4.13] by comparison with the 
spectra of both the crystalline and PEGylated ANSII for which assignment is available 
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(unpublished data) and by the analysis of the 1H-13C planes of 3D (H)CANH and 3D 
(H)CONH spectra acquired on the ANSII-GNP [Fig. 4.11, panels 2 and 3]. 
 
 
Figure 4.11 - 2D 1H-15N CP-HSQC SSNMR spectrum (panel 1) and 2D 1H-13C 
planes of the 3D (H)CANH (panel 2) and 3D (H)CONH (panel 3) spectra obtained 
from ANSII-GNP. The experiments were acquired on a spectrometer operating at 
800 MHz proton Larmor frequency, at ~282 K and MAS of 60 kHz. 
 
 
Figure 4.12 - 2D 1H-15N CP-HSQC SSNMR spectrum of ANSII-GNP (black) 
superimposed with the spectrum of crystalline ANSII (red) (a) and PEGylated ANSII 
(blue) (b). The superimposition of the spectra of crystalline and PEGylated ANSII is also 
reported (c). The spectrum of ANSII-GNP was acquired on a 800 Mhz spectrometer, 
while the spectra of crystalline and PEGylated ANSII were acquired on a 850 MHz 
spectrometer. All the spectra were recorded at ~282 K and MAS of 60 MHz. 
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Figure 4.13 - Cartoon representation of tetrameric ANSII with highlighted in 
magenta the assigned residues in the 2D 1H-15N CP-HSQC SSNMR spectrum of 
ANSII-GNP. The three C2 symmetry axes defining the D2 symmetry are displayed 
as black lines on the protein structure. 
 
The local effects of conjugation with the PEGylated GNPs were investigated by observing 
the differences in CS of the resonances in the spectra of ANSII collected at the solid state 
for the different protein preparations. The CS perturbation (CSP) analysis of the 2D 1H-15N 
CP HSQC spectrum of ANSII-GNP [Fig. 4.14] revealed that the largest variations involved 
the residues located on the protein surface or on loops. This finding is not surprising because 
the effect of packing forces in the crystalline free ANSII, and the chemical modifications in 
PEGylated ANSII involved residues at the protein surface. For most of the residues the CS 
values of ANSII conjugated to GNP are in better agreement with those of the PEGylated 
ANSII than with the crystalline free protein, and this remarked the similarity between PEG-
conjugated samples. Interestingly, the CS variations were larger for PEGylated ANSII, 
consistently with a lower level of conjugation of the lysine residues on the protein grafted 
onto the PEGylated GNPs. In the PEGylated sample 7-8 lysine residues were conjugated on 
average, as showed in the previous paragraph, whereas virtually only a single one of the 19 
exposed lysine residues at a time was reacted to the PEG-coated GNP. 
In summary, once more SSNMR disclosed to be a good tool also for the studies on protein-
based nanoparticle bioconjugates. It was indeed demonstrated that highly resolved 
heteronuclear spectra can be recorded and assigned to obtain structural information at atomic 
detail and this new evolution of the NMR methodology opens new frontiers for the 
development of the structure-based strategies applied to nanoparticles and potentially to all 
nanomaterials functionalized with proteins. 
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Figure 4.14 - CSP of PEGylated ANSII (a) and ANSII-GNP (b) with respect to the crystalline 
prepration and between ANSII-GNP and PEGylated ANSII (c), according to the reported 
formula: 
∆𝛿 = 12 ∆𝛿&' + ∆𝛿)5 ' 
The residues experiencing the highest perturbation are highlighted in red. 
 
4.3. Characterization of glycosylated ANSII 
Still in the context of development of strategies for the structural characterization of 
bioconjugates, my PhD project moved to another kind of conjugation methodology, the 
glycosylation. As widely showed in the introductive chapter, glycosylation is crucial for 
instance in the design of glycovaccines5–9 and a deep study in terms of either structure and 
efficiency is always demanding. Two aspect are fundamental: the preservation of protein 
folding after functionalization (as already investigate in the previous paragraphs) and the 
evaluation of degree of conjugation. In fact, glycosylation of an immunogenic protein (and 
in general, bioconjugation of a target) may lead to a highly random derivatization: the protein 
can be glycosylated at different sites and to different extents at each site (conjugation pattern) 
and this in turn leads to a polydispersity in the resulting protein conjugates [Fig. 4.15]. 
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Figure 4.15 - Schematic representation of the polydispersity in the population of a protein 
(green surface) with generic attaching moieties (white spheres). The steric hindrance 
(represented by red curves) of the already bound moieties prevents further conjugation of 
the surrounding reactive residues. 
 
This part of my work was aimed to fine tune an NMR-based strategy to achieve a conjugation 
pattern estimation in a large polysaccharide-protein conjugate. Even if ANSII is not an 
immunogenic protein, it was anyway chosen because of its favorable medical and spectral 
features. On the other hand, the capsular polysaccharide obtained from the meningococcal 
serogroup C was selected as sugar moiety in the conjugate. The polysaccharide is a 
homopolymer of α2-9-linked N-acetyl-neuraminic acid (NeuNAc) with partial O-acetylation 
at position C7 and C8. The reagent used for the attachment of meningococcal serogroup C 
capsular polysaccharide (MenC CP) was designed with an adipic acid linker and a reactive 
NHS ester [Fig. 3.4]. 
In order to primarily verify that glycosylation did not affect protein folding, a sample of [U-
13C,15N] ANSII was expressed, extracted and purified, then underwent functionalization with 
MenC CP glycosylating reagent. The success of the reaction was proved by SDS-PAGE 
[Fig. 4.16a]. The gel showed a significant increasing of the MW and, as expected, a 
distribution of different species with different sizes. This result was also confirmed by 
analytical-GF [Fig. 4.16b]. 
 
 
Figure 4.16 - (a) SDS-PAGE gel of ANSII (lines 1-2) before and (lines 3-4) after conjugation 
with MenC CP. (b) Analytical-GF of ANSII and ANSII-MenC CP conjugate (blue) carried out 
with a TSK 3000GelSW column in 100 mM NaPi, pH 7.2, 5% CH3CN buffer. 
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The sample of [U-13C,15N] ANSII-MenC CP conjugate was frozen with liquid N2 and 
lyophilized. As usual, the powder was introduced in a 3.2 mm rotor e re-hydrated by addition 
of water until an acceptable resolution of 1D {1H}-13C CP spectrum was reached4. The 
experiment was performed at 850 MHz under 14 kHz of MAS rate. In the same conditions, 
a 2D 13C-13C DARR SSNMR spectrum was acquired and compared with the one of 
crystalline free [U-13C,15N] ANSII [Fig. 4.17]. The superimposition of the two spectra 
demonstrated that also in this case (as already observed for PEGylation and nanoparticle 
conjugation) the protein folding was preserved. 
 
 
Figure 4.17 - (a) 2D 13C-13C DARR SSNMR spectrum of ANSII-MenC CP conjugate. (b) 
Superimposition of the DARR spectra between the conjugate (red) and crystalline ANSII (blue). 
The two regions separated by dashed lines are plotted with different relative intensities for the 
two forms to ease comparison between the spectra.   
 
The high resolution of the DARR spectrum allowed also to acquire 3D experiments, e.g. 3D 
NCACX [Fig. 4.18], which helped to reassign the resonances of the protein residues, starting 
from the assigment of the native form of ANSII. In this case, the experiment was performed 
at 800 MHz, still under 14 kHz of MAS rate. 
Nevertheless, the spectral overlap due to the large number of protein resonances did not 
allow for a straightforward identification of the lysine resonances. Therefore, selective 
labeling with 1H, 13C, and 15N labeled lysine residues was applied in an otherwise 
perdeuterated not 13C and 15N labeled protein backbone. I modified the protocol used for the 
production of triple labeled ANSII, employing a 2H-enriched Silantes OD2 medium doped 
with an excess of 13C and 15N labeled lysine to produce [U-2H, Lys-1H,13C,15N] ANSII. [U-
2H, Lys-1H,13C,15N] ANSII was studied both by solution and SSNMR, either before and after 
conjugation with MenC CP. Combining all results, it was possible to get information about 
the conjugation pattern. 
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Figure 4.18 - 3D NCACX spectrum of ANSII-MenC CP conjugate. 
 
First of all, a 2D 1H-15N TROSY-HSQC solution NMR spectrum was acquired for free [U-
2H, Lys-1H,13C,15N] ANSII, at 310 K and 950 MHz [Fig. 4.19a]. The spectrum displayed 18 
HN signals out of the 22 expected signals for the backbone HN of the lysine residues present 
in the protein sequence. All the visible signals (18) could be assigned from the previous 
spectra collected on sample of [U-2H,13C,15N] ANSII (unpublished data). The selective 
labelling strategy allowed to solve some assignment ambiguities and the assignment of  
backbone HN lysine signals was extended from 15 to 18 spin systems with respect to the 
assignment achieved on the “simple” triple labeled protein. However, three of the lysine 
residues (K44, K51 and K229) — whose signals were missing in the spectrum — were 
located on highly flexible regions of the protein and the fourth (K323) on a α-helix inside 
the hydrophobic core of the three-dimensional structure of the protein. The assignment of 
the protons of the lysine side-chains (Hα, Hβ, Hγ, Hδ and Hε) was instead obtained from the 
analysis of the 3D 1H-15N NOESY and 1H-1H-1H NOESY-NOESY solution NMR spectra 
of the free ANSII (unpublished data). 
Even after conjugation with MenC CP, a 2D 1H-15N TROSY-HSQC spectrum was acquired, 
again at 310 K and 950 MHz [Fig. 4.19b]. The profile of the spectrum dramatically changed: 
all peaks visible for free ANSII disappeared, whereas a group of new intense and shifted 
peaks appeared. These new signals corresponded to the amide groups generated by 
functionalization of the ε-amino group of lysines (Hζ-Nζ) with the MenC CP. The 
assignment of Hζ-Nζ cross-peaks was obtained for 7 lysine residues (K71, K101, K208, 
K218, K251, K273 and K310). It was achieved from the correspondence in the 3D 1H-1H 
NOESY spectra between the Hα, Hβ and Hγ CSs of the NOE cross-peaks of each H couple 
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with the proton CSs assigned for each H-N backbone couple from the spectra of free ANSII 
(unpublished data).  
 
 
Figure 4.19 - 2D 1H-15N TROSY-HSQC spectra of [U-2H, Lys-1H,13C,15N] ANSII, acquired at 
310 K and 950 MHz, (a) before and (b) after conjugation with MenC CP. The assignment of 
lysine residues is displayed. For spectrum (a) the peaks correspond to backbone H-N, whereas 
for spectrum (b) the overlapped signals correspond to side-chain Hζ-Nζ. 
 
The changes in the TROSY-HSQC spectrum after the functionalization were explained by 
the increase of MW and hydrodynamic volume which prevented the detection of H-N signals 
of the backbone. Simultaneously the appearance of Hζ-Nζ signals was a marker which could 
provide information on the number of lysine which were functionalized. The intensity of 
these signals was also thought to be correlated to the degree of functionalization, but the 
overlap of the signals and the intrinsic dynamic which could affect the intensity itself made 
the evaluation of the conjugation pattern difficult by the sole solution NMR approach. For 
this reason, it was necessary to move to SSNMR. 
Both samples of free and glycosylated [U-2H, Lys-1H,13C,15N] ANSII were frozen with 
liquid N2 and dried by lyophilization. The powders were used to fill 3.2 mm zirconia rotors 
and again re-hydration was performed until reaching a good resolation of 1D {1H}-13C CP 
spectrum, then 2D experiments were performed. All 1D and 2D spectra were acquired using 
a spectrometer operating at 800 MHz proton Larmor frequency. Temperature was set at ~291 
K and MAS at 14 kHz.  
2D 13C-13C DARR and 15N-13C NCA spectra were acquired for free and glycosylated protein. 
In the analysis of spectra of free [U-2H, Lys-1H,13C,15N] ANSII [Fig. 4.20], it was possible 
to identify 21 lysine spin systems. It was interesting to note that in the SSNMR spectra, 3 
addition spin systems were visible with respect to the 2D 1H-15N TROSY-HSQC acquired 
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in solution [Fig. 4.19a]. One of these signals was assigned to K323; unfortunately, the 
assignment of the other two spin systems was missing, but these signals could be related to 
K44, K51 or K229, that were all solvent exposed lysines. The assignment of the carbon CSs 
of the lysine side-chains (Cα, Cβ, Cγ, Cδ and Cε) was obtained from the combined analysis 
of 3D NCACX and 2D 13C-13C DARR SSNMR spectra [Fig. 20a]. For 7 lysine residues 
(K93, K94, K126, K184, K194, K282 and K323), that were buried inside the protein 
structure, it was also possible to assign the Nζ from the Nζ-Cε correlation visible in the 2D 
15N-13C NCA [Fig. 20b]; conversely the Nζ-Cε signals could not be identified for all the 
other lysines, most of which are solvent-exposed. 
 
 
Figure 4.20 - 2D 13C-13C DARR (a) and 15N-13C NCA (b) SSNMR spectra of freeze-
dried/hydrated free [U-2H, Lys-1H,13C,15N] ANSII, acquired at ~291 K and 800 MHz. The 
assignment of the lysine residues is reported on the NCA spectrum; the stars indicate the two 
spin systems for which the assignment is missing. 
 
A similar analysis was carried out for the same spectra acquired for glycosylated [U-2H, Lys-
1H,13C,15N] ANSII [Fig. 4.21], but in this case the re-assignment was simply achieved 
starting from the spectra of the free ANSII. 
Once cross-peaks visible on DARR spectra of free and glycosylated ANSII were re-assigned, 
it was possible to deeply investigate the effect of conjugation by focusing the attention to the 
region correlating Cα and Cε of the lysine side-chains [Fig. 22]. In particular, it was observed 
remarkable differences in the signal intensity among different groups of resonances in the 
spectrum of the ANSII-MenC CP conjugate [Fig. 22b] in respect to the free protein [Fig. 
22a]. The disappearance of the Cα-Cε cross-peaks in the spectra of the conjugated proteins 
could be taken as a proof of an extensive conjugation of the lysines. A complete 
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disappearance was observed for two solvent-exposed unassigned lysines (belonging to K44 
and/or K51 and/or K229), and for K273. Also, the signals of residued K65, K71, K101, 
K161, K208, K218, K235, K251, K282 and K336 exhibited a decrease in signal intensity. 
However, the corresponding cross-peaks were still visible in the spectrum of the conjugated 
protein, indicating the presence of a significant amount of unreacted residue. Conversely, for 
the residues K93, K94, K126, K129, K184, K194 and K323 bearing no solvent exposed Nζ, 
the decrease in intensity was negligible as expected for non-conjugated lysines. 
 
 
Figure 4.21 - 2D 13C-13C DARR (a) and 15N-13C NCA (b) SSNMR spectra of freeze-
dried/hydrated glycosylated [U-2H, Lys-1H,13C,15N] ANSII, acquired at ~291 K and 800 MHz. 
The assignment of the lysine residues is reported on the NCA spectrum; the stars indicate the 
two spin systems for which the assignment is missing. 
 
 
Figure 4.22 - Enlargement of the region of the 2D 13C-13C DARR spectrum of the (a) free and 
(b) glycosylated [U-2H, Lys-1H,13C,15N] ANSII, displaying the correlation between the Cα and 
the Cε of the lysine side-chains. The assignment for the Cα-Cε cross-peaks is indicated in the 
figure; the stars indicate the two spin systems for which the assignment is missing. 
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The information provided by solution and SSNMR spectroscopy were then summarized in 
a simple graph reporting the relative signal intensity in the 2D 13C-13C DARR SSNMR 
spectrum (x-axis) and 2D 1H-15N TROSY-HSQC solution NMR spectrum (y-axis) [Fig. 
23a]. The analysis of the conjugation by combining the solution and SSNMR data was then 
summarized in a surface representation of ANSII where the lysines were represented as 
spheres and color-coded from dark red (highly conjugated) to yellow (poorly conjugated) 
[Fig. 23b]. The non-conjugated lysines were represented as black spheres. 
 
 
Figure 4.23 - (a) Relative signal intensities of Hζ-Nζ cross-peaks in the 2D 1H-15N TROSY-
HSQC versus the relative signal intensities of the Cα-Cε cross-peaks in the 2D 13C-13C DARR 
of ANSII-MenC CP conjugate. The Hζ-Nζ cross-peak intensities are related to the intensity of 
the Hζ-Nζ fo K251, that is the most intense, while the Cα-Cε cross-peak intensities to the 
intensity of the Cα-Cε of K126 that is the most intense and isolated. The stars indicate the two 
spin systems for which the assignment is missing. (b) Surface representation of ANSII (PDB: 
3ECA) with the lysine residue color-coded according to the degree of conjugation.  
 
For example, lysine K273 and the two lysines for which assignment was missing were 
supposed to be highly conjugated because of the complete disappearance of their signals in 
DARR spectrum and, in the case of lysine K273, also because of the appearance of a very 
intense signal in HSQC spectrum. Instead lysines with red and orange color-code were the 
ones for which we observed a significant decrease of signal intensity in DARR spectrum. In 
particular for lysines K65, K161, K235, K284 and K336 the information provided by 
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SSNMR was fundamental because the sole information obtained in solution was not 
sufficient due to the impossibility of the assignment. Viceversa, for K310 solution NMR 
turned out to be crucial because in DARR spectra the evaluation of the intensity decrease 
was difficult. Finally, lysines represented in black were supposed to be not conjugated: we 
did not observe the appearance of any peaks in HSQC spectrum and the intensity decrease 
in DARR spectrum was null or negligible. 
In conclusion, SSNMR spectra of glycosylated ANSII showing an extremely high quality 
made it possible to confirm, first of all, the preservation of the protein folding. A compared 
analysis combining information acquired by either SSNMR and solution NMR, then allowed 
to classify lysines according to their degree of functionalization, thus getting a 
semiquantitative evaluation of the so-called conjugation pattern. 
 
4.4. Characterization of a HA/ANSII-HABP composite 
Another section of my PhD project concerned the application of SSNMR and integrated 
techniques in the characterization of biomaterials with medical interest. Since the still 
prevailing importance of ANSII in the treatment of several diseases, this protein was also 
chosen to be immobilized into a HA matrix with the aim to design a bioinspired microreactor. 
The administration of ANSII can indeed lead to severe side effects that comprise toxicity for 
liver, pancreas and kidneys, coagulation and similar disorders and allergic reaction. As 
widely described in the previous chapters, PEG coating can reduce immunogenicity, but 
sometimes may cause detrimental consequences, such as chronic kidney diseases and again 
allergic effects. A radically different strategy would be avoid contact with the immune 
systems of the patient (e.g. an extracorporeal processing/treatment of blood)10. Of course, 
the incorporation of ANSII within a device requires that the formulation has an extended 
lifetime, both on the shelf and in operando, that it is easily handled and that the active site is 
accessible and efficacious. The evaluation of all these issues is submitted by an overall and 
very deep characterization in terms of structure, topology, morphology and, certainly, 
efficiency (enzymatic activity). 
For the preparation of HA/ANSII-HABP composite, initially free ANSII-HABP construct 
was expressed, extracted and purified as described in paragraph 3.2.2. Before performing the 
entrapment, ANSII-HABP was characterized in order to assess the tetrameric quaternary 
structure. Therefore, a DLS analysis was carried out at three different concentrations of 
protein in the injected sample: 4.1, 8.2 and 20.5 mg mL-1. The three profiles showed that the 
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protein had a MW of about 80 kDa [Fig. 4.24]. Since the monomeric ANSII-HABP weights 
38.5 kDa, the result suggested that ANSII-HABP was not in its distinctive tetrameric form, 
but rather it mainly corresponded to one of the single intimate dimers. However, a small 
fraction seemed to be a tetramer. 
 
 
Figure 4.24 - DLS profiles of ANSII-HABP at different concentrations: (a) 4.1 
mg mL-1, (b) 8.2 mg mL-1 and (c) 20.5 mg mL-1. 
 
Since this unexpected result, it was fundamental to evaluate the maintenance of the activity, 
which was an essential condition for the design of biomaterial-based medical device. An 
enzymatic assay was performed exploiting the reaction of Nessler’s reagent with the 
ammonia released by the hydrolysis of L-asparagine to L-aspartic acid promoted by ANSII-
HABP itself. The enzymatic activity of ANSII-HABP was compared to the simple ANSII 
and it was found that ANSII-HABP still retained about one-fourth of the catalytic activity 
per monomer [Fig. 4.25].  
 
 
Figure 4.25 - Enzyme concentration/activity profiles for ANSII (black) and free ANSII-
HABP (red). For ANSII, the regression describing the activity is y = 11.25 x with R2 = 
0.9898, while for ANSII-HABP, it is y = 2.54 x with R2 = 0.9926. 
 
Once the activity of free ANSII-HABP was proved, the protein underwent biomimetic 
reaction with the employment of a calcium salt, BGP and ALP (see paragraph 3.2.3 for 
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details). The reaction led to the formation of a pellet which likely contained HA/ANSII-
HABP composite. 
Before characterizing the morphology of the system, it was necessary to answer three 
essential questions: 
• was effectively formed HA during the biomineralization, or rather a relevant amount 
of octacalcium phosphate (OCP) was present in the pellet? 
• which was the amount of ANSII-HABP effectively entrapped in the composite? 
• which was the amount of ANSII-HABP per milligram of pellet? 
Powder XRD and SEM allowed to solve the first issue: the XDR profile seemed to be more 
compatible with the formation of HA, even if some OCP was present11 [Fig. 4.26]. SEM 
micrographs also showed that the material was composed of fused structure, homogeneous 
in shape and sizes, which more closely resembled HA nanosheets, rather than OCP spherical 
particles12 [Fig. 4.27]. 
 
 
Figure 4.26 - XRD profile of the HA/HABP-HABP composite (top) is more similar to 
the calculated XRD diffractogram of HA (bottom, red) then of OCP (bottom, blue). 
 
 
Figure 4.27 - SEM images of the HA/ANSII-HABP composite, taken with (upper panels) 
and without (lower panels) conductive staining, revealing a highly porous structure, 
which is most suitable for maintaining the accessibility of the enzyme. 
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Regarding the amount of enzyme in the composite, a combustion elemental analysis was 
performed and it was found that ANSII-HABP was about 40% w/w in the dried composite, 
which in turn was estimated to be about 13.0% in the wet composite (pellet). Therefore, 
approximatively 55 µg (1.35 nmol) of enzyme were present per milligram of pellet. 
Activity of HA/ANSII-HABP was then evaluated by using again the Nessler’s reagent assay 
[Fig. 4.28]. In this case, enzymatic activity of the composite was measured in terms of 
milligrams of entrapped enzyme (pellet). The result was comparable with the activity of free 
ANSII-HABP. 
 
 
Figure 4.28 - Enzymatic activity profiles for immobilized ANSII-
HABP into the HA. The regression describing the activity is y = 3.95 
x with R2 = 0.9965. 
 
The efficacy of HA/ANSII-HABP composite was also tested in vitro on human ALL cells 
(697 cell line), and compared to either the wild-type enzyme or the commercial product 
Oncaspar. All ANSII preparations were added at 0.74 U mL-1 concentration, according to 
previous reports13,14 [Fig. 4.29]. 
 
 
Figure 4.29 - ALL 697 cells were treated with different preparations (HA/ANSII-HABP, ANSII and 
Oncaspar) at concentration of 0.74 U mL-1 for 24 and 48 hours and the number of live cells, determined 
via the Trypan Blue exclusion test, was measured. HA/HABP-HABP was confined in a device with 
walls of a 3.5 kDa cut-off dialysis membrane. Data are mean values of three independent experiments. 
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A further analysis of the activity of HA/ANSII-HABP system was performed using solution 
NMR. The kinetics was monitored by following the intensity variations of Hα and Hβ of L-
asparagine, used as substrate. In particular, a sample of 9.45 mM L-asparagine in 25 mM 
Tris-HCl, pH 7.4 buffer (supplied with 10% D2O) was first treated with free ANSII-HABP 
(545 nM final protein concentration in the NMR tube) and repeated 1D 1H spectra were 
acquired at 310 K. The relative intensities of L-asparagine Hβ peaks over the time were 
plotted [Fig. 4.30a] and values of kcat and KM were estimated to be 2.1 ± 0.2 s-1 and 3.0 ･ 10-
5 ± 1.0 ･ 10-5 M-1, respectively. The same values for wild-type ANSII were 29 s-1 and 1.2 ･ 
10-4 M-1 as found in literature15. The decrease of kcat for the chimera ANSII-HABP was 
related to the fewer quaternary structural contacts that probably slightly altered the structure 
of the catalytic domain in the dimeric subunit and affected the enzyme turnover. Actually, a 
factor ~4.0 difference in KM, combined with a factor ~13.8 in kcat, yielded a factor of only 
~3.4 decrease in total enzyme turnover kcat/KM. 
The same study was performed also for the HA/ANSII-HABP composite [Fig. 4.30b]. In 
this case 7.5 mg of pellet containing HA/ANSII-HABP composite were dissolved in 600 µL 
(NMR sample), thus having a concentration of about 17.0 µM of active enzyme. Fit of kinetic 
data yielded KM of 1.7 ･ 10-2 ± 1.0 ･ 10-5 M-1 and kcat of 1.5 ± 0.2 s-1. The turnover rate 
seemed to be decreased of only about 70% with respect to the free ANSII-HABP, whereas 
the affinity of the substrate was definitely reduced, as expected. 
 
 
Figure 4.30 - Kinetic profile for the reaction of (a) ANSII-HABP and (b) HA/ANSII-HABP 
composite with L-asparagine. The decrease of L-asparagine Hβ signal intensity in the 1D 1H 
solution NMR spectrum is reported over the time. The points (blue dots) are fitted (black line) 
according to the Schnell-Mendoza equation16. 
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Following the enzymatic (kinetic) characterization, HA/ANSII-HABP was further studied 
from a morphological point of view, which was essentially correlated to the composition of 
ordered and disordered layers and the protein contacts in this hydride (bio)material. As 
already showed, a part of this information was achieved by powder XRD, SEM micrographs 
and elemental analyses. However, in order to fully understand the activity of the material, it 
was necessary to link the bulk observations to the micro- and nanomolecular scale, 
answering the following questions: 
• were the ordered and disordered layers in contact with each other? 
• was the protein in contact with the ordered, disordered or both phases? 
• was the protein exposed to the solvent, thus accessible to the substrate? 
SSNMR was the methodology of choice to answer these questions. 
Primarily, 1D 1H Bloch decay (BD) and window phase-modulated-Lee-Goldburg (wPMLG) 
experiments were performed. The presence of the HA phase was confirmed by the BD 
spectrum [Fig. 4.31, red], where HA/ANSII-HABP composite had the same OH resonance 
at 0.2 ppm as synthetic HA [Fig. 4.31, green]. The BD spectrum showed also a broad intense 
water resonance at 5.3 ppm (consistent with the high water content in HA/ANSII-HABP 
pellet). The peak at 1.3 ppm was instead associated with the aliphatic side-chain protons of 
the protein chimera but might include some contribution from HA as it could be seen by 
comparing with the mineral spectrum. In the homonuclear decoupled wPMLG spectrum 
[Fig. 4.31, violet] of HA/ANSII-HABP, the water line was extensively attenuated, exposing 
three clear bands at 1.3, 4.5 and 7.2 ppm. 
Further interesting information was obtained by recording 1D 31P CP spectrum. The 
deconvolution17 [Fig. 4.32a] of the spectrum revealed two phosphate species — as observed 
in synthetic HA — that could be attributed to two different layers18. The peak at 2.9 ppm 
was typical of the phosphorus resonance in HA crystals (denoted hereafter as PHA), whereas 
the peak at 2.6 ppm to hydrogen phosphate ion (HPO42-) phosphorus (PHP) which were part 
of the discorded calcium phosphate phase that resided at HA/ANSII-HABP interface. 
Monoacid phosphate were shown to adopt a large range of CSs, depending on the 
surrounding ions. In HA/ANSII-HABP composite, this was reflected in the significant width 
of the PHP peak. 
 
	
116	
	
 
Figure 4.31 - 1D 1H SSNMR spectra of ANSII-HABP acquired using wPLMG for homonuclear 
decoupling (violet) and a simple 90°-acquisition (i.e. a Bloch decay) (red). A 1H Bloch decay 
spectrum (green) of synthetic HA is also shown for comparison. 
 
To characterize the proximity of interfacial and bulk protons and phosphates, 31P CP build-
up curves were analyzed. 31P CP build-up measurements were carried out by varying the 
contact time (CT) from 100 ms to 10 ms, and the intensities of PHA [Fig. 4.32b, black] and 
PHP [Fig. 4.32b, red] peaks were plotted against the CT. Recently, similar magnetization 
build-up curves were used to isolate magnetization transfers between interfacial protons and 
phosphates and bulk protons and phosphates in apatite sample prepared with a bone protein 
binding peptide which displayed similar properties of having a crystalline phase of HA and 
a disordered phase containing calcium phosphate ions and the biomolecule18. A similar 
strategy was followed in the case of my work. 
These intensity build-up curves showed the rate of magnetization transfer from adjacent 
protons to the two phosphate species (PHA and PHP). The integral (integrated intensity) of the 
experimental phosphate peak for each CT point was calculated and the values were 
normalized to the highest integral. Each spectrum was then deconvolved into the two 
phosphate contributions and the calculated area under each deconvolved peak was taken as 
a fraction of one. Therefore, the intensity per phosphate peak and per CT point was overall 
normalized to the fractional intensity of that phosphate species within each CT spectrum and 
to the intensity of the highest signal in the CP build-up curve. The curves for both PHA and 
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PHA were fitted with equations which took into account also relaxation processes. The kinetic 
parameters were deduced from best-fitted curves by minimizing the deviations. At the end 
it resulted that the normalized PHA intensity was 0.27, whereas 0.73 for PHP. 
The relatively low normalized PHA intensity was indicative of the low content of crystalline 
HA in HA/ANSII-HABP composite. Indeed, this line typically has an intensity larger than 
0.6 in other co-precipitation procedures of proteins with HA18. This finding suggested that 
either water or protein molecules were located close to the faces of the HA crystal and 
transferred magnetization to order (crystalline) phosphate ions in exposed crystal surfaces. 
The transfer rate of the PHP line (0.5 ms) was similar to the magnetization transfer observed 
for interfacial phosphates in the aforementioned apatite grown with an osteonectin biding 
peptide18. 
 
 
Figure 4.32 - (a) An example of the 31P CP spectrum of HA/ANSII-HABP obtained using 3.6 
ms contact time, deconvoluted using the DMFIT program. The experimental spectrum (blu) is 
shown with the sum of simulated peaks (red) and individual lines at 2.6 ppm (green) and 2.9 ppm 
(purple). (b) 31P intensity build-up with increasing CP contact time of PHA phosphates (black) 
and PHP phosphates (red). 
 
To further probe the local environment sensed by phosphate groups and identify their 
distribution within the sample, a 2D 1H-31P HETCOR spectrum was acquired [Fig. 4.33a]. 
 
	
118	
	
 
Figure 4.33 - (a) 2D 1H-31P HETCOR spectrum of HA/ANSII-HA composite. (b) 1D 1H 
projections from 2D 1H-13C HETCOR spectra with CP contact times of 0.5 ms (red) and 5 ms 
(blue), and of synthetic HA with contact time of 0.4 ms (green) for comparison. 
 
The spectrum showed an intense cross peak between HA hydroxyl group protons at 0.2 ppm 
and phosphates at 2.9 ppm (i.e. PHA). It also showed a group of narrower cross peaks 
correlating protons at 1.3, 4.0-6.5 and 7.0-8.5 ppm along with PHP phosphates. These 
resonances were attributed to the protein protons that transferred magnetization to proximal 
PHP phosphates in the mineral. The homonuclear decoupling effectively removed water 
proton excitation, and therefore no correlations were observed between water and phosphate 
species. This was quite different from other preparations of apatite minerals18,19, whereby a 
strong correlation of water protons with phosphates in a disordered calcium phosphate layer 
on HA crystallites was observed. The absence of the water resonance in the HETCOR 
spectrum was further demonstrated in the proton projections (taken along the phosphate 
maximal intensity) of these measurements as compared to similar measurements in synthetic 
HA where the relative intensity was much different [Fig. 4.33b]. Similar measurements 
without wPMLG decoupling did not show any water peaks with phosphates, so it was 
apparent that water molecules were distantly located from phosphates. 
In summary, these spectra showed that the protein resonances correlated with PHP in the 
disordered layer, which in turn was connected with the PHA phase. The latter crystalline phase 
was mostly excluded from water, suggesting also that this bulk mineral phase was overall 
distant from the biomolecule. From these data, it was possible to conclude that ANSII-HABP 
was interacting with a layer of interfacial phosphates (PHP) and had no direct interactions 
with HA crystallites. Finally, no correlations were here observed between water and 
phosphate species: this meant that the water molecules were either located far from the 
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phosphates or were too dynamic to be detected in dipolar-based magnetization transfer 
experiments. 
A last kind of SSNMR experiment performed on HA/ANSII-HABP composite was 1D 
{1H}-13C CP spectrum which however turned out to be of low intensity and resolution [Fig. 
4.34a, bottom]. When CP was hybridized with the NOE, the quality of the spectrum 
increased and a larger number of signals were visible [Fig. 4.34a, top]. Most of these 
additional peaks — highlighted in the difference spectrum [Fig. 4.34b] — appeared in the 
aliphatic region (0-75 ppm) and some peaks from aromatic side-chains also rose (110-140 
ppm). Moreover, some new peaks could be observed also in the carbonyl region (150-180 
ppm). The observed peaks around 153 ppm belonged to Cζ of the arginine side-chains, while 
those around 178 ppm related to Cγ and Cδ of the aspartate and glutamate/glutamine side-
chains, respectively [Fig. 4.34b]. These observation suggested that the additional peaks, 
observed via NOE, originated from those chemical groups or amino acid residues that 
underwent significant motion on the milliseconds timescale, and were therefore not 
detectable by the dipolar-coupling based CP. This in turn corroborated the idea that a large 
share of the protein was sizably exposed to water. 
 
 
Figure 4.34 - (a) {1H}-13C CP spectrum of HA/ANSII-HABP obtained under MAS using CP 
only (bottom) or CP-NOE (top). The spinning sidebands are marked with stars. (b) Difference 
spectrum between CP-NOE and CP experiments, showing the largest deviation between the two 
spectra, with the indication of the CS regions for amino acid side-chains. 
 
The topology (and morphology) of HA/ANSII-HABP [Fig. 4.355] that could be derived 
from integrated analyses is therefore so summarized. 
(a) The microscopic characterization (i.e powder XRD) demonstrated that the material was 
composed of small lamellar structures, that closely resembled HA. 
(b) SSNMR investigation of the inorganic part showed that the ordered HA phase was not 
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in contact with the protein and the disordered layer was in intimate contact with the protein. 
This further showed that the two inorganic phases were in contact with each other, and water 
was closer to the protein and largely excluded from the mineral phases. 
(c) Protein SSNMR indicated that the enzyme was not completely immobile in the material, 
but underwent extensive motions, suggesting that it was mainly sitting at the surface of the 
particles, rather than being entrapped within the material. Despite the preserved mobility, 
the observed chimeric ANSII-HABP was stably linked to the mineral particles. 
(d) The tests against the ALL cells and those in vivo confirmed that the protein was stable in 
the construct and demonstrated that the material was active. 
 
 
Figure 4.35 - Schematic representation of the arrangement of components 
in HA/ANSII-HABP composite. 
 
4.5. Characterization of silica matrix entrapped hCAII 
The last part of my PhD work regarded the characterization of another biomaterial system, 
i.e. hCAII entrapped in a silica matrix. Enzymes immobilized in biosilica had already been 
extensively studied by SSNMR20–24, but in this case the aim was to develop an SSNMR-
based method to monitor protein-ligand interactions being the enzyme immobilized onto a 
support, with the perspective to demonstrate the potentiality of a SSNMR-based drug 
discovery tool. 
First of all, I expressed, extracted and purified 13C and 15N-labeled hCAII (paragraph 3.3.1). 
Part of the produced protein was used to achieve a backbone assignment in solution, 
therefore a sample of 0.4 mM [U-13C,15N] hCAII sample in 20 mM HEPES, pH 7.5 buffer 
supplied with 0.02% NaN3, protease inhibitors and 10% D2O was prepared and 3D HNCA, 
3D HNCO, 3D HN(CA)CO, 3D HNCACB, and 3D CBCA(CO)NH spectra were recorded 
at 310 K on a 500 MHz spectrometer. The assignment solution was necessary for the 
successive studies at solid state. 
hCAII was then entrapped in a silica matrix, by a PLL-promoted polymerization of Si(OH)4 
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(paragraph 3.3.2). The pellet containing the immobilized protein was then used to fill a 3.2 
mm rotor and then spectra of the ligand-free system were acquired at ~291 K on an 800 MHz 
spectrometer under 14 kHz of MAS rate. All spectra showed a remarkable resolution, and at 
variance with previous observations under different experimental conditions, protein 
degradation over time was not observed. Such high resolution was most probably due to the 
fact that the protein retained its full hydration and allowed for atomic level characterization 
of the system, whereas in previous investigations by other groups the sample was 
lyophilized25. 
Because of the high resolution achieved in the 2D 15N-13C NCA spectrum, the assignment 
previously obtained in solution was easily transferable to the solid state. Cα a N chemical 
shifts observed in solution were compared with those observed in the solid state for the 
ligand-free enzyme [Fig. 4.26a]. The CSP was overall minor, with larger differences 
occurring for some residues on the protein surface, in particular, charged residues and 
residues close to them [Fig. 4.26b]. The preservation of the CS pattern of the active site was 
already indicative that its structure was preserved. 
 
 
Figure 4.36 - Comparison of solution and SSNMR data on hCAII entrapped in the silica matrix: 
(a) CSP between free and silica-immobilized hCAII according to the formula: 
∆𝛿 = 12 ∆𝛿+,2 ' + ∆𝛿)5 ' 
The bars corresponding to the residues exhibiting the largest CSP are highlighted in red. (b) CSP 
mapping on the protein surface (PDB: 1Z9Y): the charged residues are in blue (positive) and red 
(negative); the region with largest perturbation is in magenta. 
 
The preservation of structure of hCAII entrapped in biosilica was also confirmed by an 
enzymatic assay. The test exploited the esterase activity of hCAII which was able to 
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hydrolyze p-nitrophenol acetate (PNPA) to p-nitrophenoxide (PNP) which in turn exhibits a 
strong absorbance at 410 nm (yellow) that can be monitored by UV-Vis spectrophotometry. 
Kinetic curves were acquired in triplicate [Fig. 4.37, top panels] either for free hCAII and 
entrapped hCAII. In the former case, the solution contained 0.5 µM of free protein, in the 
latter case, instead, the test was with a suspension containing an amount of entrapped hCAII 
pellet which was estimated to contain 0.5 µM of protein in the whole reaction volume. The 
kinetic curves were fitted in their first part in order to estimate the initial rate of the enzymatic 
reactions [Fig. 4.37, bottom panels]. As anticipated, it was found that the initial rate for 
biosilica-entrapped hCAII was 0.12 ± 0.04 ms-1, which was of the same order of the one for 
free hCAII (0.53 ± 0.08 ms-1). 
 
 
Figure 4.37 - Kinetic curves (top panels) and their fittings (bottom panels) for free and entrapped hCAII. 
 
Once proved that hCAII preserved its structure and activity even when entrapped in biosilica, 
interactions with ligands was tested. The resolution of the SSNMR spectra was high enough 
to allow for effective localization of inhibitors, as done for the so-called protein-based drug 
screening in solution. Firstly, furosemide [Fig. 2.8], which exhibited a high affinity (with Kd 
in the nanomolar range26) was employed. Aliquots of inhibitor solutions were added directly 
in the rotor containing the entrapped protein, and the CSPs of the protein resonances were 
analyzed. The new resonances belonging to the inhibited protein could be reassigned in the 
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2D 15N-13C NCA spectrum [Fig. 4.38], also using the information from the 2D 13C-13C 
DARR spectrum. 
 
 
Figure 4.38 - Superimposition of 2D 15N-13C spectra of ligand-free hCAII (black) 
and furosemide-inhibited hCAII (red), entrapped in the silica matrix. 
 
From the analysis of the CSPs, it was apparent that active site residues exhibited the largest 
effects [Fig. 4.39a,b]. The active site of the enzyme [Fig. 4.39c] comprised three histidine 
residues that coordinated the zinc ion (H94, H96 and H119); the coordination sphere of the 
metal was completed by a water molecule, which was involved in sulfonamide inhibitors 
[Fig. 4.39d]: the NH- moiety of the sulfonamide participated in hydrogen bonding with the 
Oγ of T199, and one of the oxygen atoms of the SO2NH- moiety also engaged the backbone 
NH of T199, explaining the major perturbation at this site. Overall, the residues with the 
hightest CSPs on the protein surface were located in the active site cleft, where the inhibitor 
was bound [Fig. 4.39b,d]. 
The method was sensitive enogh to reveal differences also in the presence of a lower-affiniti 
inhibitor, sulpiride [Fig. 2.8]. To load the protein with sulpiride, the silica was removed from 
the rotor, washed with a buffered solution containing the inhibitor, previously dissolved in 
DMSO, and repacked back in the rotor. Also in this case, the CSP showed that active site 
residues exhibited the largest effects [Fig. 4.40]. 
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Figure 4.39 - SSNMR data of hCAII entrapped in the silica matrix. (a) CSP between the ligand-free 
hCAII and furosemide-inhibited hCAII; the bars corresponding to residues exhibiting the largest CSPs 
are highlighted in red. (b) CSP mapping on the protein surface (PBD: 1Z9Y): the unassigned regions 
are shown in gray, the region with the largest CSPs in blue, and the inhibitor is shown as yellow sticks. 
(c) Focus on the residues exhibiting the largest CPSs in the active site, highlighted in blue, on the 
structure of the free protein (PBD: 3KS3) and (d) on the protein inhibited with furosemide (PBD: 1Z9Y); 
the different spheres of the metal in the two cases are shown. 
 
 
Figure 4.40 - SSNMR data of hCAII entrapped in the silica matrix. (a) CSP between the ligand-free 
hCAII and sulpiride-inhibited hCAII; the bars corresponding to residues exhibiting the largest CSPs are 
highlighted in red. (b) CSP mapping on the protein surface (PBD: 1Z9Y): the unassigned regions are 
shown in gray, the region with the largest CSPs in blue. (c) CSP mapping on the protein surface (PBD: 
1Z9Y) after washing of the protein pellet: the unassigned regions are shown in gray, the region with the 
largest CSPs in blue, and the residues with a low intensity signal that disappeared are in pink. 
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In summary, even if the signal-to-noise ration was lower due to the presence of the silicic 
matrix, the use of high-field instruments and dedicated probes mitigated the problem and 
allowed for detection of the protein resonance. A very remarkable resolution was observed, 
most probably due to retention of the full hydration of the protein. It was demonstrated that 
the resolution achieved by SSNMR was high enough to track at the atomic level the 
perturbations due to the interaction of the protein with a ligand. This observation allowed to 
speculate that it might be possible to perform protein-based studies of protein-ligand 
interactions by means of SSNMR on immobilized proteins, expanding the possibilities of 
drug discovery and demonstrating once more that this technique was really efficient, 
versatile and reliable even in the characterization of biomaterials used for ligand-based 
screening. 
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Protein-based bioconjugates and bioinspired or biomimetic materials are intriguing and 
promising systems of interest because of their versatility in medical research and industrial 
applications. Their functional and structural characterization at atomic detail is therefore 
fundamental to clarify all aspects occurring during the functionalization or immobilization. 
All the studies of my PhD project, here reported, were focused on the preparation and 
conjugation/entrapment of proteins and the successive characterization by NMR and other 
integrated techniques. 
Concerning bioconjugates, ANSII turned out to be a suitable protein to be differently 
conjugated. The choice of this protein not only relied on its relevance in therapies (it is indeed 
currently used in the treatment of leukemias), but also showed to be a very good model 
system since the high quality of the its NMR spectra. ANSII was therefore PEGylated, 
grafted onto GNPs and glycosylated and, in all cases, SSNMR proved to be a powerful, 
reliable and versatile technique for the structural investigation. 
In detail, it was demonstrated that SSNMR can be efficiently employed to evaluate the 
preservation of protein folding after different bioconjugation approaches by a simple and 
direct comparison of bidimensional 13C-13C DARR or 1H-15N CP-HSQC spectra of the free 
and functionalized protein. The first work focused on the study of PEGylated proteins, 
oftentimes administered as drugs, and it was found that PEG coating did not affect the 
structural integrity of the protein1. In this case, the simplicity of a SSNMR-based method 
could make it attractive for industrial purposes: biologics are expensive, in terms both of 
design and formulation/preparation, and weighty savings might be obtained if SSNMR could 
be used to monitor optimization in the PEGylation procedure. 
SSNMR turned out to be an impressive technique even in the characterization of a 
protein grafted onto nanoparticles (i.e. ANSII-GNP)2. In this case, SSNMR was not only 
efficient in the assessment of protein folding, but also allowed to reassign the resonances of 
a protein conjugated to nanoparticles. This new evolution of the NMR methodology opens 
frontiers for the development of the structure-based strategies applied to nanoparticles and 
potentially to all protein-based nanomaterials. The accessibility to all the experiments, 
previously used only for pure protein samples, represents a breaking point for the 
engineering and GNP applications. The simplicity of the procedures for sample preparation, 
the exquisite sensitivity of magnetic resonance to structural perturbations and the possibility 
to obtain a full structural analysis of the GNP-conjugated proteins are important features of 
this methodology. A further benefit could be the possibility of monitoring protein-protein 
interactions involving the biomolecule immobilized onto the GNP surface. Moreover, this 
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strategy can be extended to nanoparticles of different sizes and shape or even with a different 
core composition. 
A more challenging and fascinating purpose was achieved in the study of ANSII 
conjugated with a polysaccharide, specifically MenC CP3. The aim was to get an evaluation 
of the degree of conjugation of each protein lysines involved in the functionalization. As 
already explained in previous chapters, polydispersity is indeed one of the most crucial issues 
in the design of glycoconjugated vaccines (glycovaccines) and the possibility to have an 
indication of which residues and to which extents each site is functionalized is actually 
desirable. In this work, SSNMR spectra of glycosylated ANSII showed an extremely high 
resolution, first making it possible to confirm the preservation of protein folding (as already 
observed for PEGylated proteins) and to achieve a residue-specific assignment of the spectral 
perturbation that occurred upon glycosylation. A strategy that was based on a combination 
of solution and SSNMR experiments permitted the identification of the residues bearing the 
polysaccharide chain and provided (semi)quantitative information on the conjugation degree 
obtained by random chemical coupling. The characterization of polysaccharide-protein 
bioconjugates is still a challenge in structural biology and an important goal for the 
development of vaccines and biologics, and the protocol we showed had the possibility to 
provide key information for rational design of novel products with improved efficiency. 
As mentioned, my PhD project regarded also the formulation of novel protein-based 
biomaterials and their characterization by NMR to obtain information about morphology and 
protein folding. A composite consisting of ANSII immobilized in a HA matrix was prepared 
in order to design a device potentially applicable in the extracorporeal processing/treatment 
of blood, thus avoiding collateral effect that can rise by the intravenously or intramuscularly 
administration of the drug. After engineering ANSII with a HA binding peptide (ANSII-
HABP), the protein underwent spontaneous formation of HA bioinspired microreactor, 
which was then characterized by enzymatic tests, combustion elemental analysis, TEM, 
XRD and, of course, solution and SSNMR4. All information provided by this integrated 
approach demonstrated that HA/ANSII-HABP composite contained well-folded ANSII, 
which was still efficient against ALL cells. SSNMR was particularly proficient in the 
characterization of morphology of the composite, giving a clear idea of the composition of 
inorganic, organic and protein layers. 
Finally, SSNMR was employed in the characterization of a biosilica-entrapped protein 
(i.e. hCAII)5. In this part of my PhD project, the recent advances in SSNMR applied to 
composites having both an inorganic and a biomolecular component were capitalized. Even 
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if the signal-to-noise ratio was lower due to the presence of the silica matrix, the use of high- 
field instruments and dedicated probes mitigated the problem and allowed for detection of 
the protein resonances. A very remarkable resolution was observed and in this work it was 
demonstrated that the resolution was high enough to track at the atomic level the perturbation 
due to the interaction of immobilized hCAII with its ligands. This observation allowed to 
speculate that it might be possible to perform protein-based studies of protein-ligand 
interaction by means of SSNMR on immobilized enzymes, expanding the possibilities of 
drug discovery, where entrapped biological targets have already been used for ligand-based 
screening. 
In summary, once more time (SS)NMR methodologies turned out to be ones of the best 
tools in the structural characterization of complex systems, such as bioconjugates and 
protein-based biomaterials which cannot in principle be studied with other methods because 
of their scarce propensity to crystallize, impeding the use of X-ray crystallography, and their 
huge sizes which put them beyond the solution NMR molecular weight limitations. Widely 
assessed the effectiveness and adaptability of SSNMR, this technique could be further 
applied in the study of other kind of bioconjugates, either varying the protein moiety (for 
instance, immunogenic proteins for the characterization of “real” glycovaccines) or the 
attached systems (e.g. other kind of nanoparticles). Finally, novel enzyme-based materials, 
composites, biomimetic reactors could be investigated by exploiting all the potentiality of a 
such powerful and versatile technique as SSNMR. 
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Abstract: PEGylated proteins are widely used in biomedicine
but, in spite of their importance, no atomic-level information is
available since they are generally resistant to structural
characterization approaches. PEGylated proteins are shown
here to yield highly resolved solid-state NMR spectra, which
allows assessment of the structural integrity of proteins when
PEGylated for therapeutic or diagnostic use.
Biological drugs (biologics)[1] are the fastest-growing cate-
gory of approved therapeutics. Most biologics are proteins
and, as such, they are the closest proxy of a “natural” help
against disease.[2] However, proteins have poor pharmacoki-
netic and safety profiles. Polyethylene glycol (PEG) coating
of biologics provides reduced renal clearance, increased
stability to degradation, and a reduced immunogenic
response (hence they are often called “stealth drugs”).[3]
PEGylation is even more important for nanocarriers and
liposomes, the lifetimes of which are otherwise shortened by
the activity of the reticuloendothelial system. Obviously,
preservation of the three-dimensional structure and activity
of the PEGylated form is mandatory for human use. While
activity can be easily measured in vitro, structural character-
ization at atomic resolution of PEGylated proteins and
protein-based nanocarriers is almost impossible. PEG coating
prevents crystallization for X-ray analysis: currently only one
crystal structure has been solved, that of the small protein
PEG-plastocyanine (PEG-Pc, 11.5 kDa, 4R0O, 4.2ä resolu-
tion). The protein carries a single PEG chain, and protein–
protein crystal contacts can still take place owing to the rather
large distance between the PEGmoieties.[4] Also, PEGylation
often pushes protein size beyond the practical limits of
solution NMR because of the increase in hydrodynamic
volume, which is increased by PEG more than it would be for
an equal increase in protein mass.[5] Exceptions are PEG-
Interferon2a
[6] and PEG-Pc,[4] where the protein size remains
sufficiently small after PEGylation to permit solution NMR
studies. Solid-state NMR (ssNMR) is becoming a better
alternative to study proteins[7] because it does not suffer from
molecular-weight limitations (although the spectral complex-
ity still increases with protein size), and high resolution
spectra can be obtained for multimeric assemblies.[8–11] How-
ever, the best resolution is usually obtained for crystalline
materials,[12,13] which are precisely what cannot be usually
achieved for PEGylated proteins.
Herein, it is shown that highly resolved ssNMR spectra
can be obtained for PEGylated proteins in the pelleted state,
a densely packed non-crystalline state of a wet macromolec-
ular sample, which can be obtained either by rehydration of
freeze-dried material,[14–17] or by ultracentrifugation[18] when
allowed by the density and molecular mass of the mole-
cule.[19, 20] Such high-quality ssNMR spectra are suitable for
extensive resonance assignment and even conventional full
structure determination. More importantly, the simple com-
parison of a standard two-dimensional ssNMR spectrum of
the pelleted PEGylated protein with that of the crystalline
state of the native protein—for which the X-ray structure is
available—can reveal whether the three-dimensional struc-
ture is maintained in the PEGylated form. Since preparing
a pelleted sample of a PEGylated protein turns out to be
particularly simple and fast, and the collection of ssNMR
spectra for the comparison is relatively rapid, the approach
proposed here can be regarded as the fast-lane to assess at
atomic detail whether or not the native conformation is
preserved after PEGylation. Assignment of the resonances
that experience perturbations, if any, can further push the
application of this approach towards tracking where modifi-
cations occur in the 3D structure.
The approach is demonstrated on three clinically/pre-
clinically relevant biologics: human CuII-ZnII-Superoxide
Dismutase (SOD), human H Ferritin (hHF), and E.coli l-
asparaginase II (ANSII). SOD is an enzyme used to scavenge
free radicals in radiation therapy and in severe inflammatory
diseases.[21] The SOD used here is the popular “AS”
C6A,C111S mutant, which is less prone to aggregation than
the wild type. SOD is a symmetric homodimer (C2) of 32 kDa
that has been extensively characterized by NMR[22,23] and X-
ray crystallography.[24] Ferritins have been proposed as
biomineralization scaffolds, MRI contrast agents, and nano-
carriers and drug delivery devices.[25] hHF is a homo-24-mer of
about 504 kDa (ca. 21 kDa per subunit) that forms a cage of
O symmetry (snub cube), as characterized by X-ray crystal-
lography.[26] Its ssNMR spectra are here reported for the first
time: it has the same architecture as the Bullfrog M ferritin,[27]
with which sedimentation for ssNMR was first developed.[18]
PEGylation increases the bloodstream circulation of ferritins
and reduces specific uptake by cells.[28] ANSII fromE.coli is in
clinical use since 1967 against childhood acute lymphoblastic
leukemia.[29] In its therapeutically active form, ANSII consists
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of a homotetrameric assembly of 144 kDa with D2 symme-
try.[30] For therapeutical applications, more recently, native
ANSII has been substituted by the PEGylated form of
ANSII, which exhibits longer-lasting activity and lower
immunogenicity.[31]
Protein PEGylation was achieved by using a linear amine-
reactive methyl-PEG reagent containing 24 ethyleneglycol
units. PEGylation increases the molecular weight of dimeric
SOD from 32 kDa to above 60 kDa, with all of the lysines and
the N-terminal moiety largely functionalized (Figures S1,S2
in the Supporting Information). PEGylation of SOD hinders
sedimentation, so the sample for ssNMR was prepared by
wetting a freeze-dried sample. In hHF, each monomer binds
3–4 PEG chains, thereby increasing the size of the tetramer
from 504 kDa up to 600–650 kDa (Figure S3) without chang-
ing its function (Figure S4–6). PEGylated hHF is still able to
sediment easily. In ANSII, each monomer binds 4–5 PEG
chains, thereby increasing the size of the tetramer from
144 kDa up to about 170 kDa (Figure S7). The ssNMR
samples of native and PEGylated ANSII were both produced
by freeze-drying and rehydration.
ssNMR spectra were collected for the three native
proteins in the crystalline form and for the three PEGylated
proteins in the pellet state (See Table S1 for detailed
experimental conditions). From the analysis of the spectra
(Figure 1 and S8) it clearly appears that line shape and
resolution for the pelleted PEGylated proteins are very good,
and comparable with those obtained from microcrystalline
samples of the corresponding native proteins (Figure S8 and
S9). Pelleted SOD and hHF in the native and PEGylated
forms show spectra of equally good quality (Figure S10).
In all three cases, the spectra of the pelleted PEGylated
protein and the crystalline native protein are largely super-
imposable, thus demonstrating for the first time a negligible
effect of PEG coating on protein structure and assembly. In
particular, preservation of chemical-shift patterns of well-
resolved isoleucine residues indicates an intact hydrophobic
core (Figure 1 and Figure S8). Figure 2 shows a superimposi-
tion of the spectra for pelleted PEGylated (blue) and
crystalline native (red) SOD, thus demonstrating the remark-
able similarity and the outstanding resolution achieved. The
availability of the assignment of crystalline SOD also allows
evaluation of the efficacy and sequence specificity of PEG-
ylation by monitoring the chemical shift of the protein
residues at the reaction sites (Figure 2B and Table S2). The
residues experiencing non-negligible chemical-shift perturba-
tions are mapped onto the SOD structure in Figure 2C.
Chemical-shift perturbations mainly occur for surface resi-
dues, as expected. Some perturbations are observed for
residues in close proximity to, or facing, the PEGylated
lysines, while some are not obviously related to it.
As an illustration of the suitability of 13C-13C solid-state
NMR for this kind of applications, Figure S11 shows the
dramatic changes that are observed in the 2D 13C-13C
correlation spectra of SOD upon chemical denaturation of
the enzyme.[32]
The simplicity of the method should make it attractive for
industrial purposes: biologics are expensive drugs, in terms
both of design and of manufacturing, and significant savings
could be obtained if ssNMR could be used to monitor
optimization of the PEGylation procedure.
The very good quality of the spectra and the high filling
factor intrinsic to protein pellets[33] also make it possible to
acquire 3D spectra for assignment (Figure S12). Since almost
all carbon atoms can be observed with simple uniform 13C/15N
labeling, and assignment does not need to rely upon extensive
mutagenesis and/or selective labeling, as needed, for example,
for methyl-TROSY,[34] for example, ssNMR is expected to lift
the limitations for the study of PEGylated biologics.
It is important to remark that the outcome of the analysis
does not strictly depend on the type of experiment used:
a) Historically, 13C-13C correlation spectra,[36,37] which are
sensitive to changes occurring in the secondary structure,
mostly through the Ca–Cb region, and allow residue-type
fingerprinting,[38–40] were used for spectral comparison.
b) With the introduction of robust NC recoupling
schemes,[41,42] such comparisons are made even easier.
Figure 1. 2D 13C-13C correlation spectra of PEGylated SOD (A), PEGy-
lated hHF (B), and PEGylated ANSII (C). Conditions: A) 16.4 T, 14 kHz
MAS, 3.2 mm rotor; B) 16.4 T, 11.5 kHz MAS, 4 mm rotor; C) 20 T,
14 kHz MAS, 3.2 mm rotor (Table S1).
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Indeed, the NC correlation spectrum of ANSII shows
remarkably resolved resonances (Figure S14).
c) More recently, 1H-detection-based ssNMR methods have
been proposed,[43–45] and it is possible to foresee that
comparison of 1H-13C or 1H-15N experiments could
become the standard, yielding more sensitive detection
on even lower amounts of sample.
Research on biologics is progressing towards the targeting
of protein–protein interactions, which requires an even
tighter control over the PEGylation processes.[46,47] The
possibility of structurally characterizing PEGylated proteins
represents a powerful tool for pushing the envelope of
structural biology applications to biologics.
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Figure 2. A) Comparison of the aliphatic portion of the 13C-13C correla-
tion spectra for crystalline native SOD (red) and pelleted PEGylated
SOD (blue). Off-diagonal regions separated by dashed gray lines in the
left panel are plotted with lowered intensities for the PEGylated form
to ease comparison between the spectra of the two forms. Resonances
marked by arrows belong to glutamate residues neighboring reacted
lysine residues. The right panel shows an enlargement of the isoleu-
cine Cd1 resonances and correlations. B) chemical-shift perturbation
between the two species (Dd à 12
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Dd2Ca á Dd2Cb
q
),[35] where lysine
residues are highlighted in red. C) Structure of the PEGylated SOD
homodimer (in blue, from the crystal structure) showing the lysine
residues as yellow stick models, and the PEG chains (modelled as
random chains) as white transparent spheres. The regions with non-
negligible chemical shift perturbation of the side chains are shown in
magenta.
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Human Cu(II)-Zn(II)-Superoxide Dismutase (SOD) 
The preservation of the protein folding and the conservation of the structure of the catalytic site is 
essential to maintain the enzymatic activity of SOD. SOD has been reported to retain its enzymatic 
activity after PEGylation. However, structural data at atomic resolution were not available so far.[1]  
Protein expression. The C6A, C111S mutant of SOD was expressed in the Escherichia coli 
TOPP1 (Stratagene) or BL21(DE3) strain and purified using previously reported protocols.[2] This 
SOD mutant is structurally and functionally equivalent to the wild type protein.[3,4] 
The apo protein was obtained by dialysis against 10 mM EDTA in 50 mM sodium acetate (pH 3.8). 
The chelating agent was removed by extensive dialysis against 100 mM NaCl in the same buffer 
and then against acetate buffer alone, gradually increasing the pH from 3.8 to 5.5. The Cu(II)-Zn(II) 
form of SOD was obtained by addition of stoichiometric amounts of ZnSO4 and CuSO4 at pH 5.5. 
PEGylation Reaction. A solution 250 mM of PEGylation reagent MS(PEG)24 (Thermo scientific, 
Rockford, Il) was prepared, according to the manual, dissolving 100 mg of reagent in 230 µL of dry 
DMF. To obtain an excess of PEGylation reagent of 20 times respect to the protein, 120 µL of the 
stock solution were added to 5 mL of SOD 4.6 mg/mL in phosphate buffer (150 mM, pH = 7.5). 
The mixture was left stirring over-night at 277 K. 
In the morning, a purification with a PD10 column was performed to remove the non-reacted and 
the hydrolyzed PEGylation reagent. Products and yield of the reaction were evaluated by SDS-
PAGE (Figure S1) and solution NMR spectra (Figure S2). 
NMR spectroscopy. The spectra of the crystalline preparation of the protein, recorded at 20 T, 
obtained from the conditions listed in Table S1, were kindly provided by Prof. Roberta Pierattelli. 
DARR mixing time was 150 ms, and 1H decoupling was 80 kHz.  
Native sedimented SOD was concentrated to 200 mg/mL. 16.4 µL of concentrated protein solution 
were transferred into a Bruker 3.2 mm rotor and spun on a tabletop spinner to remove air bubbles 
that easily form at high protein concentration. Bubbles removal is critical for rotation stability and 
shimming. The rotor was sealed with a DNP silicon plug (Bruker biospin) to avoid leakage, and 
sedimentation was achieved by MAS spinning at 14 kHz.[5] Experiments were performed on a 
Bruker Avance II 850 MHz wide-bore spectrometer (20 T, 213.6 MHz 13C Larmor frequency), 
equipped with a 3.2 mm DVT MAS probe head in triple-resonance mode. 13C -13C recoupling was 
accomplished by 50 ms Dipolar Assisted Rotary Resonance[6], where 1H-13C dipolar recoupling is 
achieved by a continuous wave radiofrequency irradiation on the 1H channel at ωH=ωr; during 
evolution and acquisition, decoupling was applied at 100 kHz (found to be optimal on the basis of 
the 13C' echo lifetime) using a swTPPM sequence.[7] At both instruments, interscan delay was 1.6 s. 
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PEGylated SOD was freeze-dried and packed in the rotor, then rehydrated by multiple additions of 
1 µL of buffer, until the resolution of the 13C 1D SSNMR spectrum stopped changing.[8] The 13C 1D 
SSNMR spectra were acquired with 16 scans each with a recycle delay of 0.9 s, after the sample 
had stably reached the desired temperature (around 280 K). 5 µL of buffer were added in total to the 
freeze-dried protein before the acquisition of the 13C-13C correlation spectra. Experiments were 
performed on a Bruker Avance II 700 MHz wide-bore spectrometer (16.4 T, 176.1 MHz 13C 
Larmor frequency), equipped with a 3.2 mm DVT MAS probe head in triple-resonance mode. 13C -
13C recoupling was accomplished by 50 ms Dipolar Assisted Rotary Resonance[6], where 1H-13C 
dipolar recoupling is achieved by a continuous wave radiofrequency irradiation on the 1H channel at 
ωH=ωr; during evolution and acquisition, decoupling was applied at 100 kHz (found to be optimal 
on the basis of the 13C' echo lifetime) using a swTPPM sequence.[7] 
Human-H Ferritin (hHF) 
The use of ferritin as a carrier to deliver imaging and therapeutic agents relies i) on the intactness of 
its nanocage architecture that ensures their efficient solubilisation and transport and ii)  on the 
accessibility of the C3 pores to iron or other metal ions able to form inorganic cores directly inside 
the inner cage.[9] 
Here we report a comparative analysis of the native and PEGylated hHF to establish the 
conservation of the nanocage 24-mer structure via DLS (Figure S6) and of the stability of the 
subunit secondary structure via CD (Figure S4).  Comparative stopped flow kinetics of the catalytic 
reactions occurring at the ferroxidase site is used as an efficient tool to demonstrate intact 
accessibility of the C3 ion channels upon PEGylation (Figure S5).[10] 
Protein Expression. pET-9a construct encoding hHF was transformed into Escherichia coli 
BL21(DE3) pLysS cells which were subsequently cultured in rich (LB) or 13C,15N-labelled minimal 
medium (M9) containing kanamycin (0.05 mg mL-1) and chloramphenicol (34 µg mL-1). Cells were 
grown at 310 K, until A600nm reached 0.6–0.8 and subsequently induced with isopropyl 1-thio-β-D-
galactopyranoside (IPTG, 1 mM final concentration) for 4 h. Ferritin was purified from the 
harvested cells, as described previously for the bullfrog M ferritin[11,12]. Briefly, cells were broken 
by sonication and the cell free extract obtained after centrifugation (40 min, 40000 rpm, 70Ti 
Beckman Coulter, at 277 K) was incubated for 15 min at 338 K as the first purification step. After 
removal of the aggregated proteins by ultracentrifugation (15 min, 40000 rpm, 70Ti Beckman 
Coulter, at 277 K), the supernatant solution was dialyzed against Tris-HCl 20 mM pH 7.5; applied 
to a Q-Sepharose column in the same buffer and eluted with a linear NaCl gradient of 0-1 M in Tris 
20 mM, pH 7.5. Fractions containing ferritin, identified by Coomassie staining of SDS-PAGE gels, 
were combined and further purified by size exclusion chromatography using a Superdex 200 16/60 
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column. Iron and other metal ions were removed by four dialysis steps at room temperature each 
using 4 L 20 mM Tris, 2.5 mM EDTA, 10 mL ammonium thioglycolate pH 7.5 to reduce and 
chelate the iron, followed by four dialysis steps at room temperature each using 4 L 20 mM Tris pH 
7.5. 
PEGylation Reaction. A solution 250 mM of PEGylation Reagent MS(PEG)24 (Thermo scientific, 
Rockford, Il) was prepared, according to the manual, dissolving 100 mg of reagent in 230 µL of dry 
DMF. To obtain an excess of PEGylation reagent of 10 times respect to the protein, 40 µL of the 
stock solution were added to 5.5 mL of hHF 3.6 mg/mL in phosphate buffer (150 mM, pH = 7.2). 
The mixture was left stirring over-night at 277 K. 
In the morning, a purification with a PD10 column was performed to remove the non-reacted and 
the hydrolyzed PEGylation reagent. Products and yield of the reaction were evaluated by SDS-
PAGE (Figure S3). 
Circular Dichroism Spectroscopy. CD spectra to assess the stability of the protein secondary 
structure were acquired in the far-UV with a Jasco J-810 spectropolarimeter using a 0.1 cm path 
length quartz cuvette and 5 µM protein concentration (in subunits) in 150 mM sodium phosphate 
buffer, pH 7.5. For temperature melting curves in the 298-358 K, a CD spectrum was first measured 
at 298 K, the protein was then incubated in thermostated cells at the desired temperatures for 5 min 
and the corresponding CD spectra was acquired in 6 min. The mean of 10 scans between 190 and 
250 nm wavelength was calculated by subtraction of the corresponding buffer spectrum. The 
resulting curves are reported in Figure S4. 
Stopped-flow kinetics. Single turnover oxidoreductase kinetics (2 Fe2+/subunit) was monitored in 
hHF, or PEGylated (PEG-hHF). Changes in A650nm, corresponding to the diferric-peroxo (DFP) 
intermediate, and A350nm, corresponding to ferric-oxo (Fe3+O)x species, were measured after rapid 
mixing (<10 msec) of equal volumes of 100 µM protein subunits in 200 mM MOPS, 200 mM NaCl, 
at pH 7 with freshly prepared solutions of 200 µM ferrous sulfate in 1 mM HCl, in a UV/visible, 
stopped-flow spectrophotometer (SX.18MV stopped-flow reaction analyzer, Applied 
Photophysics). Routinely, 4000 data points were collected during the first 5 seconds. Initial rates of 
DFP and (Fe3+O)x species formation were determined using data from three independent analyses 
through the linear fitting of the initial phases of absorbance changes at 650 nm and 350 nm traces 
(0.01–0.03 s) (Figure S5).  
Dynamic Light Scattering (DLS). DLS measurements at θ = 90° were performed using a 
Brookhaven Instrument 90 Plus (Brookhaven, Holtsville, NY). Each measurement was an average 
of five repetitions of one minute (Figure S6). The normalized electrical field time autocorrelation 
functions of the normalized intensity time autocorrelation of the scattered light were measured at 
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90° and analyzed according to the Siegert relation (Eq. (1)), which connects the first order or field 
normalized autocorrelation function g1(q, τ) to the measured normalized time autocorrelation 
function g2(q, τ)[13]:  
 
g2(q, τ) = 1+ β|g1(q, τ)|2          (1) 
 
with β being the spatial coherence factor which depends on the geometry of the detection system. 
The functions (β|g1(q, τ)|2)1/2) were also normalized to vary between 0 and 1 for display purposes. 
The field autocorrelation functions were analyzed through a cumulant analysis stopped to the 
second order, allowing an estimate of the hydrodynamic diameter of particles and of the 
polydispersity index (Figure S6)[14]. 
NMR Spectroscopy. The crystalline preparation of the protein was obtained from the conditions 
listed in Table S1. The high-salt crystallization conditions, which sizably affect the radiofrequency 
characteristics of NMR probeheads, prompt the use of a small-diameter rotor, and experiments were 
performed in a 1.3 mm rotor, at 60 kHz spinning at 20 T. 13C-13C recoupling was accomplished by 3 
ms of Radio-Frequency-Driven Recoupling[15] (number of scans 64), where 13C-13C dipolar 
recoupling is achieved with a train of rotor-synchronized π-pulses; this approach has the tendency 
to favor recoupling to the nearest neighbors, lowering the intensity of long-range cross peaks;[15] for 
this reason, the aliphatic to carbonyl correlation region was acquired at 40 kHz spinning rate with a 
CORD-xy4 sequence, with 350 ms mixing time (number of scans 128).[16] During evolution and 
acquisition, decoupling was applied at 13.5 kHz using a using a swTPPM sequence.[7] 
Both native and PEGylated hHF pelleted spectra were obtained sealing the proteins into a 4 mm 
rotor as 100 mg/ml solution, and sedimented by the rotor spinning at 11.5 kHz. For the 1D 
experiments, 128 scans with 1.5 s interscan delay was used. For the DARR Experiments were 
performed on a Bruker Avance II 700 MHz wide-bore spectrometer (16.4 T, 176.1 MHz 13C 
Larmor frequency), equipped with a 4 mm DVT MAS probe head in triple-resonance mode. 13C -
13C recoupling was accomplished by 100 ms Dipolar Assisted Rotary Resonance[6], where 1H-13C 
dipolar recoupling is achieved by a continuous wave radiofrequency irradiation on the 1H channel at 
ωH=ωr; during evolution and acquisition, decoupling was applied at 75 kHz (found to be optimal on 
the basis of the 13C' echo lifetime) using a using a swTPPM sequence.[7] Recycle delay was set to 
1.5 and the number of scans was 176.   
E. coli L-Asparaginase II (ANSII) 
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L-Asparaginase from Escherichia coli and its PEGylated derivative obtained by reacting the 
enzyme with MS(PEG)24 have been prepared and characterized. 
Protein expression. The gene encoding ANSII in pET-21a was transformed into Escherichia coli 
BL21(DE3)C41 cells which were subsequently cultured in rich (LB) or 13C,15N-labelled minimal 
medium (M9) containing ampicillin (0,1 mg mL-1). Cells were grown at 310 K, until A600nm reached 
0.6-0.8 and subsequently induced with IPTG (1 mM final concentration). Cells were further grown 
at 310 K overnight and then harvested by centrifugation at 6500 rpm (JA-10 Beckman Coulter) for 
20 min at 277 K. All the purification procedures were carried out at 277 K. The pellet was re-
suspended in 10 mM Tris-HCl, pH 8.0, 15 mM EDTA, 20% sucrose buffer (60 mL per liter of 
culture) and then kept for 20 min under magnetic stirring. Suspension was centrifuged at 10000 rpm 
(F15-6x100y Thermo Scientific) for 30 min and supernatant discarded. The pellet was re-suspended 
in H2O milli-Q (60 mL per liter of culture) and then kept for 20 min under magnetic stirring. 
Suspension was centrifuged again at 10000 rpm (F15-6x100y Thermo Scientific) for 30 min. The 
supernatant was treated with ammonium sulfate from 50% to 90% to precipitate the ANSII protein. 
Then the protein was re-dissolved in minimal amount of 20 mM Tris-HCl pH 8.0 buffer and 
dialyzed extensively! against the same buffer. The ANSII was further purified by Q-Sepharose 
column using 20 mM Tris-HCl pH 8.6 buffer with a linear NaCl gradient 0-1 M. Fractions 
containing pure ANSII were identified by Coomassie staining SDS-PAGE gels. The formation of 
the tetrameric assembly of ANSII was confirmed by gel filtration using a Superdex 200 10/300 IB 
increase column. 
PEGylation Reaction. A solution 250 mM of PEGylation Reagent MS(PEG)24 (Thermo scientific, 
Rockford, Il) was prepared, according to the manual, dissolving 100 mg of reagent in 230 µL of dry 
DMF. To obtain an excess of PEGylation reagent of 20 times respect to the protein, 120 µL of the 
stock solution were added to 6.7 mL of ANSII 4.2 mg/mL in phosphate buffer (150 mM, pH = 7.5). 
The mixture was left stirring over-night at 277 K. 
In the morning, a purification with a PD10 column was performed to remove the non-reacted and 
the hydrolyzed PEGylation reagent. Products and yield of the reaction were evaluated were 
evaluated by SDS-PAGE (Figure S7).  
NMR spectroscopy. The crystalline preparation of the protein was obtained from the conditions 
listed in Table S1. 13C -13C recoupling was accomplished by 50 ms Dipolar Assisted Rotary 
Resonance[6], where 1H-13C dipolar recoupling is achieved by a continuous wave radiofrequency 
irradiation on the 1H channel at ωH=ωr; during evolution and acquisition, decoupling was applied at 
100 kHz (found to be optimal on the basis of the 13C' echo lifetime) using a swTPPM sequence.[7] 
The interscan delay was 0.8 s. 
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PEGylated ANSII was freeze-dried and packed in the rotor, then rehydrated by multiple additions 
of 1 µL of buffer, until the resolution of the 13C 1D SSNMR spectrum stopped changing.[8] The 13C 
1D SSNMR spectra were acquired with 16 scans each with a recycle delay of 1.3 s, after the sample 
had stably reached the desired temperature (around 280 K). 5 µL of buffer were added in total to the 
freeze-dried protein before the acquisition of the 13C-13C correlation spectra. 
Experiments were performed on a Bruker Avance II 850 MHz wide-bore spectrometer (20 T, 213.6 
MHz 13C Larmor frequency), equipped with a 3.2 mm DVT MAS probe head in triple-resonance 
mode. 13C-13C recoupling was accomplished by 50 ms Dipolar Assisted Rotary Resonance[6], where 
1H-13C dipolar recoupling is achieved by a continuous wave radiofrequency irradiation on the 1H 
channel at ωH=ωr; during evolution and acquisition, decoupling was applied at 100 kHz using a 
using a swTPPM sequence.[7]  
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Supplementary Figures 
 
 
 
 
 
 
 
 
Figure S1. SDS-PAGE gel resulting from PEGylation of SOD. Lane 1: monomeric SOD; lane 2: 
monomeric PEGylated SOD. Under SDS-denaturing conditions, only the SOD monomer is 
predicted to be observable. 
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Figure S2. Solution NMR 2D 1H 15N HSQC spectrum of SOD before (A) and 2D 1H 15N TROSY 
spectrum after (B) PEGylation. In panel C a zoom of the region in the spectrum where are visible 
the 12 new amide cross-peaks obtained from the PEGylation of the flexible sidechains of the lysines 
and of the N-terminus. 
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Figure S3. SDS-PAGE gel resulting from PEGylation of hHF. Lane 1: hHF; lanes 2 and 3: PEG-
hHF obtained by two independent reactions. Under SDS-denaturing conditions, only the ferritin 
monomer is predicted to be observable; the arrow indicates the expected molecular weight of hHF 
monomer.  
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Figure S4. CD melting curves of PEG-hHF and comparison with hHF. Far UV CD spectra of hHF 
(upper panel) and PEG-hHF (lower panel) apoferritins. Spectra were acquired in the 298−358 K 
temperature range. The 298 K* traces were recorded after cooling back the samples from 358 to 
298 K, to check reversibility 
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Protein Initial rate of DFP formation 
(∆A650 nm) 
Initial rate of (Fe3+O)x 
formation 
(∆A350 nm) 
hHF 1.002 ± 0.0139 1.549 ± 0.081 
PEG-hHF 0.998 ± 0.022 1.570 ± 0.003 
 
Figure S5. PEG-hHF has the same ferroxidase activity as the hHF. Formation of (upper panel) DFP 
intermediate (A650 nm) and (lower panel) (Fe3+O)x products (A350 nm) were measured by rapid-
mixing, UV−vis spectroscopy. Shown are a set of representative curves (one of three independent 
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analyses for each protein). The table shows the rates (mean ±SEM, from data obtained by three 
independent analyses) calculated as described in the Methods section. 
 
 
 
 hHF PEG-hHF 
Dh 17.6±0.2 18.6±0.1 
PDI 0.094±0.011 0.091±0.010 
 
Figure S6. Representative normalized DLS curves obtained for the hHF and for the PEGylated 
protein (PEG-hHF). The table summarizes the data (mean ±SD, from data obtained by five 
independent analyses) for hydrodynamic diameter (Dh) and polydispersity index (PDI) of proteins’ 
dispersions calculated as described in the Methods section. 
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Figure S7. SDS-PAGE gel resulting from PEGylation of L-asparaginase II. Lanes 1, 2 and 3: L-
asparaginase II at three different concentrations; lanes 4, 5 and 6: PEGylated L-asparaginase II at 
three different concentrations. Under SDS-denaturing conditions only the L-asparaginase II 
monomer is predicted to be observable; the arrow indicates the expected molecular weight of L-
asparaginase II monomer.  
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Table S1. Samples used in the present method and experimental conditions of the presented spectra. 
Protein Crystalline Native Pelleted Native Pelleted PEGylated 
SOD Protein solution: SOD 12 
mM in unbuffered water 
Crystallization conditions 
(diffracting at 8 Å 
resolution): 
20 mM citrate pH = 5, PEG 
6k 20%[17] 
Experimental setup - 
Magnetic field: 20 T; MAS 
spinning: 20 kHz, 3.2 mm 
rotor ; CC recoupling: 
DARR  
Figure - S8A, courtesy of 
Prof. Roberta Pierattelli[18] 
Experimental setup - 
Magnetic field: 20 T; MAS 
spinning: 21 kHz, 3.2 mm 
rotor; CC recoupling: 
DARR  
Figure – S10A 
 
Experimental setup -  
Magnetic field: 16.4 T; 
MAS spinning: 14 kHz, 3.2 
mm rotor; CC recoupling: 
DARR  
Figure - 1A/S8B/S10B 
 
hHF Protein solution: hHF 13 
mg/mL, 20 mM Tris, 
pH=7.7, 0.15 M NaCl 
Crystallization conditions: 
2 M MgCl2, 0.1 M Bicine, 
pH = 8 
PDB accession code: 
4P03[19]  
Experimental setup: 
Magnetic field 20 T; MAS 
spinning: 60 kHz, 1.3 mm 
rotor; CC recoupling: 
RFDR   
Figure - S8C 
Experimental setup -  
Magnetic field: 16.4 T; 
MAS spinning: 11.5 kHz, 4 
mm rotor; CC recoupling: 
DARR  
Figure – S10C 
 
Experimental setup -  
Magnetic field: 16.4 T; 
MAS spinning: 11.5 kHz, 4 
mm rotor; CC recoupling: 
DARR  
Figure – 1B/S8D/S10D 
 
ANSII Protein solution: ANSII 0.4 
mM in 100 mM MES-
NaOH pH = 6.5. 
Crystallization 
conditions[20]: 
100 mM MES-NaOH pH = 
6.5, PEG-MME 550 25%, 
10 mM ZnSO4. 
PDB accession code : 
3ECA[21]- 
Experimental setup - 
Magnetic field: 20 T; MAS 
spinning: 14 kHz 3.2 mm 
rotor; CC recoupling: 
DARR   
Figure - S8E 
 Experimental setup - 
Magnetic field: 20 T; MAS 
spinning: 14 kHz 3.2 mm 
rotor; CC recoupling: 
DARR   
Figure -  1C/S8F 
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Figure S8. 2D 13C-13C correlation spectra of crystalline (A) and PEGylated (B) SOD; crystalline 
(C) and PEGylated (D) hHF; crystalline (E) and PEGylated (F) ANSII. 
	
154	
	
 
 
 
 
Figure S9. 1D traces of two rows (at 11.0 and 61.4 ppm, respectively) of the 2D 13C-13C correlation 
spectra of PEGylated (blue) and crystalline (red) ANSII.  
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Figure S10. Comparison of the 13C-13C correlation spectra obtained for SOD and hHF as pelleted 
native proteins (A and C) and as pelleted PEGylated proteins (B and D). 
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Table S2. Chemical shifts of carbon sidechains of crystalline native[22] and pelleted pegylated SOD. 
!
  Crystalline Native SOD  Pelleted PEGylated SOD 
                 
Num Res Cα Cβ Cγ  Cδ  Cɛ  Cα Cβ Cγ  Cδ  Cɛ 
1 GLN                
2 THR 60.83 69.21 20.97      60.97 68.94 20.97     
3 LYS 54.06 36.07 24.28  28.22  41.30  53.94 35.97 24.28  28.28  41.13 
4 ALA 49.85 22.69       49.66 22.64      
5 VAL 59.09 34.89 20.88 17.91     58.94 34.66 21.05 17.94    
6 ALA 49.64 22.58       49.65 22.63      
7 VAL 60.39 31.89 20.25 20.10     60.12 31.79 20.25 20.10    
8 LEU 53.28 39.50 28.43  23.02    53.28 39.44 28.43  22.94   
9 LYS 54.14 36.35 24.14  28.10    53.91 36.24 24.17  28.02   
10 GLY 44.50        44.50       
11 ASP 53.63 40.08       53.70 40.08      
12 GLY 43.20        43.20       
13 PRO 62.46 31.81 25.07  48.69    62.21 31.78 25.17  48.48   
14 VAL 62.02 29.37 21.47 20.83     61.58 29.52 21.50 20.81    
15 GLN 52.89 30.75 31.98      52.76 30.73 31.98     
16 GLY 45.50        45.50       
17 ILE 60.58 40.41 27.72 16.65 12.82    60.48 40.99 27.58 16.66 13.20   
18 ILE 55.55 36.95 24.93 17.48 7.00    55.57 36.97 24.54 17.55 7.11   
19 ASN 51.34 39.61       51.21 39.81      
20 PHE 53.93 42.13       54.15 42.28      
21 GLU 55.06 33.29 35.95      55.35 33.34 36.28     
22 GLN 53.52 31.21 34.17      53.45 31.24 34.46     
23 LYS 58.14 31.82 24.34  28.04    57.97 32.04 24.22  28.04   
24 GLU 53.24 31.37 34.22      53.31 31.42 34.37     
25 SER 61.06 63.06       61.09 62.93      
26 ASN 51.65 37.38       51.65 37.38      
27 GLY 44.70        44.70       
28 PRO 62.07 31.67 26.14  48.92    61.86 31.80 26.41  48.74   
29 VAL 59.92 32.51 22.39 22.00     59.70 32.40 22.39 22.02    
30 LYS 55.02 32.62 24.39  28.15    55.05 32.79 24.39  28.21   
31 VAL 59.61 32.70 19.86 19.60     59.51 32.57 19.86 19.60    
32 TRP 55.39 31.32       55.28 31.55      
33 GLY 43.60        43.60       
34 SER 55.88 64.62       56.16 64.57      
35 ILE 59.06 40.32 26.48 18.13 13.30    58.86 40.68 26.33 18.13 13.38   
36 LYS 52.67 34.19 23.46  28.43    53.11 34.30 23.49  28.54   
37 GLY 44.50        44.50       
38 LEU 52.56 43.33 25.54  24.98 22.48   51.96 43.32 25.42  25.00 22.43  
39 THR 60.16 68.73 21.86      60.46 68.41 21.93     
40 GLU 56.51 28.98       56.40 29.32      
41 GLY 41.20        41.20       
42 LEU 54.23 42.97 26.61  24.41 23.15   54.03 42.71 26.68  24.19 22.83  
43 HIS 53.37 30.91       53.23 30.78      
44 GLY 46.20        46.20       
45 PHE 55.52 41.59       55.42 41.63      
46 HIS                
47 VAL 60.77 31.07       60.70 31.22      
48 HIS 54.42 30.22       54.49 30.00      
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49 GLU 60.78 30.56 34.26      60.75 30.46 34.40     
50 PHE 55.26 38.62       55.39 38.62      
51 GLY 45.10        45.10       
52 ASP 51.18 41.42       50.97 41.43      
53 ASN 50.61 38.57       50.26 38.33      
54 THR 65.40 67.99 22.10      65.60 68.23 22.58     
55 ALA 48.57 16.77       48.03 17.27      
56 GLY 44.50        44.50       
57 CYS 50.02 41.52       50.02 41.52      
58 THR 65.04 67.83 20.80      65.09 67.67 21.28     
59 SER 57.37 61.13       57.27 61.04      
60 ALA 52.31 18.06       52.18 18.11      
61 GLY 43.20        43.20       
62 PRO 61.88 31.72 25.41  48.73    61.74 31.66 25.46  48.64   
63 HIS                
64 PHE 55.40 36.80       55.48 37.22      
65 ASN 50.19 38.48       49.93 38.47      
66 PRO 63.36 29.64 26.35  47.09    63.26 30.05 26.56  47.08   
67 LEU 53.14 39.66 26.32  23.75 22.19   52.87 39.62 26.41  24.48 22.04  
68 SER 57.84 60.10       58.16 60.12      
69 ARG 53.04 26.61       53.05 26.50      
70 LYS 54.08 29.61 24.22  27.75  40.95  53.84 29.77 24.25  27.75  40.95 
71 HIS 54.29 30.67       54.33 30.71      
72 GLY 43.40        43.40       
73 GLY 43.30        43.30       
74 PRO 62.77 30.45 26.40  47.95    62.54 30.35 26.53  47.75   
75 LYS 53.44 29.85 23.07  25.51  41.65  53.69 29.53 22.36  25.70  41.19 
76 ASP 53.31 40.81       53.20 40.86      
77 GLU 58.09 28.46 35.05      58.03 28.46 35.17     
78 GLU 54.24 28.15 35.51      54.12 28.13 35.50     
79 ARG 54.43 26.62       54.19 26.44      
80 HIS 53.44 28.39       53.29 28.42      
81 VAL 66.27 29.56 22.67 20.87     66.22 29.74 22.17 20.62    
82 GLY 44.60        44.60       
83 ASP 56.16 39.36       56.63 39.48      
84 LEU 52.91 40.60 26.23  25.00 21.48   52.72 40.70 25.96  24.98 21.48  
85 GLY 45.00        45.00       
86 ASN 51.55 43.43       51.52 43.27      
87 VAL 58.17 31.55 20.66 16.23     57.93 31.56 20.74 16.14    
88 THR 60.44 69.01 20.71      60.63 68.58 20.83     
89 ALA 48.58 20.03       48.58 20.13      
90 ASP 51.31 41.04       51.31 41.04      
91 LYS 57.65 30.79 22.72  28.22  41.28  57.44 30.99 22.62  28.32  41.07 
92 ASP 53.39 40.51       53.28 40.45      
93 GLY 45.80        45.80       
94 VAL 60.83 30.85 20.53 19.99     60.53 30.73 20.56 20.06    
95 ALA 49.10 19.26       48.95 19.38      
96 ASP 53.11 40.32       53.11 40.32      
97 VAL 61.41 32.20 20.03 19.64     61.12 32.47 20.06 19.70    
98 SER 57.01 61.83       57.10 62.18      
99 ILE 59.33 43.41 26.87 16.56 14.15    59.12 43.82 26.77 16.58 14.15   
100 GLU 54.36 31.52 36.01      54.22 31.81 36.42     
101 ASP 53.57 46.15       53.48 46.12      
102 SER 57.11 63.22       57.42 63.28      
103 VAL 63.84 31.27 22.26 21.61     63.75 31.06 22.26 21.70    
104 ILE 62.50 39.31 23.20 18.87 13.42    62.15 39.19 23.12 18.58 13.52   
105 SER 54.32 64.62       54.58 64.60      
106 LEU 52.75 39.37 25.92  24.84    52.75 39.30 25.92  24.80   
107 SER 56.81 64.89       56.58 64.79      
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108 GLY 44.00        44.00       
109 ASP 55.23 38.27       55.18 38.40      
110 HIS 52.54 26.67       52.45 26.68      
111 SER 56.62 63.04       56.94 62.91      
112 ILE 59.52 35.88 23.64 16.80 13.97    59.37 35.85 23.44 16.79 13.89   
113 ILE 60.44 34.07 26.59 17.38 10.28    60.37 34.16 26.85 17.74 10.66   
114 GLY 44.00        44.00       
115 ARG 53.82 26.04       53.75 26.12      
116 THR 61.60 70.15 23.31      61.61 69.90 23.64     
117 LEU 52.29 43.54 22.60  26.33 22.37   51.84 43.68 22.64  25.85 22.26  
118 VAL 60.37 33.82 21.41 19.67     60.37 33.79 21.42 19.75    
119 VAL 57.27 34.69 21.73 19.54     57.27 34.69 21.44 19.67    
120 HIS                
121 GLU 58.07 31.40 34.61  28.17    57.97 31.61 34.61     
122 LYS 52.67 33.96 23.80  28.14  41.24  52.62 34.10 23.80  28.14  40.97 
123 ALA 51.17 19.07       50.84 19.42      
124 ASP 55.31 41.66       55.28 41.61      
125 ASP 53.17 38.22       53.09 38.34      
126 LEU 54.02 36.83 24.79  24.27 20.71   53.80 36.73 24.79  24.27 20.56  
127 GLY 44.80        44.80       
128 LYS 53.72 32.17 24.53      53.93 32.37 24.54     
129 GLY 44.80        44.80       
130 GLY 45.00        45.00       
131 ASN 49.50 39.05       49.37 39.03      
132 GLU 57.79 28.62 34.86      57.65 28.70 34.93     
133 GLU 58.07 28.26 33.07      58.26 28.30 33.21     
134 SER 59.75 62.03       59.80 61.77      
135 THR 61.91 68.55 20.90      61.98 68.54 20.90     
136 LYS 57.91 34.63 23.75  28.44  41.13  57.85 34.63 24.12  28.44  41.13 
137 THR 59.43 71.40              
138 GLY 43.90        43.90       
139 ASN 55.45 35.89       55.25 36.02      
140 ALA 52.18 16.76       52.18 16.76      
141 GLY 44.70        44.70       
142 SER 59.10 62.88       59.10 62.88      
143 ARG 52.62 26.34       52.62 26.34      
144 LEU 55.68 41.78 25.72  27.42 20.27   55.48 41.70 25.65  27.48 20.65  
145 ALA 50.22 20.43       49.92 20.49      
146 CYS 53.68 46.48       53.66 46.37      
147 GLY 44.60        44.60       
148 VAL 61.86 31.21 20.56 20.22     61.71 31.35 20.56 20.36    
149 ILE 61.58 36.43 27.51 17.40 13.94    61.30 36.30 27.53 17.55 13.94   
150 GLY 42.10        42.10       
151 ILE 62.54 38.90 29.17 12.07 16.43    62.59 38.85 29.17 12.37 16.62   
152 ALA 48.96 20.88       48.94 20.85      
153 GLN 56.73 29.05 33.85      56.51 29.43 34.21     
!
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Figure S11. 2D 13C-13C correlation spectrum (DARR) of pelleted PEGylated SOD before (A) and 
after (B) a drastic treatment with denaturing agents (6 M guanidinium, 100 mM EDTA and 20 mM 
DTT).[23] The coating of SOD with PEG does not prevent the unfolding of the protein: the 13C-13C 
correlation spectrum of the guanidinium-treated sample shows the loss of dispersion of resonances 
typical of the folded structure of SOD. Interestingly, significant changes in 13C chemical shifts are 
observed especially for the carbons of the side-chains of the Ile residues in the hydrophobic core. 
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Figure S12. 3D CANCO and NCACX spectra performed on pelleted PEGylated L-asparaginase II. 
The experiments have been recorded on a Bruker Avance III 850 MHz wide-bore spectrometer 
(20.0 T, 213.7 MHz 13C Larmor frequency) using a 3.2 mm DVT MAS probe head in triple-
resonance mode in both cases. The MAS frequency (ωr/2π) was set to 14.0 kHz. Number of scans 
were 24 and 16 respectively, with interscan delay set to 2.2 s. From a preliminary peak picking of 
the 3D spectra 240 resolved spin systems out of 326 residues have been found (74%). 
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Figure S13. 2D NCO of crystalline native (red) and pelleted PEGylated L-asparaginase II (blue). 
The experiments have been recorded on a Bruker Avance III 850 MHz wide-bore spectrometer 
(20.0 T, 213.7 MHz 13C Larmor frequency) using a 3.2 mm DVT MAS probe head in triple-
resonance mode in both cases. The MAS frequency (ωr/2π) was set to 14.0 kHz. Number of scans 
was set to 64, interscan delay was set to 2.2 s. 
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Atomic structural details of 
a protein grafted onto gold 
nanoparticles
Stefano Giuntini1,2, Linda Cerofolini2, Enrico Ravera  1,2, Marco Fragai1,2,3 & Claudio Luchinat  1,2
The development of a methodology for the structural characterization at atomic detail of proteins 
conjugated to nanoparticles would be a breakthrough in nanotechnology. Solution and solid-state NMR 
spectroscopies are currently used to investigate molecules and peptides grafted onto nanoparticles, 
but the strategies used so far fall short in the application to proteins, which represent a thrilling 
development in theranostics. We here demonstrate the feasibility of highly-resolved multidimensional 
heteronuclear spectra of a large protein assembly conjugated to PEGylated gold nanoparticles. 
The spectra have been obtained by direct proton detection under fast MAS and allow for both a fast 
fingerprinting for the assessment of the preservation of the native fold and for resonance assignment. 
We thus demonstrate that the structural characterization and the application of the structure-based 
methodologies to proteins bound to gold nanoparticles is feasible and potentially extensible to other 
hybrid protein-nanomaterials.
Protein-inorganic conjugate nanomaterials find increasing applications in nanotechnology, cell biology and med-
icine1–4. The intrinsic hybrid nature of these materials is the major strength of their use, but also hampers the 
structural characterization at atomic detail of the different components when assembled together. Among these 
hybrid nanomaterials, specific proteins conjugated to gold nanoparticles are well-established tools for immuno-
histochemistry and promising agents for photodynamic therapy, near-infrared optical imaging and drug deliv-
ery5–8. Highly stable and biocompatible gold nanoparticles (GNPs) are obtained by grafting long polyethylene 
glycol (PEG) chains onto the surface of the inorganic core in order to decrease the uptake by reticuloendothelial 
system cells and increase the circulation half-life9,10. The use of bifunctional PEG chains bearing a gold-reactive 
group at one end and a reactive moiety at the other allows for the synthesis of PEGylated gold nanoparticles func-
tionalized with biologically relevant proteins11,12. The covalent linkage of the protein is often achieved through the 
formation of an amide bond with the ε-amino groups of at least one surface exposed lysine residue13. This simple 
and versatile synthetic strategy leads to the conjugation of the protein at different sites and to the possibility of 
binding several protein molecules per particle. Solution NMR investigations on functionalized nanoparticles 
have been already reported for small molecules and peptides covalently linked through flexible spacers14–16. More 
recently, also the potentiality of solid-state NMR has been used to characterize nanoparticles bearing relatively 
small functionalities on the surface17–19. Conversely, the use of SSNMR to obtain atomic structural details on 
proteins grafted onto GNPs has never been described before. Therefore, the functional integrity of the proteins 
conjugated to GNPs is usually assessed by biochemical assays, assuming that the structure is preserved if the func-
tionality is preserved. However, structural biology tools can provide a wealth of information that can be applied to 
the proteins grafted onto nanoparticles. Heteronuclear single quantum coherence (HSQC)20 correlating nitrogen 
and amide proton on 15N isotopically enriched proteins or acquired at natural abundance is a relatively simple and 
rapid experiment that is an extremely faithful reporter of minor changes occurring in the chemical environment 
of the observed nuclei. It is thus widely used (i) to assess the protein folding, (ii) to observe structural changes, 
and (iii) to monitor chemical modifications or protein-protein and protein-ligand interactions21–24, and it may 
be ported to larger systems through tailored sequences, even if the achievable size is still low25,26. More recently, 
amide proton-nitrogen correlation spectra have been reported on crystalline protein samples at the solid state27–32. 
1Department of Chemistry “Ugo Schiff”, University of Florence, Via della Lastruccia 3, 50019, Sesto Fiorentino, Italy. 
2Magnetic Resonance Center (CERM), University of Florence and Consorzio Interuniversitario Risonanze Magnetiche 
di Metallo Proteine (CIRMMP), Via L. Sacconi 6, 50019, Sesto Fiorentino, Italy. 3GiottoBiotech S.R.L., Via Madonna 
del Piano 6, 50019, Sesto Fiorentino, Italy. Correspondence and requests for materials should be addressed to E.R. 
(email: ravera@cerm.unifi.it) or M.F. (email: fragai@cerm.unifi.it) or C.L. (email: claudioluchinat@cerm.unifi.it)
Received: 3 October 2017
Accepted: 5 December 2017
Published: xx xx xxxx
OPEN
	
164	
	
www.nature.com/scientificreports/
2SCIENTIFIC REPORTS |  (2017) 7:17934  | DOI:10.1038/s41598-017-18109-z
However, high quality solid state 2D 1H-15N CP-HSQC can be recorded only at high magnetic fields, under fast 
magic angle spinning (MAS) conditions (60 kHz), possibly on perdeuterated samples to abolish the detrimental 
effects of proton-proton dipolar coupling on spectral resolution.
The molecular weight is not a limiting factor for solid-state NMR, and also non-crystalline samples can pro-
vide high quality spectra33–37.
We here show that the solid-state version of the HSQC experiment can be used to structurally characterize 
proteins covalently linked to GNPs. We have synthesized protein-GNPs starting from commercially available 
PEGylated GNPs with a core size of 5 nm, and the therapeutically relevant protein E. coli asparaginase II (ANSII). 
This protein has been already investigated in the solid state both in its native form, after PEGylation (PEG-ANSII 
hereafter)38 and after conjugation with polysaccharides39. The conjugation with the protein affects neither the 
stability of the GNPs in solution, nor their maximum absorption wavelength. The protein is only a fraction of 
the whole sample filling the 1.3 mm rotor, and therefore proton detection under fast MAS is necessary to achieve 
enough sensitivity. Highly resolved SSNMR spectra from ANSII conjugated to GNPs (ANSII-GNPs, hereafter) 
have been obtained after rehydration of freeze-dried material.
The 1D 1H NOESY of ANSII-GNPs shows a large group of signals in the region between 6.8 and 10.5 ppm, 
and one very intense peak around 3.6 ppm (Fig. 1). The chemical shift values in the 6.8–10.5 ppm range are typ-
ical for protein amides protons, while the intense peak observed at 3.6 ppm nicely matches with the methylene 
signals of the PEG forming the coating of the investigated nanoparticles. The large chemical shift dispersions 
of the amide protons and the presence of signals downfield of 8.5 ppm are positive markers of the protein fold-
ing and prompt the application of heteronuclear correlation experiments. The 2D 1H-15N CP-HSQC SSNMR 
of ANSII-GNPs (Fig. 2, panel 1) is of very good quality, and comparable to the 2D 1H-15N CP-HSQC spectra 
collected on PEG-ANSII and on the crystalline preparation of the free ANSII (Fig. 3). In the three spectra the 
resonances are largely superimposable, immediately demonstrating that the native three-dimensional structure 
of the protein is preserved after the conjugation with the nanoparticles and PEG38. Furthermore the spectra are 
sufficiently resolved so that 184 amide signals over a total of 224 visible cross-peaks can easily be assigned by 
comparison with the spectra of both the crystalline and PEGylated preparations of ANSII for which assignment is 
available (unpublished data), and by the analysis of the 1H-13C planes of 3D (H)CANH and 3D(H)CONH spectra 
acquired on the ANSII-GNPs (Fig. 2, panels 2 and 3).
The effects of conjugation with the PEGylated nanoparticles were investigated by observing the differences 
in chemical shift of the resonances in the spectra of ANSII collected at the solid state for the different protein 
preparations (crystalline free ANSII, PEG-ANSII and ANSII-GNPs). The chemical shift perturbation analysis of 
the 2D 1H-15N CP-HSQC spectrum of ANSII-GNPs (Fig. 4) reveals that the largest variations involve the residues 
located on the protein surface or on loops. This finding is not surprising because the effect of packing forces in the 
crystalline free ANSII, and the chemical modifications in PEG-ANSII involve residues at the protein surface. For 
most of the residues the chemical shift values of ANSII conjugated to GNPs are in better agreement with those of 
the PEG-ANSII than with the crystalline free ANSII, and this remarks the similarity between PEG-conjugated 
samples. Interestingly, the chemical shift variations are larger for the PEG-ANSII, consistently with a lower level 
of conjugation of the lysine residues on the protein grafted onto the PEGylated GNPs. In the PEG-ANSII sample 
7 lysine residues are conjugated on average, whereas virtually only a single one of the 19 exposed lysine residues 
at a time is reacted to the PEG-coated nanoparticle.
In summary, we demonstrate that highly resolved heteronuclear spectra can be recorded on protein-GNPs and 
assigned to obtain structural information at atomic detail. This new evolution of the NMR methodology opens 
new frontiers for the development of the structure-based strategies applied to nanoparticles and potentially to all 
Figure 1. 1D 1H NOESY NMR spectrum (mixing 20 ms) acquired at the solid-state on the ANSII-GNPs sample 
using a spectrometer operating at 800 MHz, 1H Larmor frequency, at ~282 K and MAS of 60 kHz. The sharp signals 
of the methylene group of the PEG chains and of the water are visible around 3.6 and 4.9 ppm, respectively. The 
top panel displays an enlargement, with a different intensity scale, of the region between 6 and 12 ppm, where the 
protein amide proton resonates. The high spreading of these signals is a positive marker of the protein folding.
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nanomaterials functionalized with proteins. The accessibility to all the experiments previously used only for pure 
protein samples represents a breaking point for the engineering and GNPs applications. The simplicity of the pro-
cedures for sample preparation, the exquisite sensitivity of magnetic resonance to structural perturbations, and 
the possibility to obtain a full structural characterization of the proteins conjugated on the GNPs, are important 
features of this methodology.
An additional benefit is the possibility of monitoring protein-protein interactions involving the biomolecule 
immobilized onto the GNPs surface. Moreover, this strategy can be extended to GNPs of different sizes and 
shapes since they retain the same chemical and structural features. However, we should point out that the signal 
to noise ratio is obviously a function of the protein-GNPs mass ratio, which is strongly correlated to the surface 
to volume ratio of the nanoparticles. Finally, this methodology is also directly applicable to nanoparticles with a 
different core composition if they are stable under MAS conditions, and if their use is not prevented by a fast MAS 
inside high magnetic fields.
Methods
Expression and purification of ANSII [U- 2H-13C-15N]. Escherichia coli C41(DE3) cells were trans-
formed with pET-21a(+) plasmid encoding ANSII gene. The cells were cultured in 2H13,C15,N-enriched Silantes 
OD2 medium supplied with 0.1 mg mL−1 of ampicillin, grown at 310 K, until A600 nm reached 0.6–0.8, then 
induced with 1 mM isopropyl β-D-1-thiogalactopyranoside. They were further grown at 310 K overnight and 
then harvested by centrifugation at 7500 rpm (JA-10 Beckman Coulter) for 15 min at 277 K. The pellet was sus-
pended in 10 mM Tris-HCl, pH 8.0, 15 mM EDTA, 20% sucrose buffer (60 mL per liter of culture) and incu-
bated at 277 K for 20 min upon magnetic stirring. The suspension was centrifuged at 10000 rpm (F15–6 × 100 y 
Thermo Scientific) for 30 min and the supernatant discarded. The recovered pellet was re-suspended in H2O 
milli-Q (60 mL per liter of culture) and newly incubated at 277 K for 20 min under magnetic stirring. Again the 
suspension was centrifuged at 10000 rpm (F15–6 × 100 y Thermo Scientific) for 30 min. The pellet was discarded, 
Figure 2. 2D 1H-15N CP-HSQC SSNMR spectrum (1) and 2D 1H-13C planes of the 3D (H)CANH (2) and 3D(H)
CONH (3) spectra obtained from ANSII-GNPs. The experiments were acquired on a spectrometer operating at 
800 MHz, 1H Larmor frequency, at ~282 K and MAS of 60 kHz. Cartoon representation of tetrameric ANSII with 
highlighted in magenta the assigned residues in the 2D 1H-15N CP-HSQC SSNMR spectrum of ANSII-GNPs. The 
three C2 symmetry axes defining the D2 symmetry are displayed as black lines on the protein structure.
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whereas the supernatant treated with ammonium sulfate. Still under magnetic stirring solid ammonium sulfate 
was added in aliquots up to 50% saturation. The precipitate was removed by centrifugation, then further ammo-
nium sulfate was added up to 90% saturation to trigger the precipitation of ANSII, which was recovered again by 
centrifugation. The precipitated ANSII was re-dissolved in a minimal amount of 20 mM Tris-HCl, pH 8.6 buffer 
Figure 3. 2D 1H-15N CP-HSQC SSNMR spectrum of ANSII-GNPs (black) superimposed with the spectrum 
of crystalline ANSII (red) (panel A), and PEG-ANSII (blue) (panel B). The superimposition of the spectra 
of crystalline and PEG-ANSII is also reported (panel C). The spectrum of ANSII-GNPs was acquired on a 
800 MHz spectrometer, while the spectra of crystalline ANSII and PEG-ANSII were acquired on a 850 MHz 
spectrometer. All the spectra were recorded at ~282 K and MAS of 60 kHz.
Figure 4. Chemical-shift perturbations of PEG-ANSII (A) and ANSII-GNPs (B) with respect to the crystalline 
preparation, and between ANSII-GNPs and PEG-ANSII (C), according to the formula δ δ∆ = ∆ + δ∆( )H
1
2
2
5
2N 40. 
The residues experiencing the highest perturbation are highlighted in red.
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and dialyzed extensively against the same buffer. ANSII was purified by anionic-exchange chromatography using 
a HiPrep Q FF 16/10 column (GE Healthcare Life Science). The protein was eluted in 20 mM Tris-HCl, pH 8.6 
buffer with a linear 0–1 M NaCl gradient. Fractions containing pure ANSII were identified by Coomassie staining 
SDS-PAGE gels, then joined and dialyzed extensively against 50 mM phosphate, pH 7.5 buffer.
Conjugation of ANSII [U- 2H-13C-15N] to 5 nm gold nanoparticles and sample preparation 
for SSNMR. A sample of ANSII [U- 2H-13C-15N] has been conjugated to gold nanoparticles with core 
size of 5 nm functionalized with 5 kDa PEG chains and bearing NHS-ester (~1 NHS group/nm2) to react 
with the protein lysine residues (Cytodiagnostic). ANSII is a tetrameric assembly of 138 kDa formed of four 
identical subunits organized as a dimer of dimers. The molecular weight of the ANSII is of the same order of 
the monoclonal antibody used for the optimization of the conjugation strategy with these nanoparticles. The 
experimental conditions used in the protein-GNPs synthesis allow us to optimize the protein loading, avoid 
protein-mediated GNPs aggregation, and minimize the amount of protein needed for the reaction. 200 µL 
of 20 mg mL−1 ANSII [U- 2H-13C-15N] solution in 50 mM sodium phosphate, pH 7.5 buffer were diluted 
up to 400 µL with the Protein Re-suspension Buffer, then further diluted up to 900 µL with the Reaction 
Buffer. The solution was splitted in ten 90 µL aliquots which were directly transferred in ten vials containing 
lyophilized NHS-activated gold nanoparticles. The reaction mixtures were immediately mixed by pipetting, 
incubated at room temperature for 2 hours, then quenched with 10 µL (per vial) of Quencher Solution. 
Protein-GNPs nanoparticles were purified from the unreacted protein by multistep washing on a centrifugal 
device with membrane nominal pore size of 10 nm (MWCO Microsep Advanced Centrifugal Device, Pall 
Corporation). Three washings were performed using 20 mM Tris-HCl, pH 8.0 buffer until all the free pro-
tein was reduced (see Figure S1), and at the end the volume was reduced down to 500 µL, splitted in 10 new 
1.5 mL eppendorfs, frozen with liquid nitrogen and lyophilized. The freeze-dried sample, corresponding 
approximately to about 0.2 mg of protein, was packed on 1.3 mm rotor for a preliminary NMR analysis, but 
rehydration was needed to collect well resolved spectra.
NMR measurements. All SSNMR spectra were recorded at ~282 K on Bruker AvanceIII HD spectrometer 
operating at 800 MHz 1H Larmor frequency, equipped with a 1.3 mm HCN probe-head, at MAS frequency of 
60 kHz, using the standard parameters reported in literature33,34.
The nonselective 90° pulses were set to 2.05 µs (1H), 4 µs (15N), and 2.8 µs (13C).
1H-15N forward cross-polarization (CP) was achieved using a contact time of 1 ms (ωH = 50 kHz, ωN = 10 kHz) 
with a 70–100 linearly ramped contact pulse on 1H. The 15N-1H back CP was achieved using a contact time of 0.4 
ms, (ωH = 50 kHz, ωN = 10 kHz) with a 100–70 linearly ramped contact pulse on 1H. The CP-HSQC was acquired 
with 2048 scans and with 156 increments in the indirect 15N dimension.
The 1H-13C forward CP had contact time of 3.5 ms for H-Cα and 2 ms for the H-CO transfer, respectively, with 
70–100 linearly ramped contact pulses on 1H (ωH = 40 kHz, ωC = 20 kHz). CA-N CP and CO-N steps had contact 
time of 6 ms and 5 ms, respectively, with a 90–100 linearly ramped contact pulse of mean rf-field amplitude of 
about 40 kHz on 13C and a constant-amplitude spin lock of about 20 kHz on 15N.
All the spectra were with the Bruker TopSpin 3.2 software package and analysed with the program CARA 
(ETH Zürich).
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Figure S1. Line 1 - pure 2H 13C 15N ANSII before conjugation reaction; Line 2 - protein marker 
(kDa); Line 3 - unbound protein after first washing; Line 4 - unbound protein after second washing; 
Line 5 – no unbound protein is detectable after the third washing 
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Table S1. 1H, 15N chemical shift of ANSII-GNPs. The spectra were collected at 800 MHz (1H 
Larmor frequency), at ~ 282 K and MAS of 60 kHz. 
 
Res num Res type H N 
    
25 ASN 9.85 122.75 
26 ILE 8.30 123.95 
28 ILE 9.46 128.24 
30 ALA 8.85 124.93 
57 LEU 7.56 122.34 
58 VAL 7.62 113.31 
59 ASN 7.70 116.96 
60 ALA 7.50 120.27 
61 VAL 7.51 117.37 
63 GLN 9.30 118.98 
64 LEU 8.43 117.85 
65 LYS 7.48 114.83 
66 ASP 7.28 115.14 
67 ILE 7.57 113.20 
68 ALA 8.10 119.24 
69 ASN 8.85 118.19 
70 VAL 8.61 124.69 
71 LYS 8.46 126.78 
72 GLY 8.75 109.64 
73 GLU 8.98 120.39 
74 GLN 9.16 126.98 
75 VAL 8.87 129.42 
76 VAL 7.75 110.70 
77 ASN 8.69 120.82 
81 GLN 9.95 128.46 
82 ASP 7.74 119.65 
83 MET 7.28 120.46 
84 ASN 6.44 113.47 
85 ASP 8.81 117.92 
86 ASN 8.02 115.55 
87 VAL 7.56 122.21 
88 TRP 7.35 121.42 
89 LEU 8.19 117.47 
90 THR 7.94 115.48 
91 LEU 7.02 120.46 
92 ALA 7.46 125.11 
93 LYS 7.84 114.28 
94 LYS 8.00 121.68 
95 ILE 8.59 126.18 
96 ASN 8.01 115.92 
97 THR 8.37 116.64 
98 ASP 8.26 121.24 
99 CYS 7.49 120.49 
100 ASP 8.53 112.81 
101 LYS 8.05 117.15 
102 THR 7.31 115.28 
103 ASP 8.60 118.80 
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104 GLY 7.68 108.51 
105 PHE 7.38 117.34 
106 VAL 8.37 121.47 
107 ILE 9.12 126.34 
109 HIS 9.09 129.06 
110 GLY 8.53 111.36 
114 MET 7.33 126.19 
116 GLU 7.89 122.73 
117 THR 7.70 115.64 
126 LYS 9.35 124.43 
127 CYS 6.85 118.19 
128 ASP 8.91 128.35 
134 VAL 8.95 122.02 
135 GLY 8.71 112.28 
136 ALA 8.94 122.29 
137 MET 11.58 124.53 
138 ARG 9.98 124.92 
157 THR 7.98 108.35 
159 ALA 9.13 123.02 
160 ASP 7.20 122.08 
161 LYS 8.93 129.48 
162 ALA 9.26 121.34 
164 ALA 7.16 121.36 
165 ASN 8.67 112.31 
166 ARG 7.95 115.83 
167 GLY 7.78 107.82 
168 VAL 7.65 119.82 
180 ARG 7.93 120.74 
181 ASP 8.56 120.49 
182 VAL 7.20 117.18 
183 THR 8.79 121.84 
184 LYS 7.73 128.78 
185 THR 7.89 118.18 
187 THR 7.56 117.14 
188 THR 7.60 108.06 
189 ASP 8.30 125.63 
190 VAL 9.19 123.15 
191 ALA 9.45 127.15 
192 THR 7.15 111.83 
193 PHE 9.45 124.40 
194 LYS 8.55 122.49 
195 SER 9.14 126.07 
196 VAL 6.01 112.48 
197 ASN 9.74 118.55 
198 TYR 9.10 119.11 
199 GLY 7.42 106.12 
206 ASN 9.51 128.16 
207 GLY 8.69 102.65 
208 LYS 7.64 119.55 
209 ILE 8.97 124.35 
210 ASP 8.41 126.90 
211 TYR 8.50 124.97 
212 GLN 8.38 120.62 
214 THR 8.32 114.96 
217 ARG 8.04 115.83 
218 LYS 7.35 121.46 
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219 HIS 7.88 115.52 
220 THR 9.74 110.01 
221 SER 8.48 118.56 
222 ASP 8.93 120.65 
223 THR 7.43 110.50 
225 PHE 6.53 119.53 
226 ASP 7.92 122.61 
227 VAL 8.92 118.68 
228 SER 8.27 117.72 
235 LYS 9.13 123.60 
236 VAL 9.40 125.99 
237 GLY 8.68 116.35 
238 ILE 9.73 118.59 
244 ASN 7.93 117.90 
245 ALA 5.43 119.38 
250 ALA 7.51 117.17 
251 LYS 8.55 117.51 
252 ALA 8.52 118.63 
253 LEU 10.39 120.78 
255 ASP 9.00 122.94 
256 ALA 7.36 118.66 
257 GLY 8.17 107.97 
258 TYR 7.99 120.57 
259 ASP 8.07 121.02 
266 VAL 8.42 110.13 
268 ASN 9.85 129.79 
269 GLY 7.87 105.18 
270 ASN 9.02 123.18 
271 LEU 8.52 118.06 
272 TYR 7.89 123.83 
273 LYS 7.12 128.58 
274 SER 6.47 113.21 
275 VAL 7.41 126.32 
276 PHE 8.76 121.61 
277 ASP 8.51 118.37 
278 THR 7.53 116.73 
279 LEU 8.68 122.06 
280 ALA 9.40 123.86 
281 THR 7.69 115.78 
282 ALA 8.21 125.43 
283 ALA 8.74 122.24 
284 LYS 7.60 117.79 
285 THR 7.75 107.82 
286 GLY 7.55 107.57 
287 THR 8.06 122.06 
288 ALA 7.93 129.82 
289 VAL 9.24 124.29 
291 ARG 9.40 126.24 
293 SER 8.84 115.31 
294 ARG 9.72 126.42 
295 VAL 8.94 124.61 
297 THR 7.27 107.99 
298 GLY 8.71 109.55 
299 ALA 7.77 118.74 
300 THR 7.93 121.67 
301 THR 8.96 119.05 
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302 GLN 8.34 119.29 
303 ASP 9.14 118.91 
304 ALA 8.26 124.25 
305 GLU 8.35 119.48 
306 VAL 7.60 117.29 
307 ASP 8.33 127.32 
308 ASP 7.99 126.88 
309 ALA 8.47 120.97 
310 LYS 7.37 118.93 
311 TYR 6.90 113.46 
312 GLY 7.91 107.41 
313 PHE 7.49 116.58 
314 VAL 8.01 120.27 
315 ALA 9.26 131.03 
317 GLY 8.65 116.18 
319 LEU 7.04 120.22 
320 ASN 7.38 124.84 
333 THR 7.71 110.55 
334 GLN 8.11 119.26 
335 THR 8.65 116.00 
336 LYS 8.14 121.23 
337 ASP 8.55 124.98 
339 GLN 8.17 117.04 
340 GLN 7.70 119.90 
341 ILE 8.88 121.76 
342 GLN 8.78 121.26 
343 GLN 7.80 118.58 
344 ILE 8.07 121.97 
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Characterization of the Conjugation Pattern in Large Polysaccharide–
Protein Conjugates by NMR Spectroscopy
Stefano Giuntini, Evita Balducci, Linda Cerofolini, Enrico Ravera, Marco Fragai,*
Francesco Berti,* and Claudio Luchinat*
Abstract: Carbohydrate-based vaccines are among the safest
and most effective vaccines and represent potent tools for
prevention of life-threatening bacterial infectious diseases, like
meningitis and pneumonia. The chemical conjugation of
a weak antigen to protein as a source of T-cell epitopes
generates a glycoconjugate vaccine that results more immuno-
genic. Several methods have been used so far to characterize
the resulting polysaccharide–protein conjugates. However,
a reduced number of methodologies has been proposed for
measuring the degree of saccharide conjugation at the possible
protein sites. Here we show that detailed information on large
proteins conjugated with large polysaccharides can be achieved
by a combination of solution and solid-state NMR spectros-
copy. As a test case, a large protein assembly, l-asparaginase
II, has been conjugated with Neisseria meningitidis serogroup
C capsular polysaccharide and the pattern and degree of
conjugation were determined.
Encapsulated bacteria, such as Neisseria meningitidis, Strep-
toccoccus pneumoniae and Haemophilus influenzae, have
polysaccharides on their exterior.[1] The capsular polysaccha-
rides protect the microorganism from adverse environmental
conditions, prevent the activation of the host immune system
and improve adhesion to invade the host.[2–4] Capsular
polysaccharides of pathogens have been used to produce
vaccines that are effective in adults,[5,6] but result ineffective in
children below 2 years of age:[7–9] being T-cell-independent
antigens, they do not induce B-cell memory and do not
stimulate the production of immunoglobulin G (IgG). How-
ever, a T-cell-dependent response (thus inducing B-cell
memory) can be obtained by chemical coupling of polysac-
charides to immunogenic proteins. Polysaccharide–protein
conjugates are commonly obtained by covalent linkage of
reactive precursors to the e-amino groups of surface-exposed
lysine residues or other reactive amino acids.[10] This con-
jugation strategy may lead to a highly random derivatization:
the protein can be glycosylated at different sites and to
different extents at each site (conjugation pattern); this in
turn leads to a polydispersity in the resulting protein
conjugates (Figure 1). To overcome this limitation, dedicated
synthetic strategies are being developed.[11]
Together with the conjugation pattern of the polysaccha-
ride, the preservation of the native protein structure may
influence the immunogenicity and efficacy of the glycoconju-
gate vaccines.[12–14] Therefore, the structural characterization
of the protein component, the identification of the conjuga-
tion sites, and the evaluation of the conjugation degree at
different lysine sites are a compelling requirement towards
structure-based development[15–18] of glycoconjugate vaccines.
The presence of polysaccharide chains prevents the crystal-
lization of the protein conjugates, and extends the molecular
weight of the system beyond the limits of solution NMR
spectroscopy,[19] similarly to what happens upon PEGyla-
tion.[20–22] Solution NMR spectroscopy is currently used to
characterize both the polysaccharide[23,24] and the protein
components separately before the conjugation.[25] Several
solution-based analytical methods have been used so far to
characterize the polysaccharide–protein conjugates.[13,26, 27]
SDS-PAGE and HPLC-SEC are often used to determine
the size and hydrodynamic volume of the conjugates, and to
estimate the number, but not the position, of the polysaccha-
ride chains covalently bound to the protein. Also small-angle
X-ray/neutron scattering and light scattering provide infor-
mation on the size and shape of the coated proteins, but
cannot map the conjugation sites.[28,29] More detailed infor-
mation on the conjugation sites along the primary sequence of
the protein can be achieved by mass spectrometry.[27] How-
ever, also for mass spectrometry the evaluation of the
conjugation degree at the different sites in polydisperse
populations of isomers is a challenge. Recently, we have
shown that structural information on large PEGylated
proteins, such as E. coli l-Asparaginase-II (138 kDa,
ANSII, see the Supporting Information), can be obtained
by solid-state NMR spectroscopy.[30] Several excellent reports
on capsular polysaccharides, bacterial cell walls and their
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maturation have been obtained by the same technique.[31–33]
ANSII is not used as carrier protein in glycoconjugate
vaccines, however, it yields highly resolved SSNMR spec-
tra,[30] and approximately 74% of the resonances have been
assigned (unpublished data). We have thus selected ANSII as
a model system for this investigation. In the present work,
ANSII has been conjugated to the capsular polysaccharide
obtained from the meningococcal serogroup C (MenC). The
polysaccharide is a homopolymer of a2-9-linked N-acetyl-
neuraminic acid (NeuNAc) with partial O-acetylation at
position C7 and C8, and has been coupled to lysine residues
through an adipic acid linker. This work shows for the first
time that highly glycosylated proteins are now an affordable
target for structural characterization by SSNMR spectrosco-
py, and the pattern and the degree of conjugation can be
identified.
ANSII-MenC was investigated through solution and
solid-state NMR spectroscopy. The increase in hydrodynamic
volume of the ANSII after the conjugation with MenC
prevents the detection of the HN signals of the backbone by
standard solution 1H-15N TROSY-HSQC spectra. However,
such a spectrum of ANSII-MenC [U- 2H 13C 15N] displays
about 10 new HN signals in the region between 125 and
128 ppm on the 15N dimension. As already observed in the
case of PEGylation,[30] these signals correspond to the amide
groups generated by functionalization of the e-amino group of
lysines (Hz-Nz) with the MenC polysaccharide moieties. The
resonances of the non-functionalized lysines would appear at
very low 15N chemical shift values (around 30 ppm), but are
usually wiped out by exchange. On the contrary, when they
become amides, exchange is slowed down and the intrinsic
flexibility of the sidechain justifies the appearance of the Hz-
Nz cross-peaks. These signals are markers that can provide
direct information on the number of lysine residues involved
in the formation of new bonds with the MenC polysaccharide.
However, the assignment of each Hz-Nz couple to the
corresponding H-N of the backbone is a difficult task because
of the high overlap between Hz-Nz signals, and the lack of
connections between the two H-N couples across the side
chain. For the solid-state NMR investigation, ANSII (either
free or its MenC conjugate) was freeze-dried, packed into the
magic-angle spinning (MAS) rotors, then rehydrated to
restore the resolution.[30,34–36] The spectra collected on the
pelleted ANSII-MenC conjugate (Figure 2) are largely super-
imposable to those of the native and PEGylated forms of the
enzyme (see Figure S2 in the Sup-
porting Information) making pos-
sible the assessment of the preser-
vation of the protein fold after
conjugation with the MenC poly-
saccharide.[37–40] The resonances of
the protein residues were easily
reassigned starting from the assign-
ment of the native form of ANSII,
by using a carbon-detection
approach (Figure S3).[41] However,
the spectral overlap due to the
large number of protein resonan-
ces does not allow for straightfor-
ward identification of the lysine resonances. Therefore,
selective labeling with 1H, 13C, 15N lysine residues was applied
in an otherwise U-2H, NAC, NAN sample of ANSII, hereon [U-
2H, Lys-1H, 13C, 15N]. Assignment of 19 out of 22 lysine side-
chains of free and functionalized ANSII was achieved
through such a combination of solution and solid-state
NMR spectra (see the Supporting Information for details).
The three unassigned lysine residues (K44, K51 and K229) are
all solvent-exposed. Two spin systems could be identified in
the SSNMR spectra, while the third is probably lost because
of overlap.
The evaluation of the conjugation pattern was achieved by
integrating solution and solid-state NMR data. The Hz-Nz
cross-peaks corresponding to seven lysine residues could be
assigned in the 2D 1H-15N TROSY-HSQC (Figure 3b, top).
The intensity of the signals was used as a parameter to
evaluate the functionalization degree, although the signal
overlapping and the different dynamics of each lysine residue
do not make possible a precise quantitative measurement. In
this respect, the high signal intensity of K251, K101 and K273
is consistent with a high degree of conjugation, while for
K208, K218, K273 and K310, the lower signal intensity
indicates a lower derivatization. Complementary information
has been obtained from the analysis of the changes in the
Figure 2. 2D 13C-13C DARR solid-state NMR spectra of ANSII-MenC
acquired at 850 MHz and 290 K (mixing time 50 ms).
Figure 1. Schematic representation of the polydispersity in the population of ANSII-MenC conjugates.
The steric hindrance (represented by red curves) of the already bound polysaccharide chains prevents
further conjugation of the surrounding lysine residues.
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relative intensity of the cross-peaks correlating the Ca and the
Ce of the lysine side chains in the 2D
13C-13C dipolar-aided
rotary resonance (DARR) of the free and conjugated protein
(Figure 3b, bottom). In particular, we have observed remark-
able differences in the signal intensity among different groups
of resonances in the spectrum of ANSII-MenC (Figure 3b,
bottom). The disappearance of the Ca-Ce cross-peaks in the
spectra of the conjugated protein can be taken as a proof of an
extensive conjugation of the lysines. A complete disappear-
ance of the Ca-Ce cross-peak was observed for two solvent-
exposed unassigned lysines (belonging to K44 and/or K51
and/or K229), and for K273. Also, the signals of residues K65,
K71, K101, K161, K208, K218, K235, K251, K284 and K336
exhibit a decrease in signal intensity. However, the corre-
sponding cross-peaks are still visible in the spectrum of the
conjugated protein, indicating the presence of a significant
amount of unreacted residue (Figure 3b). Conversely, for the
residues K93, K94, K126, K129, K184, K194, K323 bearing no
solvent exposed Nz the decrease in intensity is negligible as
expected for non-conjugated lysines.
For better evaluation of the conjugation degree, the
information provided by solution and solid-state NMR
spectroscopy is summarized in a simple graph reporting the
relative signal intensity in the 13C-13C DARR and 1H-15N
TROSY-HSQC (Figure 3a). The analysis of the conjugation
degree obtained by combining the solution and solid-state
data is summarized in Figure 3c where the lysines are
represented as spheres and color-coded from dark red
(highly conjugated) to yellow (poorly conjugated). The non-
conjugated lysines are represented as black spheres.
In conclusion, solid-state NMR spectra of glycosylated
proteins showing an extremely high quality were obtained,
Figure 3. a) Relative signal intensities of Hz-Nz cross-peaks in the 2D
1H-15N TROSY-HSQC versus the relative signal intensities of the Ca-Ce cross-
peaks in 2D 13C-13C DARR of ANSII-MenC. The Hz-Nz cross-peak intensities have been related to the intensity of the Hz-Nz of K251, that is the
most intense, while the Ca- Ce peak intensities have been related to the intensity of the Ca- Ce cross-peaks of K126 that is the most intense and
isolated. The stars indicate the two spin systems for which the assignment is missing. b) Enlarged region of the 2D 1H-15N TROSY-HSQC of
ANSII-MenC acquired at 950 MHz, 310 K (top). Enlargement of the region of the 2D 13C-13C DARR spectrum of the ANSII-MenC displaying the
correlation between the Ca and the Ce of the lysine sidechains (bottom). The assignment of each lysine is reported in the Figure. The stars
indicate the two spin systems for which the assignment is missing. c) Surface representation of ANSII (PDB code: 3ECA) with the lysine residue
color-coded according to the degree of conjugation, from dark red (highly conjugated) to yellow (poorly conjugated). The non-conjugated lysines
are represented as black spheres.
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making it possible to confirm the preservation of the protein
fold and to achieve a residue-specific assignment of the
spectral perturbations that occur upon glycosylation. A
simple comparison of patterns of the Hz-Nz and Ca-Ce
cross-peaks, respectively in solution and solid state, can be
used to assess the preservation of the saccharide conjugation
degree at the protein sites, for instance after major changes in
the production process of the glycoconjugate vaccines. We
have here applied a strategy that is based on a combination of
solution and solid-state NMR experiments, which permits the
identification of the residues bearing the polysaccharide chain
and provides semi-quantitative information on the conjuga-
tion degree obtained by random chemical coupling. The
traditional strategy based on the generation of several single
point mutants of a protein to assign a specific amino acid may
be risky under this circumstance to assign the single lysines
and to evaluate their degree of conjugation, since the
functionalization of a lysine may sterically hinder nearby
lysine residues (Figure 1). The present approach allowed us to
assign 19 lysines, to identify two additional spin systems while
one is still missing or in overlap, without altering the reaction
propensity of any of the lysines. The characterization of large
polysaccharide–protein conjugates and highly glycosylated
proteins is still a challenge in structural biology and an
important goal for the development of vaccines and biologics,
and this protocol has the possibility to provide key informa-
tion for rational design of novel products with improved
efficacy.
Experimental Section
Preparation of ANSII-MenC conjugates is described in the
Supporting Information.
Solution NMR spectra were recorded at 310 K on Bruker
AVANCEIII-HD NMR spectrometers operating at 900 and
950MHz 1H larmor frequency, equipped with triple resonance cryo-
probes (see the Supporting Information). Protein samples were in
water buffered solution [20 mm sodium phosphate, pH 7.5, 0.02%
NaN3, 0.1 mgmL
ˇ1 protease inhibitors (Pefabloc)].
SSNMR spectra were acquired on a Bruker AvanceIII spectrom-
eter operating at 800 MHz (Bruker 3.2 mm Efree NCH probehead)
or on a Bruker Avance III spectrometer operating at 850 MHz
(Bruker 3.2 mmNCHDVT probehead). All spectra were recorded at
14 kHz MAS frequency and the sample temperature was kept at
290 K.
Samples of freeze-dried free ANSII (U- 2H, Lys-1H, 13C, 15N ca.
10 mg of material) and ANSII-MenC (U-13C-15N ca. 14 mg of
material; U-2H, Lys-1H, 13C, 15N ca. 5 mg of material) were packed
into Bruker 3.2 mm zirconia rotors, then rehydrated until the
resolution of the 13C 1D SSNMR spectrum stopped chang-
ing.[30,34–36,42–44] Standard 13C-detected two-dimensional spectra [13C-
13C DARR,[45,46] 15N-13C NCA,[47] 15N-13C NCO[48]] were acquired
according to reference.[49] These experiments last around 5 and
10 days for samples of free ANSII and ANSII-MenC, respectively. 1H
decoupling was set to 80 kHz using the swept-frequency two-pulse
phase modulation scheme[50] and the optimal interscan delay was
found to be 2.2 s.
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Supporting text 
L-asparaginase II from E. coli (ANSII) has been used as a model protein to develop a new 
strategy for the identification of the polysaccharide conjugation sites and for a semi quantitative 
characterization of the conjugation degree of the different lysine residues. ANSII is one of the 
oldest biologics approved for clinical use, as PEGylated protein, in the treatment of acute 
lymphoblastic leukemia.[1] In the native form, ANSII consists of a dimer of dimers of 138 kDa.[2] 
The assignment of backbone resonances of about 74% of the residues of the ANSII has been 
obtained by a combination of proton-detected and carbon-detected solid-state NMR (SSNMR) and 
solution NMR experiments on perdeuterated samples of the native protein (unpublished results).  
Methods 
Uniformly labeled 13C and 15N [U- 13C, 15N] ANSII was obtained as already described,[3] 
whereas modified media were used for the production of the perdeuterated samples, [U-2H, 13C, 
15N] ANSII and [U- 2H, Lys-1H, 13C, 15N] ANSII. 2H, 13C, 15N-enriched Silantes OD2 was used for 
the production of [U-2H-13C-15N] ANSII, whereas 2H-enriched Silantes OD2 medium supplied with 
241.5 mg L-1 13C,15N-labeled lysine (purchased by Sigma-Aldrich) was used for the production of 
[U- 2H, Lys-1H, 13C, 15N] ANSII. Expression in these media, extraction and purification were then 
performed as previously reported.[3] 
MenC polysaccharide, terminally activated with adipic acid N-hydroxysuccinimide ester 
was obtained from GSK Vaccines (Siena, Italy). 
ANSII-MenC conjugates were obtained by reacting ANSII protein ([U- 13C, 15N], [U-2H, 
13C, 15N] and [U- 2H, Lys-1H, 13C, 15N]) with an adipic acid N-hydroxysuccinimide ester derivative 
of the MenC polysaccharide (protein concentration of a1 mg/mL in 0.1 M sodium phosphate buffer 
pH 7.2 and MenC to protein molar ratio of 12:1). After overnight incubation at room temperature 
with gentle stirring, the conjugates were purified from the unreacted polysaccharide by size 
exclusion chromatography (SEC) on Superdex™ 200 resin (GE Healthcare) and dialyzed on 10 
MW cut-off membrane against 150 mM sodium phosphate pH 7.5 buffer.  
The total saccharide and protein content of ANSII-MenC conjugates were determined by 
colorimetric sialic acid assay[4] and BCA assay (Thermo, Pierce).  
SDS-PAGE and HPLC-SEC chromatography analyses of ANSII-MenC conjugates, in 
comparison with ANSII, were performed to assess the covalent conjugation and product size 
(Figure S1). HPLC-SEC analysis was performed on a TSK3000GelSW analytical column with 
TSKguard column (Tosoh Bioscience) connected to an UltimateTM3000 HPLC system (Dionex-
Thermo Fisher Scientific) equipped with a PDA detector. Chromatography was performed in 0.1 M 
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sodium sulfate 0.1 M sodium phosphate 5% CH3CN pH 7.2 at flow rate of 0.5 mL/min. Data were 
recorded and processed using ChromeleonTM 6.7 software. 
3D tr-HNCA[5] and tr-HNCACB[6] solution NMR spectra have been acquired on samples of 
[2H-13C-15N] ANSII (0.7 mM) functionalized with the polysaccharide. For these three-dimensional 
experiments the TROSY approach was required because of the high molecular weight of the 
protein.[7] 3D 1H-15N NOESY (mixing time 100 ms) and 3D 1H-1H-1H NOESY-NOESY [8] (100 ms 
for both mixing times) NMR spectra have been acquired on solutions of [U- 2H, Lys-1H, 13C, 15N] 
ANSII as free protein (1 mM) and functionalized with the MenC (0.5 mM). 3D 1H-13C NOESY 
(mixing time 100 ms) has been also acquired on ANSII-MenC. Each 3D NOESY spectrum lasts 
from 3 to 5 days. 
The SSNMR spectra of [U-13C-15N] ANSII were acquired at 850 MHz. Pulses were 2.6 μs 
for 1H, 4.4 μs for 13C and 6 μs for 15N. In the 2D 15N-13C NCA and 2D 15N-13C NCO experiments, 
1H-15N cross polarization (CP)[9] was achieved by 1H-15N (ωH = 49 kHz, ωN = 35 kHz) with a 95-
105 linearly ramped contact pulse on 1H[10] and a contact time of 2.2 ms; the double cross-
polarization (DCP) was achieved at the matching conditions ωH = 76 kHz, ωN = 35 kHz, ωC = 21 
kHz for NCA, with 6 ms contact time and ωH = 76 kHz, ωN = 35 kHz, ωC = 49 kHz for NCO, with 
4.5 ms contact time. In both cases a 95-105 linearly ramped contact pulse on 13C[10] was used. In 2D 
13C–13C DARR the 1H-13C CP contact time was set to 1 ms (ωH = ωC = 50 kHz) with a 95-105 
linearly ramped contact pulse on 1H;[10] DARR mixing time was 50 ms with ωH = ωR. The 3D 
NCACX experiment (Figure S3) was acquired at 800 MHz and the Cα-CX mixing time was set to 
40 ms; the non-uniform sampling approach was implemented (NUS 33%) and the number of scan 
was 256. 
The SSNMR spectra of [U- 2H, Lys-1H, 13C, 15N] ANSII were acquired at 800 MHz. Pulses 
were 2.12 μs for 1H, 3.5 μs for 13C and 5.6 μs for 15N. In the 2D 15N-13C NCA experiments 1H-15N 
CP was achieved by 1H-15N (ωH = 49 kHz, ωN = 35 kHz) with a 100-70 linearly ramped contact 
pulse on 1H[10] and a contact time of 1 ms; DCP was achieved at the matching conditions ωH = 80 
kHz, ωN = 35 kHz, ωC = 21 kHz, with 3.5 ms contact time and a tangential contact pulse on Cα was 
used; the number of scan was set to 512 for the sample of free ANSII and 1056 for the ANSII-
MenC sample. In the 3D NCACX experiments, acquired on the samples of free, the Cα-CX mixing 
time was set to 30 ms and the non-uniform sampling approach was implemented (NUS 24%); the 
number of scan was 64 and the duration of about 4 days and a half. In 2D 13C–13C DARR the 1H-
13C CP contact time was set to 1.5 ms (ωH = 74 kHz, ωC = 60 kHz) with a 100-70 linearly ramped 
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contact pulse on 1H; DARR mixing time was 100 ms; the number of scans was set to 144 for the 
sample of free ANSII and 240 for the ANSII-MenC sample. 
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Data analysis 
Analysis of NMR spectra of free ANSII [U- 2H, Lys-1H, 13C, 15N] 
The 2D 1H-15N TROSY-HSQC of the free [U- 2H, Lys-1H, 13C, 15N] ANSII in solution 
(Figure S4) displays 18 HN signals out of the 22 expected signals for the backbone HN of the lysine 
residues present in the protein sequence. All the visible signals (18) could be assigned from the 
previous spectra collected on samples of U- 2H-13C-15N free ANSII (unpublished data). The 
selective labelling strategy, allowed for solving some assignment ambiguities and the lysine 
assignment could be extended from 15 to 18 spin systems. Three of the lysine residues (K44, K51 
and K229), whose signals are missing in the spectrum, are located on highly flexible regions of the 
protein and the fourth (K323) on a α-helix inside the hydrophobic core of the three-dimensional 
structure of the protein. In the 2D 1H-15N HSQC, acquired with a larger 15N spectral window, a 
single signal is visible for the sidechains Hζ-Nζ correlation at the 15N frequency of 33.9 ppm. 
The assignment of the protons of the lysine side-chains (Hα, Hβ, Hγ, Hδ, Hɛ) was obtained 
from the analysis of the 3D 1H-15N NOESY and 1H-1H-1H NOESY-NOESY solution NMR spectra 
of the free ANSII. 
In the analysis of 2D 15N-13C NCA and 2D 13C-13C DARR solid-state NMR spectra (Figure 
S5) of freeze-dried/hydrated free ANSII (U- 2H, Lys-1H, 13C, 15N) it was possible to identify 21 
lysine spin systems. It is interesting to note that in the solid-state NMR spectra 3 additional spin 
systems are visible with respect to the 2D 1H-15N HSQC acquired in solution. One of these signals 
has been assigned to K323; unfortunately, the assignment of the other two spin systems is missing, 
but these signals can be related to K44, K51 or K229, that are all solvent exposed lysines. The 
assignment of the carbon chemical shifts of the lysine side-chains (Cα, Cβ, Cγ, Cδ, Cɛ) was obtained 
from the combined analysis of the 3D NCACX and 2D 13C-13C DARR SSNMR spectra. For 7 
lysine residues (K93, K94, K126, K184, K194, K284, K323), that are buried inside the protein 
structure, it was also possible to assign the Nζ from the Nζ-Cɛ correlations visible in the 2D 15N-13C 
NCA; conversely the Nζ-Cɛ signals could not be identified for all the other lysines, most of which 
are solvent-exposed.  
Figure S6 shows the region of the 2D 13C-13C DARR spectrum displaying the correlation 
between the Cα and the Cɛ of the lysine sidechains. The relative intensity of these cross-peaks can be 
affected by different factors: i) the flexibility of the protein region where the residue is placed (a 
secondary structure element or a loop), and ii) its solvent accessibility. In particular, the Cα-Cɛ 
cross-peaks with the highest intensity correspond to residue K93, K94, K126, K129, K184, K194 
and K323, that are buried inside the protein structure. 
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Analysis of NMR spectra of functionalized ANSII [U- 2H, Lys-1H, 13C, 15N]. 
The assignment of H]1] cross-peaks of the functionalized lysine residues has been 
obtained for 7 lysine residues (K71, K101, K208, K218, K251, K273, K310) (Figure 3b, top). This 
assignment has been obtained from the correspondence in the 3D NOESY spectra between the Hα, 
Hβ, Hγ chemical shifts of the NOE cross-peaks of each H]1]couple with the proton chemical 
shifts assigned for each HN-N backbone couple from the spectra of free ANSII. In most cases the 
assignment is validated also by the presence of a NOE cross-peak between the H]and the backbone 
HN (K71, K101, K208, K251, K273, K310).  
The 2D 15N-13C NCA and 13C-13C DARR solid-state NMR spectra of freeze-dried/hydrated 
ANSII-MenC (U- 2H, Lys-1H, 13C, 15N) (Figure S7) were reassigned starting from the spectra of 
free ANSII.  
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A)  
 
B)  
 
 
1. MW marker reference 
2. ANSII unlabeled 
3. ANSII 13C15N labeled 
4. ANSII unlabeled-MenC conjugate 
5. ANSII 13C15N-MenC conjugate 
 
1          2               3            4              5 
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C) 
 
 
Figure S1. Synthesis and characterization of MenC-ANSII conjugates. (a) Schematic 
representation of conjugation method and conjugates’ structure, (b) SDS-Page and (c) HPLC-SEC 
profiles.  
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Figure S2. 2D 13C-13C DARR solid-state NMR spectra of polysaccharide-ANSII (red) and 
crystalline ANSII (blue) acquired at 850 MHz and 290 K (MAS = 14 kHz, mixing time 50 ms). The 
two regions separated by dashed lines are plotted with different relative intensities for the two forms 
to ease comparison between the spectra. 
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Figure S3. 3D NCACX spectrum performed on freeze-dried/hydrated ANSII-MenC (U- 13C, 15N) 
at 800 MHz and 290 K. The MAS frequency was set to 14.0 kHz. 
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Figure S4. 2D 1H-15N TROSY-HSQC of the free ANSII (U- 2H, Lys-1H, 13C, 15N) in solution 
acquired at 950 MHz, 310 K. The assignment of the lysine residues is displayed on the spectrum. 
 
	
191	
	
 
Figure S5. 2D 13C-13C DARR (A) and 2D 15N-13C NCA (B) solid-state NMR spectra of freeze-
dried/hydrated free ANSII (U- 2H, Lys-1H, 13C, 15N) acquired at 800 MHz and 290 K. The 
assignment of the lysine residues is reported on the 2D 15N-13C NCA spectrum, the stars indicate 
the two spin systems for which the assignment is missing. 
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Figure S6. Enlargement of the region of the 2D 13C-13C DARR spectrum of the free ANSII (U- 2H, 
Lys-1H, 13C, 15N) displaying the correlation between the Cα and the Cɛ  of the lysine sidechains. The 
assignment for the Cα-Cɛ cross-peaks is indicated in the figure, the stars indicate the two spin 
systems for which the assignment is missing. 
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Figure S7. 2D 13C-13C DARR (A) and 2D 15N-13C NCA (B) solid-state NMR spectra of freeze-
dried/hydrated polysaccharide-ANSII (U- 2H, Lys-1H, 13C, 15N) acquired at 800 MHz and 290 K. 
The assignment of the lysine residues is reported on the 2D 15N-13C NCA spectrum, the stars 
indicate the two spin systems for which the assignment is missing. 
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Engineering L-asparaginase for spontaneous
formation of calcium phosphate bioinspired
microreactors†
Alexandra Louka, ab Irina Matlahov, ‡c Stefano Giuntini, ab
Linda Cerofolini, a Andrea Cavallo,d Serena Pillozzi, e Enrico Ravera, *ab
Marco Fragai, *ab Annarosa Arcangeli, e Ayyalusamy Ramamoorthy, fg
Gil Goobes c and Claudio Luchinat *ab
Active bioinspired materials are appealing biotechnological targets, and their study is gaining momentum.
These materials, which comprise of an inorganic matrix and one or more biomolecules, are extremely
variable and therefore may result difficult to characterize in their intimate structure. In this work we have
prepared a hydroxyapatite–L-asparaginase composite, with the perspective of using it in acute leukemia
treatment. We demonstrate that the use of electron microscopy and powder X-ray diffraction, combined
with the atomic-resolution information coming from solid-state NMR, allows us to understand the
topology of the material and how the different components interplay to obtain an active composite.
Introduction
Biological drugs (biologics1) are the fastest-growing category of
approved therapeutics, with most biologics being represented
by proteins.2 L-Asparaginases, which catalyze the hydrolysis of
L-asparagine (Asn) to L-aspartate (Asp), are one of the earliest
examples of biologics. The depletion of Asn from circulating
blood induces cell death in acute lymphoblastic leukemia
(ALL) cells, which lack the Asn-synthetase enzyme.3,4 The most
commonly used biologics in therapy are type-II bacterial
L-asparaginases (ANSII), with E. coli ANSII being in clinical use
since 1967.5 ANSII is indispensable in ALL treatment protocols
and is used for remission induction and intensification in all
pediatric and most adult regimens.6 However, treatment with
ANSII can lead to severe side effects that comprise hepato- and
pancreas toxicity, coagulation disorders and, most relevant,
allergic reactions. ANSII can be administered both intravenously
(IV) or intramuscularly (IM), the latter route being better
tolerated and less often resulting in increased hypersensitivity
reactions.7 The relevance of antibodies directed against ANSII in
children with ALL has been highlighted in the Berlin–Frankfurt–
Mu¨nster (BFM) studies, and recently reviewed:8 adverse reactions
to the enzyme mediated by either IgG or IgE antibodies, or both,
have been described.9 The appearance of antibodies increases
ANSII clearance and neutralizes the catalytic activity of the
enzyme.10 Therefore, it is of capital importance to reduce
the interaction of the enzyme with the immune system of
the patients. Several strategies have been devised to reduce
immunogenicity, the most common being PEGylation.11
However, PEG may cause severe side effects in patients with
progressive chronic kidney disease12 and can induce allergic
reactions even when administered IM.7
A radically different strategy would be to avoid contact with
the immune system of the patient altogether. Extracorporeal
processing of blood has been proposed almost forty years ago,
with limited follow-up in clinical practice, mostly because of
the limited compliance of the treatment.13 Nowadays, better-
designed biomedical devices that can be used to physically
confine active components within a membrane are available.
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This possibility mitigates the need of obtaining an enzyme that
is able to evade immune recognition. On the other hand, the
incorporation of an enzyme within a device requires that the
formulation has a long lifetime, both on the shelf and in operando,
that it is easily handled (weighted, transferred, etc.) and that the
active site is accessible. For these reasons, the possibility of
extracorporeal processing has triggered a strong interest in the
protein immobilization community.14,15
Here, we describe the design of a biomaterial that carries an
ANSII chimera attached to a hydroxyapatite (HA) support, because
HA-based composites have already been used as new biomedical
devices,16–18 drugs and vaccine carriers,19–24 and because immobili-
zation of enzymes often results in stabilization.25
The characterization of bioinspired materials is a complex
accomplishment because it needs to rely upon the character-
ization of both the inorganic matrix and the biomolecular
component.26–31 In this context, NMR plays a very important
role, as it is the only methodology that can access atomic-level
information on both components.32–41
Results and discussion
Native, therapeutically active ANSII is a homotetrameric assembly
of about 140 kDa with D2 symmetry (a dimer of two intimate
dimers)42 with four catalytic sites per tetramer. We have previously
provided the NMR characterization of ANSII in its free, PEGylated,43
sugar-conjugated forms44 and bound to gold nanoparticles.45 We
fused ANSII with a C-terminal tail encompassing the HA-promoting
peptide (HABP) W6p (RWRLEGTDDKEEPESQRRIGRFG; Fig. S1,
ESI†).46 Gel-electrophoresis and dynamic light scattering show that
ANSII–HABP is smaller (B80 kDa) than the native enzyme, and
likely corresponds to a single intimate dimer (Fig. S2–S4, ESI†).
However, it still retains about one-fourth of the catalytic activity per
monomer (Fig. S5, ESI†).
The HA/ANSII–HABP composite was prepared by self-promoted
biomimetic mineralization of HA driven by HABP (see ESI†). After
repeated washings to remove the unbound enzyme, the activity of
HA/ANSII–HABP was assayed using NMR (Fig. S6 and S7, ESI†),
under the same conditions used for metabolomic profiling of serum
(Fig. S7, ESI†).47 HA/ANSII–HABP was still active after more than
three months of storage at 4 1C. The efficacy of HA/ANSII–HABP was
then tested in vitro on human ALL cells (697 cell line), and compared
to either the wild-type (WT) enzyme or the commercial product
Oncaspar (i.e. PEG-ANSII). All ANSII preparations were added at
0.74 U mL!1 concentration, according to previous reports.48,49
HA/ANSII–HABP was kept separated from leukemic cells via a
3.5 kDa cut-off dialysis membrane. HA/ANSII–HABP reduced the
leukemic cell viability to the same extent (after 24 hours of
incubation) and evenmore (at 48 hours of incubation) compared
to either the free enzyme or the commercial product (Fig. 1).
HA/ANSII–HABP was further characterized using powder
X-ray diffraction (XRD), scanning electron microscopy and solid-
state NMR. The XRD profile (Fig. 2), shows the typical diffraction
pattern of HA,50 while the diffraction at low 2y suggests the
simultaneous presence of some octacalcium phosphate (OCP).51
The diffraction peaks are broad, as expected for crystallites
of small size. By elemental analysis, the protein content was
found to be on the order of 40 " 1% in the dried material.
Fig. 1 Effects of different ANSII preparations on the proliferation of ALL cells.
ALL 697 cells were treatedwith different ANSII preparations (HA/ANSII–HABP,
WT ANSII and Oncaspar) at a concentration of 0.74 U mL!1 for 24 and
48 hours and the number of live cells, determined via the Trypan Blue
exclusion test, was measured. HA/ANSII–HABP was confined in a device
with walls consisting of a 3.5 kDa cut-off dialysis membrane. Data are
mean values" standard error of the mean of three independent experiments.
48 hours: HA/ANSII–HABP vs. WT ANSII, p = 0.00116; HA/ANSII–HABP vs.
Oncaspar, p = 0.00449, as tested by one way ANOVA.
Fig. 2 Top: XRD profile of the HA/ANSII–HABP composite (black line).
Bottom: Calculated XRD diffractogram of hydroxyapatite (red) and octa-
calcium phosphate (blue) shown as stick plots.
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SEM micrographs show that the material is composed of
fused structures, homogeneous in shape and size (Fig. 3),
which more closely resemble HA nanosheets,52 rather than
OCP spherical particles.
Combustion elemental analysis provided the elemental
composition and a quantitative determination of the protein
content, found to be of the order of 40% in the dried material.
After reacting 1 mL of the mixture, and rinsing it several times,
about 28 mg of wet material are obtained. From the content of
the reaction mixture (see ESI†), the theoretical yield of the dry
material can be calculated: assuming that only HA will form, with a
40% w/w protein content in the material, 4 mg of the composite
should precipitate. If, on the contrary, only OCP is formed, about
2mg of the composite should precipitate. Thus, in the wetmaterial,
we can estimate that 6.5–13% will consist of HA/ANSII–HABP.
HA/ANSII–HABP was further characterized in terms of their
elemental composition using energy dispersive X-ray spectro-
scopy (EDS). Inductively coupled plasma (ICP) emission
was additionally used for elemental analysis of the total Ca
and P content in the sample (Table 1). The ICP measurement
shows a Ca/P ratio of 1.78, higher than the theoretical HA value
of 1.67 (Tables 1 and 2). Such a phosphate depletion has been
also observed53 for HA prepared in the presence of a mineral
binding peptide, and is possibly due to a disordered phase in
addition to the ordered HA phase.53
In order to fully understand the activity of the material, it is
necessary to link the bulk observations to the molecular scale,
answering the following questions:
(a) are the ordered and the disordered layers in contact with
each other?
(b) is the protein in contact with the ordered phase, with the
disordered one or with both?
(c) is the protein exposed to the solvent, thus accessible to
the substrate?
We here demonstrate how solid-state NMR is the methodology
of choice to answer these questions.
A Bloch decay (BD), a homonuclear decoupled 1H spectrum
of HA/ANSII–HABP and a BD spectrum of HA are shown in
Fig. 4. The presence of the HA phase is confirmed by the BD
spectrum (red), where HA/ANSII–HABP has the same OH!
resonance at 0.2 ppm as synthetic HA (green). The BD spectrum
shows a broad intense water resonance at 5.3 ppm (consistent
with the high water content in HA/ANSII–HABP); however, as will
be shown, these water molecules are not necessarily residing at
the enzyme–mineral interface. The peak at 1.3 ppm is associated
with the aliphatic side-chain protons of the protein chimera but
may include some contribution from HA as can be seen by
comparing with the mineral spectrum. In the homonuclear
decoupled wPMLG spectrum (violet) of HA/ANSII–HABP, the
water line is extensively attenuated, exposing three clear bands
at 1.3 ppm, 4.5 ppm and 7.2 ppm from ANSII–HABP protons.
Although the wPMLG experiment is intended to enhance
resolution by 1H–1H decoupling, in this biomaterial sample we
find that it improves the capability to observe the protein
proton lines via a simple solvent suppression mechanism.
Exposing the protons to a strong effective field tilted at the
magic angle causes exclusive broadening of the water signal
beyond detection due to coincidental matching of the water
motional time scale with the field’s decoupling cycle period
(15 ms). The motions experienced by ANSII–HABP are quite
different and therefore are not affected similarly by the homo-
nuclear decoupling. The widths of the ANSII–HABP proton
lines are 3–6 ppm and they result from immobile protein
molecules: these lines are collectively associated with ANSII–
HABP protons belonging to side-chains, Ha and amide protons.
The peak at 1.3 ppm may mask a smaller contribution from HA
(see the spectrum of synthetic HA).
The deconvolution54 of 1H–31P cross-polarization (CP)53
spectra of HA/ANSII–HABP obtained under MAS (Fig. 5a and
Fig. S8, ESI†) reveals two phosphate species, as synthetic HA,53
that can be attributed to two different layers. The peak at
2.9 ppm (FWHM 1.2 ppm) is typical of the phosphate resonance
in HA crystals (denoted hereafter as PHA) while the peak at
Fig. 3 SEM images of the HA/ANSII–HABP composite, taken with (upper
panels) and without (lower panels) conductive staining, revealing a highly
porous structure, which is most suitable for maintaining the accessibility of
the enzyme. The high protein loading at the surface reduces the achiev-
able resolution.
Table 1 Secondary electron emission analysis of HA/ANSII-HABP
Element Average wt% Std% Average atom count Std
C 23 3 1.9 0.2
N 10 3 0.7 0.2
Ca 26 4 0.7 0.1
P 14 2 0.44 0.06
Table 2 Summary of the elemental composition of HA/ANSII–HABP,
compared with expected values
Ratio Measured – EDS Measured – ICP
Expected
for HA
Expected
for OCP
Ca/P 1.6 " 0.3 1.78 1.67 1.33
Ratio Measured Expected for current protein chimeric construct
C/N 2.8 " 0.9 3.57
Protein% 47 " 7
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2.6 ppm (FWHM 3 ppm) is attributed to hydrogen phosphate
ions (HPO4
2!) (denoted hereafter as PHP) which are part of the
disordered calcium phosphate phase that resides at the HA/
ANSII–HABP interface55 (this peak cannot be attributed to beta-
glycerophosphate because it exhibits a higher chemical shift56).
Mono-acid phosphates were shown to adopt a large range of
chemical shifts, depending on the surroundings ions. In HA/
ANSII–HABP this is reflected in the significant width, 7 ppm
(FWHM), of the PHP peak.
55
To characterize the proximity of interfacial and bulk protons
and phosphates, 31P CP build-up curves were analyzed.53
31P CP build-up measurements were carried out by varying
the contact time from 100 ms to 10 ms, and the intensities of
the PHA (black) and PS (red) peaks were plotted against the
contact time (see Fig. 5b). Recently, similar magnetization
build-up curves were used to isolate magnetization transfers
between interfacial protons and phosphates and bulk protons
and phosphates in apatite samples prepared with a bone
protein binding peptide which displays similar properties of
having a crystalline phase of HA and a disordered phase
containing calcium phosphate ions and the biomolecule.53
Here, we follow a similar strategy.
These intensity buildup curves show the rate of magnetiza-
tion transfer from adjacent protons to the two phosphate
species. The relative line intensity in Table 3 is derived from
the fit to the experimental phosphate line, in Fig. 5 as described
below. The integral (integrated intensity) of the experimental
phosphate peak for each contact time point was calculated and
the values were normalized to the highest integral to obtain the
buildup normalized to 1. Each spectrum was then deconvolved
into the two phosphate contributions and the calculated area
under each deconvolved peak was taken as a fraction of one.
Therefore, the intensity per phosphate peak and per contact
point was overall normalized to the fractional intensity of that
phosphate species within each contact time spectrum and
to the intensity of the highest signal in the CP buildup curve.
The curve of PHA was fitted using eqn (1) and that of PHP was
fitted using the extended eqn (2) which accounts for relaxation
processes which further influence transfer.
IðtÞ ¼ I0 % 1! e
! ttCP
! "" #
(1)
IðtÞ ¼ I0
1! tCP
TH1r
 !% e ! tTH1r
# $
! e !
t
tCP
! "264
375 (2)
In these equations, I0 is the overall intensity of phosphate
magnetization, tcp is the typical CP time and (TH1r) is the
longitudinal rotating frame relaxation time of the protons.
The kinetic parameters, summarized in Table 1, were
deduced from best-fitted curves calculated by minimizing the
deviations of signal intensity I0, the magnetization transfer
time constant (tcp) and the 1H rotating frame relaxation time
(TH1r) in calculations and in experiments.
The relatively low normalized PHA intensity, 0.27, is indica-
tive of the low content of crystalline HA in ANSII–HABP. This
line typically has an intensity 40.6 in other co-precipitation
procedures of proteins with HA.53 The extracted magnetization
transfer time of PHA, 3.1 ms (Table 3), closely resembles the
value for synthetic HA (see Fig. 6),53 and is somewhat inter-
mediate between hydroxyl-to-phosphate transfer time in apatite
crystals grown with an osteonectin binding peptide and inter-
facial transfer time from protons outside the crystals to crystal-
line phosphates in that same sample.53
This finding suggests that either water or protein molecules
are located close to the faces of the HA crystal and transfer
magnetization to ordered (crystalline) phosphate ions in
exposed crystal surfaces. The transfer rate of the PHP line,
0.5 ms, is similar to the magnetization transfer observed for
interfacial phosphates in the aforementioned apatite grown
with an osteonectin binding peptide.
Fig. 4 1H NMR spectra of ANSII–HABP acquired using wPMLG for
homonuclear-decoupling (violet) and a simple 901-acquisition (i.e. a Bloch
decay) (red). A 1H Bloch decay spectrum (green) of synthetic hydroxy-
apatite prepared without calcination is also shown for comparison.
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To further probe the local environment sensed by phosphate
groups and identify their distribution within the sample,
we recorded two-dimensional 1H–31P HETCOR MAS NMR
spectra (Fig. 7).
During the 1H magnetization evolution under the chemical
shift in t1, the PMLG decoupling sequence was used to suppress
1H–1H dipolar couplings. Fig. 7 shows an intense cross peak
between HA hydroxyl protons at 0.2 ppm and phosphates at
2.9 ppm (i.e. PHA). It also shows a group of narrower cross peaks
correlating 1H at 1.3 ppm, 4.0–6.5 and 7.0–8.5 ppm along F1
with PHP phosphates. These resonances are attributed to the
protein protons that transfer magnetization to proximal PHP
phosphates in the mineral. The homonuclear decoupling
employed in t1 effectively removes water proton excitation,
and therefore no correlations are observed between water and
phosphate species. This is quite different from other preparations
of apatite minerals,53,57 whereby a strong correlation of water
protons with phosphates in a disordered calcium phosphate layer
on HA crystallites was observed. The absence of the water reso-
nance in the 2D HETCOR spectra is further demonstrated in the
1H projections (taken along the phosphate maximal intensity) of
Fig. 5 (a) An example of the 31P CP spectrum of HA/ANSII–HABP obtained using 3.6 ms contact time deconvoluted using the DMFIT program. The
experimental spectrum (blue) is shown with the sum of simulated peaks (red) and individual lines at 2.6 ppm (green) and 2.9 ppm (purple). (b) 31P intensity
buildup with increasing CP contact time of PHA phosphates (black) and PHP phosphates (red).
Table 3 Kinetic parameters of 31P magnetization buildup of phosphates in
HA/ANSII–HABP
Peak position
(ppm) Assignment
Width
(ppm) tcp (ms) T1r (ms)
Normalized
intensity
2.9 PHA 1.4 3.1 — 0.27
2.6 PHP 5.0 0.5 13.1 0.73
Fig. 6 31P CP buildup curves of PHA (black) and of the HA phosphate line
in hydroxyapatite prepared via a titration method at 310 K (green53). It
shows that the rate of magnetization buildup of PHA in ANSII–HABP is
similar to that of HA, suggesting that this line represents a 31P nucleus in a
crystalline environment.
Fig. 7 1H–31P heteronuclear correlation (HETCOR) spectra of HA/ANSII–
HABP using contact times of 0.5 ms.
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these measurements as compared to similar measurements in
synthetic HA where the relative intensity is much different
(see Fig. S9, ESI†). Similar 1H–31P 2D HETCOR measurements
without PMLG decoupling did not show any water cross peaks
with phosphates, so it is apparent that water molecules are
distantly located from phosphates.
In summary, these spectra show that the protein resonances
correlate with PHP in the disordered layer, which in turn is
connected with the PHA phase. The latter crystalline phase is
mostly excluded from water, suggesting also that this bulk
mineral phase is overall distant from the biomolecule. From
these data, we can conclude that ANSII–HABP is interacting
with a layer of interfacial phosphates (PHP), probably of the
mono-acid type, and has no direct interactions with HA crystal-
lites. Finally, no correlations are here observed between water
and phosphate species: this means that the water molecules are
either located far from the phosphates or are too dynamic to be
detected in dipolar-based magnetization transfer experiments.
The 1H–13C CP58,59 MAS spectrum with ramped 1H amplitude
(ramp-CP60) has low intensity and resolution (Fig. 8, middle
trace) that are both increased when ramp-CP is hybridized with
the nuclear Overhauser effect (NOE, Fig. 8, top trace):61 this
sequence results in the appearance of a larger number of
signals. Most of these additional peaks appear in the aliphatic
region (0–75 ppm) and some peaks from aromatic side chains
also appear (110–140 ppm). Moreover, some new peaks can be
observed also in the carbonyl region (150–180 ppm). The
observed peaks around 153 ppm belong to Cz of the arginine
side-chains, while those around 178 ppm relate to Cg or Cd of
the aspartate and asparagine or glutamate and glutamine side-
chains, respectively (Fig. S10, ESI†). These observations suggest
that the additional peaks, observed via NOE, originate from
those chemical groups or amino acid residues that undergo
significant motion on the milliseconds (or faster) timescale,
and are therefore not detectable by the dipolar-coupling based
CP. One needs to consider the hypothesis of a substantial
water–protein magnetization transfer (either through intermo-
lecular NOE, which is prevailing at high spinning rates and low
temperature, or through chemical exchange followed by spin
diffusion, which is most probably dominant under the present
experimental conditions62) at the time of the NOE mixing, plus
the contribution due to direct 13C excitations which is intrinsic
for the pulse sequence applied.61 Either of the two mechanisms
does not detract from the idea, but rather corroborates it, that a
large share of the protein is sizably exposed to water.
The topology of HA/ANSII–HABP (Fig. 9) that can be derived
from our integrated analysis is summarized below.
(a) The microscopic characterization demonstrates that the
material is composed of small lamellar structures that closely
resemble hydroxyapatite, and PXRD confirms this conclusion.
(b) The secondary electron analysis shows that there is
a phosphate depletion, consistent with previous reports on
HA/peptide composites.
(c) Solid-state NMR investigation of the inorganic part shows
that the ordered HA phase is not in contact with the protein
and the disordered layer is in intimate contact with the protein.
This further shows that the two inorganic phases are in contact
with each other, and water is closer to the protein and largely
excluded from the mineral phases.
(d) Protein solid-state NMR indicates that the enzyme is not
completely immobile in the material, but undergoes extensive
motions (Fig. S10, ESI†), suggesting that it is mainly sitting
at the surface of the particles, rather than being entrapped
within the material (Fig. 9). Despite the preserved mobility, the
observed chimeric ANSII–HABP is stably linked to the mineral
particles, as discussed above.
(e) The tests against the cells and those in vitro confirm that
the protein is stable in the construct for several months and
demonstrate that the material is active.
Fig. 8 13C NMR spectra of HA/ANSII–HABP (black) and PEGylated
wtANSII43 (red) obtained under MAS using CP only (middle and bottom
spectra) or CP–NOE (topmost). The spinning sidebands are marked as ‘*’.
NOE mixing was set to 1.3 s and the CP contact time was 1.2 ms.
Fig. 9 Scheme of the arrangement of the components of HA/ANSII–
HABP.
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Nowadays ANSII is still indispensable6 in the treatment of
ALL patients and new ANSII preparations are needed to over-
come the limitations of the current ANSII therapy, especially
immunogenicity. The results obtained in an in vitro assay on
human leukemic cells with HA/ANSII–HABP, and the protocols
for its characterization, provide new perspectives for the devel-
opment of microreactors to be used as possible innovative
biomedical devices able (i) to increase the stability of ANSII,
(ii) to extend Asn depletion in the serum and at the same time
(iii) virtually to reduce immunogenicity. Collectively, our results
show that enzymes processing small substrates can be effi-
ciently and profitably bound to the surface of a HA matrix by
engineering the wild-type construct with HA promoting
peptides.
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Protein cloning, expression and purification
Construction of expression vector pET21-HABP - To endow any target enzyme with 
the ability to act as a template for accelerated hydroxyapatite precipitation and 
binding, we have created an expression vector that hosts two copies of the W6p. W6p 
is an acidic analog of the amino-terminal 15-residues fragment of salivary statherin 
and core motif of dentin matrix protein 1, an acidic protein that can trigger calcium 
phosphate formation in vitro by binding calcium ions.1 In order to generate pET21-
HABP, the multiple cloning site of the pET21a vector between XhoI and XbaI was 
removed, and sequentially replaced by DNA sequence coding for a) a His6 tag, b) a 
TEV protease cleavage site, c) the nucleating peptide W6p 
(RWRLEGTDDKEEPESQRRIGRFG) followed by a thrombin protease cleavage site, 
d) a multiple cloning site (containing restriction sites NdeI and BamHI), e) a second 
W6p nucleating peptide (see Figure S1).
LPNITILATGGTIAGGGDSATKSNYTVGKVGVENLVNAVPQLKDIANVKGEQVVNIGSQDMNDNVW
LTLAKKINTDCDKTDGFVITHGTDTMEETAYFLDLTVKCDKPVVMVGAMRPSTSMSADGPFNLYNAV
VTAADKASANRGVLVVMNDTVLDGRDVTKTNTTDVATFKSVNYGPLGYIHNGKIDYQRTPARKHTS
DTPFDVSKLNELPKVGIVYNYANASDLPAKALVDAGYDGIVSAGVGNGNLYKSVFDTLATAAKTGTAV
VRSSRVPTGATTQDAEVDDAKYGFVASGTLNPQKARVLLQLALTQTKDPQQIQQIFNQYGSASLEGG
MGGCGRWRLEGTDDKEEPESQRRIGRFG
Figure S1: L-ANSII HABP sequence post expression. In blue the HABP co-
expressed at the C-terminus of the protein. Schematic representation of the designed 
construct. A) Construction of expression vector pET21-HABP. MCS stands for 
multiple cloning site, where the gene encoding the protein of interest is cloned. B) 
Gene encoding L-ASNII with signal peptide targeting the protein to the periplasmic 
space. C) L-ANSII expressed in E. coli.
The correct cDNA sequences of the expression clones were confirmed by DNA 
sequencing. The multiple cloning site between the thrombin protease cleavage site 
and the second W6p nucleating peptide permits the insertion of the gene encoding the 
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protein of interest. Therefore, the chimeric protein can be co-expressed with one or 
two W6p units at the amino or carboxyl-terminal. The cleavage sites permit post-
purification removal of the His6-tag using the TEV protease or the removal of the 
amino terminal W6p using thrombin protease. In the case of ANSII, the His6-W6p 
peptide of the N-terminal domain is not present post-expression due to the removal of 
the protein’s pro-domain during the secretion into the periplasmic space.
Expression of E. coli L-Asparaginase II (ANSII) HABP- The DNA encoding the 
ANSII was cloned between NdeI and BamHI into the pET21-HABP vector. The 
ANSII was expressed as a fusion protein with an HABP peptide at the C-terminus. 
The gene encoding ANSII HABP in pET-21a-HABP was transformed into 
Escherichia coli BL21(DE3)C41 cells which were subsequently cultured in rich (LB) 
medium containing ampicillin (0.1 mg/mL). Cells were grown at 310 K, until A600nm 
reached a value of 0.6-0.8, and subsequently induced with IPTG (0.75 mM final 
concentration). Cells were further grown at 298 K overnight and then harvested by 
centrifugation at 6500 rpm (JA-10 Beckman Coulter) for 20 min at 277 K. All the 
purification procedures were carried out at 277 K. The pellet was re-suspended in 20 
mM Tris-HCl, pH 9.5, 15 mM EDTA, 20% sucrose buffer (60 mL per liter of culture) 
and then kept for 20 min under magnetic stirring. The suspension was centrifuged at 
10000 rpm (F15-6x100y Thermo Scientific) for 30 min and the supernatant discarded. 
The pellet was re-suspended in H2O Milli-Q (60 mL per liter of culture) and then kept 
for 20 min under magnetic stirring. The suspension was centrifuged again at 10000 
rpm (F15-6x100y Thermo Scientific) for 30 min. The supernatant was treated with 
ammonium sulfate from 30% to 90% to precipitate the ANSII HABP protein. Then 
the protein was re-dissolved in minimal amount of 20 mM Tris-HCl buffer at pH 9.5 
and dialyzed extensively against the same buffer. The ANSII HABP was further 
purified by Q-Sepharose column using 20 mM Tris-HCl buffer at pH 9.5 with a linear 
0-1 M NaCl gradient. Fractions containing pure ANSII HABP were identified by 
Coomassie staining 13.5% SDS-PAGE gels (Figure S2). The ANSII was further 
purified by gel filtration using a Superdex 75 26/60 column in 25 mM Tris-HCl buffer 
at pH 7.4 and concentrated with Amicon ultrafiltration device to a final concentration 
of 0.4 mM. The overall yield of purified protein was 35 mg/L. The purified protein 
was analyzed on native PAGE gel (BioRad Mini-PROTEAN Precast Gel) to estimate 
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the molecular mass of the protein assemblies and on a 13.5% SDS-PAGE gel to 
estimate the molecular mass of the monomeric protein (Figure S3).
Figure S2. Coomassie-stained 13.5% SDS–PAGE showing expression, purification 
and immobilized ANSII HABP. Expected molecular weight 41 kDa. Lane1: Low 
Molecular weight Marker. Lane2: ANSII HABP extracted after osmotic shock. 
Lane3: ANSII HABP after 60% ammonium sulfate saturation. Lane4: ANSII HABP 
post purification. Lane 5: ANSII from the composite. 
Figure S3. Native Page Gel
Dynamic Light Scattering (MALS-QELS) — Purified protein samples were analyzed 
by size exclusion chromatography connected to a multiangle light scattering (MALS) 
equipped with QELS module (quasielastic light scattering) for RH measurements. 100 
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μL samples were loaded on a Superdex 200 10/30 column (GE Health-care) 
equilibrated in 25 mM Tris-HCl buffer at pH 7.4. A constant flow rate of 0.5 mL/min 
was applied. Elution profiles were detected by an Optilab rEX interferometric 
refractometer and a Dawn EOS multiangle laser light-scattering system at 690 nm 
(Wyatt Technology Corp.). Data acquisition and processing were carried out using 
ASTRA 5.1.9.1 software (Wyatt Technology). Determination of molecular masses 
and hydrodynamic radii are reported as mean values ± S.D. of duplicate experiments 
(Figure S4).
Figure S4. SEC-LS profiles, showing the simultaneous presence of the dimer and of 
the tetramer of ANSII-HABP. Light Scattering (LS) and differential Refractive Index 
(dRI) are plotted alongside fitted molecular weights (Mw). ANSII-HABP 
concentration A) 4.1 mg/mL B) 8.2 mg/mL C) 20.5 mg/mL.
Enzymatic Activity Assay – The analysis of the enzymatic activity of ANSII and 
ANSII HABP was performed according to the Sigma-Aldrich protocol with slight 
modifications. The protocol comprises the following steps. A 2 mL solution 
containing 10 mM of L-asparagine, solubilized in 25 mM Tris-HCl buffer at pH 8.6, 
is incubated at 310 K for 10 minutes. Then, an enzyme solution of known 
concentration or 0.5-6 mg or entrapped enzyme is added to the solution containing L-
asparagine and the mixture is incubated for 30 minutes at 310 K. The reaction is then 
stopped by adding trichloroacetic acid (TCA) to a final concentration of 68 mM. Then 
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0.2 mL of the reaction were added to 4.3 mL of deionized water and the sample was 
treated with 1 mL of Nessler’s reagent. After 1 minute of incubation the optical 
density was measured at 436 nm using a UV/VIS spectrophotometer. The activity 
values of samples were average of three repeated measurements (Figure S5).
Figure S5. Concentration/activity profiles for wtANSII, free ANSII-HABP and 
HA/ANSII-HABP. In the first graph (free enzymes, top panel), for the wt ANSII the 
regression describing the activity is Y=11.25x with R2 =0.9898, while the regression 
describing the activity of ANSII HABP is Y=2.537x with R2 =0.9926. In the second 
graph (entrapped enzyme, bottom panel) the activity is described by the following 
regression Y=3.947x with R2 =0.9965
Biomimetic Mineralization Reaction
To assess the mineralization capabilities of the chimeric proteins co-expressed with 
the peptides, a mineralization model based on an alkaline phosphatase (ALP) solution 
was used.2 The ALP is added to the protein solution to allow the diffusion of Ca2+ and 
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the enzymatic hydrolysis of the β-glycerophosphate ions to the protein. ALP then 
releases the PO43- groups, which react with the calcium ions to form HA. 
The protocol for biomineralization proposed by Gungormus et al.3 requires a protein 
concentration of 0.4 mM in 25 mM Tris-HCl buffer at pH 7.4 supplied with 24 mM 
Ca2+ and 14.4 mM of β-glycerophosphate, with a final concentration of alkaline 
phosphatase at 1.4 μg/mL. The reaction mixture was then incubated at 310 K for 24 h, 
and finally centrifuged at 10000 rpm (Hettich Mikro 200R) for 15 min at 273 Κ. 
Then, the supernatant of the reaction was removed and the pellet was washed with 
MilliQ water until all free protein was removed. 
Cell viability assay
B cell precursor (BCP)-acute lymphoblastic leukemia (ALL) cell line 697 was 
cultured in RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% fetal 
bovine serum (Euroclone). Cell viability was assessed through the Trypan Blue 
exclusion test (Sigma-Aldrich). Cells were seeded in flasks (Costar Corning) (5x104 
cells/mL) in complete medium and incubated for 24 and 48 hours with different 
ANSII preparations. The free enzymes (wild-type recombinant ANSII and 
commercial Oncaspar) were added in the medium at the concentrations reported in the 
legend of Figure 1, whereas the composite was confined by a 3.5 kDa-cutoff 
Millipore membrane for dialysis. Cells were then harvested and counted by the 
Trypan Blue exclusion test using a hemocytometer. All the experiments were 
performed in triplicate. 
Statistical analysis
Data of cell viability are given as mean values ± standard error of the mean (SEM). 
Statistical comparisons were performed with OriginPro 2015 (Origin Lab, 
Northampton, Massachusetts). The normality of data distribution was analyzed with 
Kolmogorov-Smirnov (K-S) test. For multiple comparisons, one-way ANOVA 
followed by Bonferroni’s post-hoc test was performed to derive P values. The 
individual P values are reported in the Figure 1.
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Enzyme kinetics by NMR
Solution NMR experiments for the evaluation of the enzymatic activity were carried 
out at 310 K on Bruker AVANCE NMR spectrometers equipped with triple-
resonance cryoProbes and operating at the 1H Larmor frequency of 700 and 900 MHz. 
A Carr-Purcell-Meiboom-Gill (CPMG) spin echo sequence was applied in the case of 
the protein in bovine serum, to suppress signals arising from high molecular weight 
molecules. CPMG spectra were acquired using 8 scans, 16 k data points, 14005 Hz 
spectral width, 584 ms acquisition time, 4 s recycle delay and 77 ms mixing time. A 
kcat value of 2.1 ± 0.2 s-1, against 29 ± 1 s-1 reported in the literature for the wild-type 
(wt) ANSII,4 was measured for the chimera by NMR (Figure S6),5,6 with KM = 3.0·10-
5 ± 1.0·10-5 M-1 and 1.3·10-4 M-1 for the chimera and the wt enzyme, respectively. The 
decrease of kcat is related to the fewer quaternary contacts that probably slightly alter 
the structure of the catalytic domain in the dimeric subunit and affect the enzyme 
turnover. Actually, a factor ~4 difference in KM, combined with a factor ~14 in kcat, 
yields a factor of only ~3.2 decrease in total enzyme turnover kcat/KM.
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Figure S6. Kinetic measurement of free ANSII-HABP activity (top panel) and 
HA/ANSII-HABP composite activity (bottom panel). The decrease in the Hβ signal 
intensity is measured (1% error assumed), represented as blue points, and fitted 
(black) to the Schnell-Mendoza equation:  where S is 
𝑆
𝐾𝑀
(𝑡) =𝑊[ 𝑆0𝐾𝑀𝑒( 𝑆0𝐾𝑀 ‒ 𝑉𝑚𝑎𝑥𝑡𝐾𝑀 )]
the substrate concentration and W is the Lambert-W function.5,6 In both cases the 
concentration of asparagine is 9.45 mM; the concentration of free enzyme is 0.545 
µM, whereas 7.5 mg of wet composite are used. Based on the amount of enzyme in 
the dried composite (40 ± 1 %) and the amount of dry composite in the wet composite 
(6.5 or 13 % for OCP and HA respectively) the concentration of the enzyme in the 
composite is calculated to be about 16 µM.
The chimera-HA composite was found to be active also in bovine serum with 7.5 mg 
of wet composite capable of clearing 50 mM of Asn from a volume of 550 µl in 4.5 h. 
This was observed by detecting the disappearance of Asn Hα and Hβ2,3 NMR signals, 
under the conditions usually employed for NMR-based metabolomic profiling of 
serum (Figure S7).7
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Figure S7. Portion of the CPMG-filtered 1H NMR spectrum of bovine serum, in the 
presence of composite (7.5 mg), upon spiking with 50 mM Asn. Asn Hα and 
Hβ signals, which are apparent in the initial spectrum, are sizably reduced over 150 
min with an increase of the corresponding Asp signals. Asparagine drops below the 
current NMR detection limit in about 4.5 h.
From the elemental analysis (see main text), we can estimate that 6.5% to 13% of the 
wet material will consist of the biocomposite material. These numbers are key to the 
analysis of the kinetic profile of the entrapped enzyme. With these concentrations, fit 
of kinetic data (Figure S6, bottom, measured on 7.5 mg of wet material in 550 µL) 
yields KM= 0.017 ± 0.002, and kcatHA=1.5 ± 0.2 s-1 or kcatOCP=2.9 ± 0.2 s-1 can be 
obtained. Assuming that the activity is unaffected, an enzyme weight concentration of 
10% in the wet material would be obtained. In any case, the turnover rate is 
unaffected, while the affinity of the substrate is markedly reduced, as usual.8 
Interestingly, even in the case that the whole material is HA, the kcat would be only 
reduced to about 70% of its free enzyme value.
Electron Microscopy - Sample morphology analysis was carried out on FEI Magellan 
400L high-resolution SEM instrument using accelerating voltage of 5 kV. HA/ 
ANSII-HABP was suspended in absolute ethanol and sonicated for 10 min. About 4 
μL of suspension were dropped on a piece of silicon that was adhered by a double-
sided carbon tape to a special grid. The sample was left overnight for complete 
solvent evaporation before EM measurements. Morphology and elemental 
composition of samples were also investigated by FESEM (Field Emission Scanning 
Electron Microscope) and EDS (Energy Dispersive Spectroscopy), using a ZEISS 
MERLIN - GEMINI 2 Equipped With an X-Max 50 (Oxford) EDS detector. The 
secondary electron micrographs were obtained at 1.7 mm of working distance (WD), 
at 0.7 kV of acceleration voltage (EHT) using in lens detector, whereas for chemical 
analysis the parameters were 8.5 mm WD and 10 kV of EHT. A special Charge 
Compensator allowed us to analyze the sample without special preparation or coating, 
so the sample was directly adhered by double-sided carbon tape to the grid.
Solid-state NMR characterization
Solid-state NMR experiments - Protein solid-state NMR spectra were acquired using a 
Bruker Avance II NMR spectrometer operating at 700 MHz 1H Larmor frequency, 
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equipped with a 3.2 mm HCN MAS probe with a λ/4 insert. Samples were packed 
into 3.2 mm zirconia rotors (Bruker), center packed with a silicon insert. The 90° 
radio-frequency (RF) pulse widths were 2.6 µs for 1H, 3.5 µs for 13C and 7 µs for 15N. 
An optimal interscan delay was found to be 1.3 s. During 13C evolution/detection 
SWfTPPM9–12 was applied to decouple protons with a 90 kHz RF field, an optimal RF 
power was chosen based on 13C T2 measured by echo decay.13 The sample spinning 
frequency was regulated to 10 kHz. Sample temperature was regulated to 255 K at the 
stator outlet, corresponding to 280 K in the sample, and temperature was calibrated by 
measuring the PEG-H2O chemical shift difference on a different sample.14,15 The 
spectrum of the PEGylated asparaginase was acquired on a Bruker Avance III NMR 
spectrometer operating at 850 MHz 1H Larmor frequency, as described in reference.16
NMR experiments for characterization of the biomineral were carried out using a 
Bruker Avance III spectrometer operating at 500 MHz 1H Larmor frequency, 
equipped with a 4 mm MAS VTN probe, and the spinning frequency was adjusted to 
10 kHz. 1D 1H Bloch decay and window phase-modulated-Lee-Goldburg (wPMLG)17 
experiments were carried out using 1H 90° pulse of 2.55 μs. 8 scans with a recycle 
delay of 2 s were used in the Bloch decay measurement. In the wPMLG measurement, 
6 s recycle delay and 528 repetitions were used. 1D 31P cross polarization (CP) 
measurements with a varying contact time for polarization transfer were carried out 
using TPPM heteronuclear proton decoupling during acquisition.18 Each experiment 
employed a 5 s recycle delay and 256 repetitions. 2D 1H-31P heteronuclear correlation 
(HETCOR) measurements employed 505 t1 increments, CP contact times of either 
500 μs or 5 ms, PMLG5 scheme19 for 1H homonuclear decoupling during t1 and a 
TPPM pulse scheme for heteronuclear proton decoupling during acquisition. A 
recycle delay of 1 s and 128 repetitions per each t1 point were used.
The deconvolution of the 31P CP spectrum of HA/ANSII-HABP (Figure S8a, blue) 
performed using DMFIT20 shows that the peak observed is composed of two 
resonances at 2.6 ppm (fwhm 3 ppm) and at 2.9 ppm (fwhm 1.2 ppm). Similar 
analysis using automated deconvolution to deduce the components of the phosphate 
line in HA by the DMFIT program was shown before (see ref [33] in main text). The 
best fit was obtained using DMFIT. It uses frequency, intensity, width and 
Gaussian/Lorentzian ratio of each spectral line. It also reports a standard deviation 
value (stdev) between experimental and fitted lines in DMFIT which confirms the 
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best fit in the minimization process. A single-line fitting resulted in a higher stdev 
than two-line fitting (see Figure S8). 
       20                 15               10               5                 0                -5              -10              
-15             -20 ppm
(a)
         20               15               10               5                 0                -5              -10              
-15             -20 ppm
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Figure S8. Automatic fitting comparison in DMFIT program. (a) A fit using single 
peak produced a line located at 2.85 ppm with a linewidth of 2.54 ppm and stdev of 
0.46. (b) A fit using two peaks produced two lines at 2.9 and 2.6 ppm with a stdev of 
0.29. The experimental spectrum is 31P CP recorded with a contact time of 3.6 ms. 
Gray lines in both spectra represent subtraction spectra (delta) between the 
experimental signal (blue) and the computed signal (red). 
The absence of the water resonance in the 2D HETCOR measurements is further 
demonstrated in the 1H projections (taken along the phosphate maximal intensity) of 
these measurements as compared to similar measurements in synthetic HA where the 
relative intensity is much different (see Figure S9). Similar 1H-31P 2D HETCOR 
measurements without PMLG decoupling (data not shown) did not show any water 
cross peaks with phosphates, so it is evident that water molecules are distantly located 
from phosphates. 
Figure S9. 1D 1H projections from 2D 1H-31P HETCOR spectra of HABP with CP 
contact times of 0.5 ms (red), 5 ms (blue) and of synthetic hydroxyapatite with contact 
time of 0.4 ms (green) for comparison.
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The resulting spectra for the HA/ANSII-HABP composites are shown in black in 
Figure 8, and compared to the CP spectrum of the PEGylated wtANSII from 
reference.16 The HA/ANSII-HABP composite turned out to be a peculiar sample from 
the solid-state NMR standpoint: the first observation is that the overall spectral 
resolution of the CP spectrum is low (Figure 8, middle row). The second remarkable 
feature is that a significant share of the protein is not responsive to the dipolar-based 
ramp-CP experiment (Figure 8, middle row), whereas it appears in a sedimented 
sample of WT ANSII (Figure 8, bottom row). On the other hand the 13C spectra 
obtained via the combination of ramp-CP and NOE exhibited many additional 13C 
peaks. 
Figure S10. Difference 13C NMR spectra of HA/ANSII-HABP between CPNOE 
experiment (Figure 8, top) and CP experiment (Figure 8, middle), showing the largest 
deviation between the two spectra, with the indication of the chemical shift regions 
for amino acid side-chains.
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ABSTRACT: Solid-state NMR is becoming a powerful tool to detect atomic-level
structural features of biomolecules even when they are bound to (or trapped in) solid
systems that lack long-range three-dimensional order. We here demonstrate that it is
possible to probe protein−ligand interactions from a protein-based perspective also when
the protein is entrapped in silica, thus translating into biomolecular solid-state NMR all of
the considerations that are usually made to understand the chemical nature of the
interaction of a protein with its ligands. This work provides a proof of concept that also
immobilized enzymes can be used for protein-based NMR protein−ligand interactions for
drug discovery.
■ INTRODUCTION
Several chemical applications including fine chemistry,
diagnosis, and decontamination rely on the use of immobilized
proteins. The immobilization of enzymes is of particular
interest because of the variety of reactions that they can catalyze
under mild, physiological, conditions,1−6 reducing the environ-
mental footprint of chemical processing.7 Protein immobiliza-
tion often results in improved stability;8 furthermore, the
immobilized enzyme becomes a heterogeneous catalyst that can
be easily removed from the reaction mixture, thus reducing the
problems of using enzymes in an industrial setting.9
Several different approaches have been proposed for the
purpose of protein immobilization,8,10,11 mainly clustered in the
categories of adsorption,12,13 covalent linkage,6,14−16 encapsu-
lation by confinement in a physical barrier,17 and entrapment
within a matrix.18 Among the entrapment methods, one very
interesting approach is the creation of a bioinspired silica
scaffold around the protein.19−22 This approach ensures higher
immobilization than mere adsorption and, at the same time,
does not foresee the creation of any covalent bond; hence, it
less likely perturbs the native fold of the enzyme. Furthermore,
enzymes immobilized through this approach have been
reported to have higher stability.8,23,24
Checking the preservation of the active fold of the protein
when immobilized often requires a combination of different
experimental techniques,25−27 so that most of the character-
izations are performed either by the assessment of the
enzymatic activity or by immunochemical assays.28 However,
recent developments in solid-state biomolecular NMR29−36
have demonstrated that SSNMR is becoming a powerful tool
for the characterization of hybrid inorganic/biomolecular
composites lacking long-range order; evidence has accumulated
over the years that it is possible to characterize the inorganic
component, the composition of the biomolecular compo-
nent,37−45 and changes in the spectra of the entrapped
protein46 down to structural features at the atomic level for
entrapped47−51 as well as for adsorbed proteins52 and also to
probe the biomolecule−matrix interactions.53−56
Because sufficient resolution is achieved to observe changes
in the chemical environment of individual atoms, in principle,
this would make it possible to probe protein−ligand
interactions from the protein perspective. We here describe
the application of SSNMR to detect the interaction between
silica-immobilized human carbonic anhydrase (hCAII) and two
of its inhibitors, the weaker sulpiride and the stronger
furosemide. We have chosen hCAII because it has been already
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characterized by NMR.57−61 hCAII is a very efficient enzyme
that catalyzes the hydration of CO2 to HCO3
−, which would
occur too slowly on the physiological time scale. Immobilized
hCA has an industrial relevance for CO2 sequestration,
62−66
and its esterase activity67,68 may have biotechnological
applications.69 In addition to this, the different isoforms of
hCA are found to be overexpressed in several pathologies; thus,
they are interesting targets for drug development.70−73
■ MATERIALS AND METHODS
Expression of Human Carbonic Anhydrase II (hCAII).
The gene encoding hCAII into the pCAM vector was
transformed into Escherichia coli BL21(DE3) Codon Plus RIPL
cells, which were subsequently cultured in a rich (LB) medium
containing ampicillin (0.1 mg/mL) and chloramphenicol
(0.034 mg/mL). Cells were grown at 310 K overnight and
then harvested by centrifugation at 4000 rpm (JA-10 Beckman
Coulter) for 20 min at 298 K. After switching the cells into the
minimal medium containing ampicillin (0.1 mg/mL) and
chloramphenicol (0.034 mg/mL), (15NH4)2SO4 and
13C-
glucose, the bacterial cells were cultured at 310 K for 30 min
and subsequently induced with IPTG (1 mM final concen-
tration) and 0.5 mM ZnSO4. Cells were further grown at 310 K
for 5 h and then harvested by centrifugation at 6500 rpm (JA-
10 Beckman Coulter) for 20 min at 277 K. All of the
purification procedures were carried out at 277 K. The pellet
was resuspended in 20 mM Tris-sulfate, pH 8.0, 0.5 mM
ZnSO4 (200 mL per liter of culture). Cell disruption was
performed on ice by sonication alternating 30 s of sonication
and 5 min of resting for 10 cycles. The suspension was
ultracentrifuged at 40000 rpm for 30 min at 277 K. The
supernatant, containing crude hCAII protein, was purified by
nickel affinity chromatography using a linear 0−0.5 M
imidazole gradient. Fractions containing pure hCAII were
identified by Coomassie staining 13.5% SDS-PAGE gels. Then,
the protein was dialyzed against 20 mM Tris-sulfate buffer at
pH 8.0, 10 mM EDTA and then against 20 mM Tris-sulfate
buffer at pH 7.0, 0.5 mM ZnSO4. The hCAII was further
purified by gel filtration using a Superdex 75 26/60 column
(Amersham Biosciences) in 10 mM HEPES buffer at pH 7.2
and concentrated with an Amicon ultrafiltration device to a final
concentration of 40 mg/mL. The overall yield of purified
protein was 250 mg/L.
Silicification Reaction. The silicification reactions of
hCAII were performed as previously reported14 using poly-L-
lysine as a promoter for the polymerization of silica, but at
higher pH (7.2 instead of 7.0) on the other side of the
isoelectric point of the enzyme (7.1374). hCAII (400 μL, 40
mg/mL in 10 mM HEPES, pH 7.2) and poly-L-lysine (100 μL,
10 mg/mL in H2O; MW: 4000−15000 Da) were added to 1.5
mL vials and shaken for 10 min. To the resulting solution, a 100
mM solution of silicic acid (500 μL) in 10 mM HEPES, pH 7.2
[freshly prepared from a stock solution of 1 M silicic acid
obtained by the addition of 1 mM HCl (850 μL) to pure
tetramethyl orthosilicate (TMOS;150 μL)] was added, and the
mixture was left for 10 min at room temperature to react. The
suspension was used to fill a 3.2 mm rotor using an
ultracentrifugal device.75
NMR Measurements. All solution NMR experiments for
backbone assignment (3D HNCA, 3D HNCO, 3D HN(CA)-
CO, 3D HNCACB, and 3D CBCA(CO)NH) were performed
on a sample of 13C−15N hCAII at a 0.4 mM protein
concentration in 20 mM HEPES, pH 7.5, 0.02% NaN3, with
proteases inhibitors, at 310 K, on a Bruker DRX 500
spectrometer equipped with a triple-resonance cryoprobe.
All solid-state NMR spectra were acquired with a Bruker
AvanceIII HD spectrometer operating at a 800 MHz 1H
Larmor frequency, equipped with a 3.2 mm E-free HCN
probehead, at ∼291 K; the magic-angle spinning (MAS)
frequency was 14 kHz, and 1H decoupling was applied at a
nutation frequency of 80 kHz with the swfTPPM scheme.
76−79
Samples of hCAII encapsulated in a silica matrix were packed
into Bruker 3.2 mm zirconia rotors with silicon plugs (courtesy
of Bruker Biospin) to preserve hydration.80 The 90° pulses
were 2.5 μs for 1H, 3.5 μs for 13C, and 5.6 μs for 15N. Interscan
delay was set to 2 s.
In the 2D 15N−13C NCA experiments, 1H−15N cross-
polarization (CP)81 was achieved by a 1H−15N CP contact time
of 1 ms (ωH = 63 kHz at match, ωN = 35 kHz) with a 100-70
linearly ramped contact pulse on 1H, and the double cross-
polarization (DCP)82,83 contact time was 3 ms (ωH = 78 kHz,
ωN = 35 kHz, ωC = 21 kHz at match). The number of scans
was 1216 for furosemide spectra and 2432 for the initial
spectrum of the sample used for interaction with sulpiride. After
loading of the sample with the sulpiride solution, the signal
decreased and the number of scans was increased to 3600 to
partially compensate for the loss in intensity.
In the 2D 13C−13C dipolar-aided rotary resonance
(DARR)84,85 spectrum, the 1H−13C CP contact time was set
to 2 ms (ωH = 78 kHz at match, ωC = 50 kHz) with a 100-70
linearly ramped contact pulse on 1H; the DARR mixing time
was set to 50 ms, and the number of scans was 288.
All of the spectra were processed with the Bruker TopSpin
3.2 software package and analyzed with the program CARA
(ETH Zürich).86
The protein backbone assignment was obtained from analysis
of the solution NMR spectra acquired on hCAII and compared
with literature data.60,61 The final percentage of assignment was
88% because residues 1−22 and some residues belonging to
loops could not be identified in the spectra, in line with
previous reports.60,61
■ RESULTS AND DISCUSSION
Recently, we have demonstrated that high-resolution SSNMR,
based on 13C detection, can be applied to observe the spectra of
silica-encapsulated enzymes47 and to monitor the perturbations
induced by the silicification with respect to the protein when
free in solution.47,48 Incidentally, we note that the silica
prepared under these experimental conditions is rather
reproducible in terms of quaternary site distribution48 and
that in previous reports we have not observed any strong site-
specific interaction between the protein and the matrix.48,50
We have here applied the same strategy to the character-
ization of the interaction of hCAII with furosemide, with the
aim of proving that it is possible to observe a protein−ligand
interaction when the protein is immobilizedentrapped in
silica in the present case. The spectra show remarkable
resolution, and at variance with previous observations under
different experimental conditions,47,87 protein degradation over
time is not observed. Such high resolution is most probably due
to the fact that the protein retains its full hydration and allows
for atomic-level characterization of the system, whereas in
previous investigations by other groups the sample was
lyophilized.46
Because of the high resolution achieved in the 2D 15N−13C
NCA spectrum, the assignment obtained in solution is easily
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transferable to the solid state. We have thus compared the Cα
and N chemical shifts observed in solution with those observed
in the solid state for the uninhibited enzyme (Figure 1A). The
perturbation is overall minor, with larger differences occurring
for some residues on the protein surface, in particular, charged
residues and residues close to them (Figure 1B), as already
observed for other systems.47,48 The preservation of the
chemical shift pattern of the active site is already indicative
that its structure is preserved, in line with previous enzyme
kinetic data on carbonic anhydrase entrapped in silica with a
different chemistry87 as well as with the enzymatic activity
measured for our composite (see the Supporting Information).
We also observe that lysine signals in the 2D 15N−13C NCA
show reduced intensities, as already reported50,89,90 and in line
with the expected interaction of positively charged residues
with the disordered silica matrix.54−56,91−95 It is interesting to
notice that the opposite holds true for the same protein when
using an immobilization strategy based on the formation of a
covalent linkage of lysine residues with an epoxy-linker grafted
on the silica surface.46 This is possibly due to the more
homogeneous environment for lysine residues that is achieved
by covalent linkage.46,96
The resolution of the SSNMR spectra is high enough even to
allow for effective localization of an inhibitor when bound to
the enzyme, as done for the so-called protein-based drug
screening in solution.97,98 We have here focused our attention
on the detection of the interaction of the furosemide inhibitor
with the enzyme. This inhibitor has high affinity (with Kd in the
nM range99) for the active site and is thus expected to be in the
slow exchange regime with respect to the NMR time scale.
Aliquots of inhibitor solutions were added directly in the rotor
containing the entrapped protein, and the chemical shift
perturbations (CSPs) of the protein resonances were analyzed.
The new resonances belonging to the inhibited protein could
be reassigned in the 2D 15N−13C NCA spectrum (Figure 2),
also using the information from the 2D 13C−13C DARR
spectrum.
From the analysis of the CSP, it is apparent that active site
residues exhibit the largest effects (Figure 3A,B). The active site
of the enzyme (Figure 3C) comprises three histidine residues
that coordinate the Zn(II) (H94, H96, H119); the coordina-
tion sphere of the metal is completed by a water molecule,
which is involved in hydrogen bonding with T199. This water
molecule is removed upon binding to sulfonamide inhibitors
(Figure 3D): the NH− moiety of the sulfonamide participates
in hydrogen bonding with the Oγ of T199, and one of the
oxygen atoms of the − SO2NH− moiety also engages the
backbone NH of T199,100−102 explaining the major perturba-
tion at this site. Overall, the residues with the highest CSP on
the protein surface are located in the active site cleft, where the
inhibitor is bound (Figure 3B,D).
The method is sensitive enough to reveal differences also in
the presence of a lower-affinity inhibitor, sulpiride in the
present case. To load the protein with sulpiride, the silica was
removed from the rotor, washed with a buffered solution
containing sulpiride, previously dissolved in DMSO, and
repacked. Also in this case, the CSP shows that active site
residues exhibit the largest effects (Figure 4A,B).
Figure 1. Outcome of the comparison of solution and SSNMR data on hCAII entrapped in the silica matrix: (A) chemical shift perturbation (CSP)
between free and silica-immobilized hCAII according to the formula δ δ δΔ = Δ + Δα(1/2) ( /2) ( /5)C 2 N 2 .88 The bars corresponding to the
residues exhibiting the largest CSP are highlighted in red. (B) CSP mapping on the protein surface (PDB code: 1Z9Y): the charged residues are in
blue (positive) and red (negative); the region with the largest perturbation is in magenta.
Figure 2. 2D 13C−15N NCA correlation spectra of uninhibited hCAII
(black) and furosemide-inhibited hCAII (red), encapsulated in the
silica matrix using poly-L-lysine. Two of the histidine residues that
coordinate the Zn(II), that exhibit the largest CSP, are indicated in the
figure.
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■ CONCLUSIONS AND OUTLOOK
In this work, we capitalize on the recent advances in the
SSNMR applied to composites having both an inorganic and a
biomolecular component. Even if the signal-to-noise ratio is
lower due to the presence of the silicic matrix, the use of high-
field instruments and dedicated probes mitigates the problem
and allows for detection of the protein resonances. We observe
a very remarkable resolution, most probably due to retention of
the full hydration of the protein. We here demonstrate that the
resolution is high enough to track at the atomic level the
perturbations due to the interaction of the protein with a
ligand. This observation allows us to speculate that it will be
possible to perform protein-based studies of protein−ligand
interactions by means of SSNMR on immobilized proteins,
expanding the possibilities of drug discovery, where immobi-
lized enzymes have already been used for ligand-based
screening.28,104−109 A possible pitfall in this strategy is the
Figure 3. SSNMR data of hCAII encapsulated in the silica matrix: (A) CSP between the uninhibited hCAII and hCAII in the presence of furosemide
;88 the bars corresponding to residues exhibiting the largest CSP are highlighted in red. (B) CSP mapping on the protein surface (PDB code: 1Z9Y):
the unassigned regions are shown in gray, the region with the largest perturbation is in blue, and the inhibitor is shown as yellow sticks. (C) Focus on
the residues exhibiting the largest CPS in the active site, highlighted in blue, on the structure of the free protein (PDB code: 3KS3103) and (D) on
the protein inhibited with furosemide (PDB code: 1Z9Y); the different coordination spheres of the metal in the two cases are shown.
Figure 4. SSNMR data analysis of hCAII encapsulated in the silica matrix: (A) CSP between the uninhibited hCAII and hCAII in the presence of
sulpiride. The bars corresponding to residues exhibiting the largest CSP are highlighted in red. (B) CSP mapping on the protein surface: the
unassigned regions are shown in gray, and the region with the largest perturbation is in blue. (C) CSP mapping on the protein surface after washing
of the protein pellet: the unassigned regions are shown in gray, the residues still experiencing a CSP are in blue, and the residues with a low intensity
signal that disappeared are in pink.
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accessibility of the enzyme by the substrate87 as well as by the
candidate drugs, but this is easily checked by performing
enzymatic activity tests.
We have focused our attention on the selection of
experiments that can be rapidly acquired and at the same
time allow for direct translation of the resonance assignments
obtained in solution for the free target. The present results
obtained on the 13C−15N-labeled protein, combined with the
possibility to apply proton detection110,111 to immobilized
enzymes,50 suggest that a larger sensitivity and improved
throughput will be possible by a proton detection strategy
applied on the 2H−13C−15N-labeled protein, exploiting the
advantages linked to the larger sensitivity of proton resonances
to changes in the local chemical environment. Finally, we
expect that by use of fusion tags to improve immobiliza-
tion112−115 and of open-ended rotors to be used as “cartridges”
for loading with ligand and subsequent washing it will be
possible to test several inhibitors on the same sample.
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MAS magic-angle spinning
SSNMR solid-state nuclear magnetic resonance
swfTPPM swept-frequency two-pulse phase modulation
TMOS tetramethyl orthosilicate
■ REFERENCES
(1) Cao, L. Carrier-Bound Immobilized Enzymes: Principles, Application
and Design; John Wiley & Sons, 2006.
(2) Guisan, J. M. Immobilization of Enzymes and Cells; Springer, 2006.
(3) Garcia-Galan, C.; Berenguer-Murcia, Á.; Fernandez-Lafuente, R.;
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tion; Baüerlein, E., Ed.; Wiley-VCH Verlag GmbH, 2007; pp 19−38.
(42) Tesson, B.; Masse, S.; Laurent, G.; Maquet, J.; Livage, J.; Martin-
Jeźeq́uel, V.; Coradin, T. Contribution of Multi-Nuclear Solid State
NMR to the Characterization of the Thalassiosira Pseudonana Diatom
Cell Wall. Anal. Bioanal. Chem. 2008, 390, 1889−1898.
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Enzymatic assay for free and silica-entrapped Zn-αCAII 
Enzymatic activity of Zn-αCAII can be measured by performing the following reaction: 
 
 
 
PNP absorbs at 410 nm (yellow) and its formation can be followed by UV/Vis measurements. 
 
Enzymatic activity of the free protein 
We have mixed 900 µL of 555 nM Zn-αCAII at pH 7.5 with 40 mM sodium phosphate buffer and 
100 µL of 0.5 mM PNPA in CH3CN at RT in a cuvette. Immediately absorbance measurements 
were performed at 410 nm by recording a point every 15 seconds for 60 minutes. These 
measurements were repeated in triplicate and three kinetic curves were plotted (Fig. S1). 
 
 
Figure S1 – kinetic curves for free carbonic anhydrase (triplicate) 
 
By fitting the first part of the curves it was possible to determine the slope of the lines which 
corresponds to the initial rate of the enzymatic reaction (Fig. S2). 
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Figure S2 – initial slope of the kinetic curves for free carbonic anhydrase (triplicate) and linear 
fitting for extracting the initial rate of the enzymatic reaction. 
 
Averaging the three values, initial rate of the enzymatic reaction for free protein is found to be 
5.3·10-4 ± 0.8·10-4 s-1. 
 
Enzymatic activity of the silica-entrapped protein 
First of all a suspension of silica-entrapped Zn-αCAII was prepared by estimating the yield of 
entrapment and dissolving the material in a suitable volume of solution at pH 7.5 with 40 mM 
sodium phosphate buffer in order to obtain a “formal” 555 nM solution (in term of protein). 
In a cuvette 900 µL of 555 nM silica-entrapped Zn-αCAII in solution at pH 7.5 with 40 mM sodium 
phosphate buffer and 100 µL of 0.5 mM PNPA in CH3CN were mixed at RT. Immediately 
absorbance measurements were performed at 410 nm by recording a point every 15 seconds for 60 
minutes. These measurements were repeated in triplicate and three kinetic curves were plotted (Fig. 
S3). 
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Figure S3– kinetic curves for silica-entrapped carbonic anhydrase (triplicate) 
 
Again by fitting the first part of the curves it was possible to determine the slope of the lines which 
corresponds to the initial rate of the enzymatic reaction (Fig. S4). 
 
 
Figure S4 – initial slope of the kinetic curves for silica-entrapped carbonic anhydrase (triplicate) 
and linear fitting for extracting the initial rate of the enzymatic reaction. 
 
Averaging the three values, initial rate of the enzymatic reaction for the entrapped protein is found  
to be 1.2·10-4 ± 0.4·10-4  s-1. 
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